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Abstract 
A method for the efficient production of RNA-free particles of Cowpea mosaic virus 
(CPMV) has been developed. These are generated by co-expression of the 
precursor of the coat proteins (VP60) and the viral proteinase (24K) using the 
highly-efficient plant expression system, CPMV-HT, in the model plant Nicotiana 
benthamiana. Particles thus produced were shown to be identical to CPMV on the 
outside and devoid of RNA on the inside and were hence named CPMV empty 
virus-like particles (eVLPs). The availability of large quantities of purified eVLPs 
represents a significant milestone in the development of CPMV-based particle 
technologies and their potential applications in nanotechnology have been 
investigated.   
eVLPs were shown be genuinely empty unlike other VLPs which package random 
cellular RNAs from the host. The high specificity of CPMV in packaging led to the 
investigation of the requirements for efficient packaging in CPMV where the 
functional coupling of replication and encapsidation was identified. Methods have 
been presented to extend this approach for packaging heterologous nucleic acids 
in eVLPs for their application as delivery vehicles. 
To obtain a continuous supply of eVLPs, methods for its stable expression were 
developed for which the suppressor of silencing deployed in the CPMV-HT system, 
P19, was modified as the use of wt P19 inhibits regeneration of leaf tissue. A 
mutant form of P19, R43W, with reduced but still substantial suppressor activity 
was shown to permit the regeneration of transgenic plants. P19/R43W was used 
for the stable expression of a variety of heterologous proteins showing the broad 
applicability of this system. To reduce the possibility of homologous 
recombination, an alternative to the CPMV-HT system was developed by deploying 
the UTRs from CPMV RNA-1. Expression with RNA-1 UTRs was rapid as compared 
to CPMV-HT and hence, the expression system was named Rapid-Trans.   
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Chapter 1: Introduction 
1.1 Nanotechnology 
Nanotechnology is a relatively new, multi-disciplinary field that involves 
manipulation of matter on the nanometre (10-9 m) scale. It advocates the bottom-
up approach to build and shape matter, i.e. one atom at a time. The underlying 
principle of this field is manipulation at the atomic/molecular level for precise 
control at the macromolecular level (Goodsell, 2004).  
The first concepts of nanotechnology were introduced by physicist Richard 
Feynman in 1959 in his ground-breaking lecture, ‘There’s plenty of room at the 
bottom’ where he presented his vision on miniaturization and controlling things 
on a small scale (Feynman, 1959). Later in 1986, K. Eric Drexler popularised the 
idea of nanotechnology in his book, ‘Engines of Creation: the coming era of 
nanotechnology’, which presents ideas on developing a nano-scale machine for 
forcibly pressing atoms together into desired molecular shapes (Drexler, 1986). 
Since then, the field of nanotechnology has grown by leaps and bounds and today, 
nanotechnology ranges from improvisation of conventional devices such as 
semiconductor wires and transistors to completely new approaches like molecular 
self-assembly.  
Bio-nanotechnology or nano-biotechnology is a subset of nanotechnology that 
involves using concepts of nanotechnology to monitor and engineer biological 
systems (Gazit, 2007). Being able to manipulate biomolecules on the nanoscale has 
the potential to revolutionalise medical sciences and for this reason, today, 
nanotechnology approaches are being developed for diagnostic as well as 
therapeutic applications in medicine. Nano-scale machines are being designed to 
perform specific biological tasks, such as monitoring the environment of living 
cells or to seek out and destroy cancerous cells. Nano-scale sensors for diagnosing 
diseased states and vehicles for controlled drug release are under development. 
Nanoparticles are also being developed as scaffolds for the presentation of 
epitopes to elicit immune responses in mammalian systems.  
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1.2 Nanoparticles  
Generally, nanotechnology works with materials with at least one dimension in the 
range of 1-100 nm. Examples of such nanoparticles and their potential applications 
are given in Table 1.1.  
Nanoparticle Description Applications 
Fullerenes Molecules composed entirely of 
carbon such as carbon nano-
tubes (cylindrical) or 
buckyballs (spherical) 
Semiconductors (Dekker, 
1999); Drug delivery vehicles 
and imaging contrast agents 
(Bakry et al., 2007) 
Liposomes Lipid-based liquid crystals Drug and vaccine delivery 
vehicles (Gregoriadis, 1995) 
Nanorods Elongated objects made of 
silicon, gold or inorganic 
phosphate 
Semiconductors for solar cells, 
detectors for biomolecules 
(Sadeghi, 2012) 
Dendrimers Highly branched structures 
made of natural polymers 
Drug delivery vehicles and 
imaging contrast agents 
(Dykes, 2001) 
Magnetic 
Nanoparticles 
Superparamagentic iron oxide 
or iron platinum nanoparticles  
High-density data storage (Lu 
et al., 2007); Tumour 
destruction via heating 
(hyperthermia) (Armijo et al., 
2012) 
Quantum 
Dots 
Semiconductor nano-crystals Imaging of live cells, in  situ 
tissue profiling (Xing and Rao, 
2008) 
Viruses Natural nanoparticles of 
various shapes and sizes that 
infect bacteria, plants and 
animals 
Building blocks for multi-
layered arrays, biomedical 
imaging, novel vaccines and 
delivery vehicles (Manchester 
and Steinmetz, 2009) 
Table 1.1 Examples of organic and inorganic materials being developed for 
applications in nanotechnology. 
Nanotechnology is still quite a new field and a number of unexplored avenues 
exist. New nanoparticles are constantly being developed expanding the breadth of 
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this field. The next section discusses the development of viruses for use in 
nanotechnology and the progress that has been made so far. 
1.3 Viruses in nanotechnology 
For over a hundred years, viruses have been looked at as ‘disease-causing entities’ 
and studies on viruses have mainly focused on understanding viral infection to 
develop strategies for prevention and treatment of viral diseases. However, the last 
20 years have seen a shift in this paradigm and more and more studies on the use 
of viruses in nanotechnology have been published. Today, several animal viruses, 
plant viruses and bacteriophages are being developed for beneficial uses in a range 
of applications from material sciences to medicine.  
Viruses are the most abundant biological entities on earth and exist in various 
shapes and sizes, ranging from 17 to 700 nm [smallest virus known: Porcine 
circovirus (Finsterbusch and Mankertz, 2009); largest virus known: Megavirus 
chilensis (Arslan et al., 2011)], thereby presenting a whole library of viral 
nanoparticles to choose from. Thanks to extensive studies on viral diseases, there 
is a wealth of information available about the biological, chemical and physical 
properties of viruses, including crystallographic structures of the particles of some, 
allowing precise genetic and chemical modifications to be made to the viral 
capsids.  
In addition to their nano-scale size, there are a number of properties that make 
viruses ideal for use in nanotechnology. Firstly, viruses have the ability to self-
assemble into highly regular particles. Viruses usually have very simple structures 
consisting of multiple copies of one or more type of subunit arranged in either 
icosahedral (for spherical viruses) or helical (for rod-shaped viruses) symmetry. 
The repetitive structure of the viral capsid serves as a platform for presentation of 
multiple copies of a peptide or for attachment to multiple sites in a 
macromolecular system. The fact that virus capsids are homogeneous makes it 
easy to modify them, both chemically and genetically, in a predictable manner. 
A property that puts viral nanoparticles above other available nanoparticles is 
their plasticity. Viral capsids are designed for protection of encapsulated nucleic 
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acids and so, the capsids are very robust. But at the same time, capsids are 
designed to disassemble under certain physiological conditions to release their 
genome to initiate infection. This means that the capsid has the potential to both 
survive in harsh environments (for instance a range of temperatures, pH 
conditions and in a variety of solvents) and to break apart releasing its cargo when 
needed.  
Viruses are naturally occurring, which makes them both bio-compatible and 
biodegradable. This is very important for applications in mammalian systems 
where it is essential that nanoparticles are cleared from the system after they have 
served their purpose. Toxicity and bioavailability studies of several viruses are 
being undertaken. From a human health perspective, bacteriophages and plant 
viruses are safer to use in medicine compared to animal viruses, due to their 
inability to replicate in mammalian systems. However, detailed risk assessments 
would still need to be carried out.   
A significant advance in the field of viruses in nanotechnology has been the ability 
to produce virus-like particles (VLPs) by expression of viral coat proteins in 
heterologous systems. VLPs are devoid of genomic nucleic acid, rendering them 
non-infectious. This reduces bio-safety concerns associated with their use, 
extending the range of their applications. Also, since VLPs do not have to be 
functional in a virological sense, i.e. they don’t have to be capable of causing an 
infection, a more extensive range of modifications can be made to the capsid. The 
only factor that would need to be considered is that the modifications do not 
interfere with the ability of coat proteins to assemble into particles.  
Last but not the least, viruses are easy to produce and purify. When expressed in 
their natural host, viruses replicate and assemble in vivo often resulting in high 
titres of virions. In addition, viruses and VLPs can be produced in heterologous 
hosts to high levels. For example, cowpea chlorotic mottle virus (CCMV) VLPs can 
be produced using the yeast-based Pichia pastoris heterologous expression system 
to levels of 0.5 g/kg wet cell mass (Brumfield et al., 2004). Bacteriophage M13 
yields 200 mg of particles from a 1 litre cell culture (Mao et al., 2004).  
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Virus-based nanoparticles can be modified at three levels to impart various 
applications: the exterior surface, the capsid interface and the interior (Douglas 
and Young, 2006; Young et al., 2008). The exterior surface of viral capsids provides 
for the multivalent display of ligands and peptides for use in 2D/3D arrays and as 
novel vaccines (Blum et al., 2011; Smith et al., 2009). The interface can be 
manipulated to control capsid architecture to generate particles for use as bio-
templates (Bothner et al., 2005; Brumfield et al., 2004). The interior cavity of viral 
nanoparticles, especially in case of empty particles, provides a constrained 
environment where the interior surface can direct attachment or nucleation of 
nano-materials (Douglas and Young, 1998). The interior space can also be filled 
with contrast agents for use in imaging or desired cargos for delivery to specific 
locations in a biological system (Aljabali et al., 2010a).  
Modifications to the viral capsid can be introduced chemically (by conjugation to 
surface residues or by incubation under different reaction conditions) or 
genetically (by making mutations in the nucleotide sequence encoding viral coat 
proteins). Often, both chemical and genetic approaches are used together. For 
instance, in an approach to develop adenovirus particles for targeted gene therapy, 
capsids were first genetically modified to incorporate cysteine residues at solvent-
exposed positions and subsequently chemically modified by covalent coupling of 
incorporated cysteines to the ligand transferrin (Kreppel et al., 2005).  
Table 1.2 shows examples of viruses that have been developed for potential uses in 
nanotechnology. The focus of this thesis will be the further development of cowpea 
mosaic virus (CPMV) VLPs for such applications.  
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Virus  Potential applications 
Adenovirus  Gene delivery vehicles for treatment of 
cancer (Bachtarzi et al., 2008) 
Brome mosaic virus  Scaffold for gold nanoparticles (Chen et al., 
2005); Semi-conductor quantum dots (Dixit 
et al., 2006) 
Canine parvovirus  Tumour targeted drug delivery (Singh et al., 
2006)  
Cowpea chlorotic mottle virus  Nano-reaction vessel; Delivery vehicle 
(Douglas and Young, 1998) 
Cowpea mosaic virus  2D/3D arrays (Blum et al., 2011); Quantum 
dot decoration (Medintz et al., 2005); 
Imaging agents (Lewis et al., 2006) 
Tobacco mosaic virus  Carrier for immunogenic epitopes (Smith et 
al., 2009); Nanowires (Niu et al., 2007)  
Bacteriophage Q-beta Delivery vehicle for DNA/RNA aptamers 
(Lau et al., 2011) 
Bacteriophage M13 Nanotubes for batteries (Nam et al., 2008) 
Bacteriophage MS2 Imaging contrast agents (Meldrum et al., 
2010) 
Table 1.2 Viruses exploited in nanotechnology. Examples of some spherical and 
rod-shaped viruses that are being developed for various applications in 
nanotechnology have been presented in the above table.  
1.4 Cowpea mosaic virus (CPMV) 
CPMV is a non-enveloped plant virus that belongs to the Comoviridae family and is 
the type member of the genus Comovirus. It was first identified and characterised 
by H. O. Agrawal (1964). Based on similarities in capsid structure, genome 
organisation and replication strategies, comoviruses are thought to be 
evolutionarily related to mammalian picornaviruses (family Picornaviridae), which 
include important pathogens such as the foot-and-mouth disease virus, poliovirus 
and rhinovirus (Lin and Johnson, 2003).   
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1.4.1 CPMV infection 
CPMV naturally infects legumes such as the cowpea plant (Vigna unguiculata; 
family Leguminosae) and soybean (Glycine max; family Fabaceae). Upon infection 
in cowpea, CPMV causes yellowing of leaves resulting in a mosaic pattern (Figure 
1.1a). Other symptoms include a decrease in leaf area, reduced flower production 
and yield losses of up to 75%. CPMV is mechanically transmissible and in nature, 
CPMV is transmitted by crysomelid beetles (family Coleoptera).  
For a number of years, many studies on CPMV were conducted using cowpea 
mesophyll protoplasts (Hibi et al., 1975). However, today, with the advent of 
Agrobacterium-mediated plant transformation techniques for the efficient 
establishment of infections (Liu and Lomonossoff, 2002), CPMV is most easily 
studied in its experimental host Nicotiana benthamiana. CPMV infection in N. 
benthamiana is typified by crinkling of leaves and vein clearing in young leaves 
(Figure 1.1b).    
   
 
Figure 1.1 CPMV infections in its natural host cowpea (a) and experimental host 
N. benthamiana (b). In cowpea, chlorotic spots with diffuse borders (diameter of 1-
3 mm) are produced in inoculated primary leaves. Trifoliate leaves develop a 
bright yellow mosaic. Plants do not show necrosis. In N. benthamiana, leaves show 
crinkling and vein clearing.   
CHAPTER 1 
 
  23 
 
1.4.2 CPMV capsid 
CPMV exists as isometric particles with T=1 (pseudo T=3) symmetry and a 
diameter of 28-30 nm. Each virion comprises 60 copies of two coat proteins: the 
Large (L) coat protein (374 residues) with two β-barrel domains and the Small (S) 
coat protein (213 residues) with one β-barrel domain. The three domains form one 
asymmetric unit, sixty of which are arranged in icosahedral symmetry to form the 
CPMV capsid (Figure 1.2).  
Figure 1.2 CPMV capsid. (a) Asymmetric unit comprising the Large coat protein 
with two domains (in green and red) and the Small coat protein with one domain 
(in blue). (b) 60 asymmetric units are arranged in icosahedral symmetry to form 
the CPMV capsid. Images from VIPER database, Scripps Research (Shepherd et al., 
2006).  
The structure of the CPMV capsid is known to atomic resolution (Lin et al., 1999; 
Stauffacher et al., 1987). The only portion of the capsid that is not visible in the 
crystal structure is a peptide of 24 amino acids at the carboxyl-terminus of the S 
coat protein (residues 190-213). This peptide is exposed on the surface of the virus 
and is frequently lost by proteolysis at Leucine 189 (Lomonossoff and Johnson, 
1991; Taylor et al., 1999). Loss of the peptide occurs during late stages of a natural 
infection and, though not affecting the stability of the particles, is thought to 
increase the specific infectivity of virions (Niblett and Semancik, 1969, 1970).  
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Amongst the 24 residues in the C-terminal peptide are several positively charged 
amino acids (four arginines and two lysines) contributing to its pI of 11.9. Loss of 
this peptide results in loss of both mass and positive charge, resulting in faster 
migration of particles towards the anode upon electrophoresis. Hence, C-
terminally processed particles are referred to as CPMVfast. Conversion of CPMV 
from its slow to its fast form takes place through proteolysis, either naturally by 
ageing or synthetically using chymotrypsin (Niblett and Semancik, 1969).  
Analysis of deletion mutants shows that the 24 amino acid peptide plays a role in 
packaging of RNA (Taylor et al., 1999) and in suppression of virus-induced 
silencing (Canizares et al., 2004), both of which are important during the early 
stages of infection; loss of the peptide during late stages of infection does not have 
any deleterious effects on particle viability. Recent studies have shown that the 
presence of the intact peptide inhibits internal mineralization of CPMV VLPs 
suggesting a possible role of the peptide in controlling permeability of the CPMV 
capsid (Sainsbury et al., 2011).  
1.4.3 CPMV genome 
The CPMV genome consists of two separately encapsidated positive-sense single 
stranded RNA molecules: RNA-1 and RNA-2 (Figure 1.3). RNA-1 is 5889 bases long 
and encodes the replication machinery of CPMV, including the RNA-dependent 
RNA polymerase and the helicase. RNA-2 is of 3481 bases in length and encodes 
proteins essential for cell-to-cell movement and systemic spread of the virus, 
namely the movement proteins (48K and 58K) and coat proteins (L and S). Both 
RNAs are polyadenylated and possess a small (28 amino acids) genome-linked 
viral protein (VPg) covalently attached to their 5’ end (Hull, 2009).  
Both RNA-1 and RNA-2 are required for an infection since RNA-2 depends on RNA-
1 for its replication and RNA-1 depends on RNA-2 for production of coat proteins 
for its encapsidation. 
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Figure 1.3 CPMV genome. The CPMV genome consists of two plus-sense ssRNA. 
RNA-1 encodes a 32 kDa proteinase co-factor (ProC); a 58 kDa helicase; a 2 kDa 
genome-linked viral protein (VPg); a 24 kDa viral proteinase (Pro) and a 87 kDa 
RNA-dependent RNA polymerase (polymerase). RNA-2 encodes the 58 kDa and 48 
kDa viral movement proteins (MP) and the large and small coat proteins (L and S). 
The circle at the 5’ end denotes covalently-attached VPg and ‘AAAA’ at the 3’ end 
denotes the poly-A tail.   
Purified preparations from a natural CPMV infection can be fractionated into three 
kinds of particles on the basis of their buoyant density (van Kammen, 1967) 
(Figure 1.4). These are: RNA-1 containing particles (Bottom component), RNA-2 
containing particles (Middle component) and empty particles (Top component). 
The proportion of Top component in a natural infection is usually less than 10%, 
while Middle and Bottom are found in approximately equal amounts.  
The natural occurrence of Top particles shows that the presence of RNA is not 
necessary for capsid formation. However, comparison of the pressure stability of 
the three kinds of particles shows that the presence of RNA stabilizes particles. 
Middle and Bottom particles were found to be 50% more stable than Top at a 
pressure of 2.5 kbar (Da Poian et al., 1994). It was also found that the capsid 
proteins continued to be bound to the RNA even after protein-protein contacts 
were broken by pressure, highlighting the strength of these RNA-protein 
interactions.  
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Figure 1.4 Three components of CPMV. CPMV can be separated into its three 
components using a density gradient. All three components have identical protein 
compositions but differ in their RNA contents. The Bottom component comprises 
RNA-1 containing particles, Middle comprises RNA-2 containing particles and Top 
comprises RNA-free/empty particles of CPMV. Bands visualised on the gradient 
are shown along with cartoons of the corresponding particles. 
1.4.4 Translation in CPMV 
Expression of CPMV RNA occurs via the production and subsequent processing of 
polyproteins, a strategy common amongst viruses. Using the host cell machinery, 
RNA-1 is translated from a start codon AUG at position 207 to produce a single 200 
kDa polyprotein, which is processed in cis by the RNA-1 encoded proteinase, 24K 
to generate proteins for RNA replication. By contrast, initiation of translation of 
RNA-2 occurs at two positions, namely at AUG 161 and at AUG 512 (Holness et al., 
1989), generating polyproteins of 105 kDa and 95 kDa respectively. As both these 
start codons are in-frame, the polyproteins generated as a result of each initiation 
are cleaved by 24K to yield: (i) the movement protein of 58 or 48 kDa depending 
on the site of initiation and (ii) the coat protein precursor VP60. VP60 is 
subsequently cleaved by 24K to generate coat proteins L and S (Franssen et al., 
1982). 
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A 32 kDa proteinase co-factor (32K) encoded by RNA-1 appears to be needed for  
processing at the junction between the 58K/48K proteins and VP60 (Vos et al., 
1988). The reason for the presence of two start codons is not fully understood, 
although it is speculated to be a mechanism for regulation of translation. 90% of 
the time, translation is initiated from AUG 512 and is thought to be a result of both 
reinitiation and leaky scanning by the ribosomes (Holness et al., 1989).   
1.4.5 Replication in CPMV 
CPMV replicates in the cytoplasm in small membranous vesicles produced from 
the endoplasmic reticulum (ER) (Carette et al., 2000).  Replication occurs via a 
double-stranded RNA replicative intermediate (Lomonossoff et al., 1985). Viral 
RNA is first transcribed into a negative-sense RNA complement, which is used as a 
template for the formation of positive-sense progeny RNA. Newly synthesised 
progeny RNA are either used as mRNA for translation of viral proteins or are 
packaged within capsids to form mature virions. To the 5’ untranslated regions 
(UTRs) of both RNA strands in the replicative intermediate is attached a VPg (28 
amino acid protein encoded by RNA-1), which is thought to have a role in initiation 
of RNA synthesis (Lomonossoff et al., 1985).  
RNA-1 replication occurs in cis whereas RNA-2 is replicated in trans (Van 
Bokhoven et al., 1993). Consequently, RNA-1 is capable of replicating 
independently (Goldbach et al., 1980). Work done in cowpea protoplasts suggests 
that replication and translation of CPMV RNAs are tightly linked (Wellink et al., 
1994). Moreover, analysis of RNA-1 mutants shows that RNA-1 molecules function 
as a template only for its own proteins (Van Bokhoven et al., 1993).  
Translation of the N-terminal of the 58K protein has been shown to be necessary 
for replication of RNA-2 as removal of AUG 161 or disruption of the reading frame 
downstream of this start codon effectively eliminates replication of RNA-2 
(Holness et al., 1989; Van Bokhoven et al., 1993). In addition to the N-terminal 
region of 58K, it has been shown that both the 5’ and 3’ UTRs of RNA-2 are 
essential and sufficient for its replication (Canizares et al., 2006; Eggen et al., 1989; 
Rohll et al., 1993).   
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1.4.6 Assembly of CPMV particles 
Although the structure of CPMV is known to atomic resolution, the mechanism by 
which sixty copies of the L and S coat proteins come together to form each capsid 
remains unknown. Reconstitution of CPMV particles in vitro has not been possible  
till date due to the lack of solubility of L and S in absence of strong denaturants 
(Wu and Bruening, 1971). In vivo, CPMV VLPs have been generated by co-
expression of L and S from separate promoters in cowpea protoplasts (Wellink et 
al., 1996) and Spodoptera frugiperda insect cell expression systems (Shanks and 
Lomonossoff, 2000). However, in both cases, the yields of assembled particles 
obtained were low suggesting the requirement of other viral or host proteins for 
efficient assembly.  
Given that during a natural CPMV infection, L and S coat proteins are generated 
upon processing of the RNA-2-encoded protein VP60 by the RNA-1-encoded 
proteinase 24K (Franssen et al., 1982), Saunders et al. (2009) attempted to express 
VLPs by mimicking this situation in vivo and indeed, co-expression of VP60 and 
24K, first in insect cells and subsequently in plants, resulted in efficient generation 
of empty VLPs of CPMV, abbreviated as eVLPs. eVLPs thus generated appeared to 
be identical to wt CPMV from the outside and devoid of RNA on the inside, 
resembling natural Top component.  
Furthermore, co-expression of VP60 and wt RNA-1 resulted in production of 
particles containing RNA-1 (Saunders et al., 2009), demonstrating the ability of 
24K to cleave VP60 both when expressed independently and as a part of RNA-1. 
This work was the first demonstration of efficient production of CPMV VLPs 
without an infection. eVLPs have been discussed in detail in Section 1.8.  
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1.5 Applications of CPMV in nanotechnology  
CPMV was the first plant virus to be successfully developed as a system for display 
of foreign peptides (Porta et al., 1994; Usha et al., 1993). Subsequently, CPMV has 
been used extensively as a template for both genetic and chemical modifications to 
develop CPMV as a nanoparticle for various applications in medicine and in 
electronics (Steinmetz et al., 2009), such as vehicles for drug delivery, carriers for 
imaging agents, templates for mineralization and templates for immobilization of 
active enzymes (Aljabali et al., 2012a; Aljabali et al., 2010b; Aljabali et al., 2012b; 
Steinmetz, 2010).  
CPMV attracts attention as a candidate for use in nanotechnology for a number of 
reasons. CPMV particles can be readily obtained through infection of plants. Yields 
of 1 gram of CPMV per kilogram of infected leaves are obtained routinely in 
cowpea plants. The virus capsid is stable over a variety of reaction conditions, such 
as moderately high temperatures of around 60 °C, across the range of pH 4 – 9 and 
in a variety of organic-solvent mixtures. This level of stability increases the range 
of modifications that can be made to CPMV through chemical reactions. The 
availability of the crystal structure of CPMV (Lin et al., 1999) and infectious clones 
of its RNA (Liu and Lomonossoff, 2002) mean that precise changes to the CPMV 
capsid can be introduced both genetically by modification of cDNA sequences and 
chemically by modification of amino acids exposed on the surface of the capsid.  
1.5.1 Genetic modification of CPMV 
CPMV particles have been genetically modified successfully for presentation of 
foreign peptides including epitopes (Lomonossoff and Hamilton, 1999; Porta et al., 
2003; Porta et al., 1996; Porta et al., 1994). Using the crystal structure of CPMV, 
sites for peptide insertion were determined such that the inserted peptides were 
surface exposed yet did not interfere with particle assembly.  In most cases, the 
foreign peptide was inserted into the most exposed loop of the virus surface: the 
βB-βC loop of the S coat protein. The chimeric particles displayed 60 copies of the 
inserted peptide on its surface. An assessment of immunological properties of 
chimeric particles revealed CPMV’s ability to stimulate protective immunity 
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demonstrating the potential utility of CPMV as a vaccine (Dalsgaard et al., 1997). 
However, there are some limitations on the sizes and charges of peptides that can 
be stably incorporated in CPMV capsids without affecting virus assembly, 
transmissibility and yield (Porta et al., 2003).     
1.5.2 Chemical modification of CPMV 
CPMV particles have been chemically modified extensively by addressing 
functional molecules on its exterior surface. For instance, surface lysines of CPMV 
have been conjugated to peptides that promote specific mineralization of metals 
such as FePt and CoPt, to generate mixed-metal nanoparticles for applications in 
nanoelectronics (Aljabali et al., 2010b). Similarly, carboxylates exposed on the 
surface of CPMV have been labelled with drugs such as doxorubicin to develop 
CPMV for drug delivery applications (Aljabali et al., 2012b).  
Genetic and chemical modifications have been combined in certain cases to achieve 
a higher degree of flexibility. For instance, in an approach to develop CPMV as 
building blocks for use in material sciences, cysteine residues were genetically 
introduced on the outer surface of the CPMV capsid for subsequent chemical 
modification with thiol-selective moieties (Wang et al., 2002). 
A particular attraction to use of plant viruses is that they are non-infectious to 
animals and humans and so can be developed for application in mammalian 
systems with reduced bio-safety concerns. However, toxicity and bio-availability 
need to be determined before deploying any nanoparticle for applications in 
medicine. In vivo studies on CPMV in mice have shown CPMV to be safe, non-toxic 
and naturally bio-available (Rae et al., 2005; Singh et al., 2007). When CPMV was 
administered to mice by oral or intravenous inoculation, CPMV was found to be 
stable in the gastrointestinal tract and was found to disseminate to a wide variety 
of tissues throughout the body, including the spleen, kidney, liver, lung, stomach, 
small intestine, lymph nodes, bone marrow and brain (Rae et al., 2005). CPMV 
particles were found to clear rapidly from blood plasma, falling to undetectable 
levels and accumulating in the liver and spleen by the end of 30 minutes (Singh et 
al., 2007). This process can be slowed down if desired, as in the case of specific 
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targeting to cells or tissues, by coating the particles with polyethylene glycol (PEG) 
or other immune masking agents (Raja et al., 2003). CPMV is internalized in 
endothelial cells through binding to vimentin, the intermediate filament protein 
present on the surface of endothelial cells (Koudelka et al., 2009) 
Over the past twenty years, publications on the development of CPMV as a 
potential vaccine, extensive chemical modifications to the CPMV capsid and studies 
on the bio-availability of CPMV have highlighted the promise that CPMV holds for 
diverse applications in nano-technology and nano-medicine.  
1.6 Limitations with wild-type (wt) CPMV  
Despite several advantages of CPMV, there are some limitations with the use of 
naturally occurring CPMV particles. Firstly, the presence of RNA within CPMV 
capsids leaves little room for encapsulation of desired cargos, such as drugs and 
nucleic acids, limiting its application as a delivery vehicle or nano-container. 
Secondly, CPMV from a natural infection retains its ability to infect plants and 
spread in the environment. The use of such particles raises bio-safety concerns.  
To address the problem of bio-containment, there have been some attempts to 
inactivate viral RNA in capsids by irradiation with ultraviolet (UV) light (Langeveld 
et al., 2001; Rae et al., 2008). Attempts have also been made to eliminate viral RNA 
by changing pH conditions (Ochoa et al., 2006)  or by chemical treatment (Phelps 
et al., 2007). However, all these processes have to be carefully monitored as they 
risk altering the structural properties of the particles. Further, the processes that 
rely on inactivation of RNA do not actually remove RNA from the particles, posing 
limits on the space available within the capsid for loading.   
There is also a regulatory concern about the introduction of nucleic acids into 
humans. Although CPMV cannot infect mammals, there is a possibility that its RNA 
could replicate if introduced into individual cells, given the similarities between 
CPMV and mammalian picornaviruses.  
A related problem with the use of infection to produce CPMV particles is that only 
particles which are functional viruses, i.e. competent in terms of genome packaging 
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and cell-to-cell movement, can be produced in this way.  Porta et al (2003) found 
that in order to maintain the ability to systemically infect the plant and produce 
high yields of chimeric particles, inserted sequences were strictly required to be 
shorter than 30 residues and have a pI below 8. This greatly restricts the range of 
modifications that can be introduced genetically, further limiting applications of 
these particles.  
Given the limitations with the use of wt CPMV for applications in nanotechnology 
and promising data on production of eVLPs by processing of VP60, it was 
recognised that eVLPs have the potential to be a superior substitute for wt CPMV 
for applications in nanotechnology. The next section introduces the expression 
system used for production of eVLPs in plants.  
1.7 Plant expression  
Plants are being developed as a commercial platform for production of 
recombinant proteins since they offer several advantages over current established 
bacterial, yeast or animal cell production systems. These include high biomass, 
ease of scalability, cost effectiveness and a low risk of contamination with 
endotoxins or human pathogens (Fischer et al., 2004; Ma et al., 2003; Twyman et 
al., 2003). Unlike prokaryotic expression systems, plants are capable of introducing 
eukaryotic post-translational modifications such as glycosylation and hence, can be 
used for expression of complex eukaryotic-derived proteins. Another advantage 
with the use of plants for production of biopharmaceuticals is that products 
expressed in edible plant organs can be administered directly as unprocessed plant 
material (Sala et al., 2003).  
Work described in this thesis uses plants for expression of numerous proteins 
including reporter proteins such as the green fluorescent protein (GFP), human 
antibodies and enzymes, viral proteins and virus-like particles. In all cases, 
expression was carried out in the model plant Nicotiana benthamiana. Two 
approaches have been used for expression of heterologous proteins in N. 
benthamiana: (i) stable transformation of the genome of the plant; (ii) transient 
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transformation of plant tissue. Both approaches involve vector-mediated gene 
transfer into plant cells using the soil bacterium Agrobacterium tumefaciens.  
A. tumefaciens is a pathogenic bacterium that has the ability to transfer genetic 
material from its tumour-inducing plasmid (Ti plasmid) to its plant host. Once 
within the plant cell, this transferred DNA (T-DNA) targets the nucleus where it 
eventually integrates into the host genome (Figure 1.5). This allows the T-DNA to 
be transcribed by the plant cell as if it were a part of the normal complement of 
plant genes (Gelvin, 2005). The natural ability of Agrobacterium to transfer DNA 
into plants has been exploited in biotechnology for genetic engineering of plants. 
The Ti plasmid of the agrobacteria is disarmed by deletion of its T-DNA region and 
the T-DNA component is carried on another plasmid called the binary plasmid. The 
binary plasmid has the following features:  
(i) The ability to replicate in A. tumefaciens; 
(ii) Origin of replication for high copy number in Escherichia coli (ColEI);  
(iii) T-DNA region with the natural border sequences referred to as the left 
border (LB) and the right border (RB). Genes to be transferred are cloned in 
between the left and right borders along with their promoters, such as the 
35S promoter from cauliflower mosaic virus (CaMV) and terminators, such as 
nopaline synthase (nos) terminator for expression in plants; 
(iv) A selectable marker gene for selection of transformed bacteria and in case of 
stable transformation, for selection of transformed plant cells. For instance, 
gene encoding the neomycin phosphotransferase (npt) II or III which confers 
resistance to kanamycin.  
N. benthamiana was selected as the host as it is particularly amenable to agro-
infiltration, with negligible damage being caused to the inoculated tissue during 
the process. This is particularly beneficial in case of GFP where wound-derived 
auto-fluorescence can interfere with quantification of expression (Sainsbury et al., 
2008). For transient expression of proteins, Agrobacterium cultures are infiltrated 
into leaves of 3-4 week old plants. The gene of interest is only expressed in the 
infiltrated region from the time of infiltration until the leaf reaches senescence. 
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Transient expression enables quick testing of constructs before undertaking the 
time-consuming process of leaf disc regeneration for stable expression.  For stable 
expression of proteins, leaf discs are dipped in Agrobacterium cultures and 
regenerated on agar to obtain transgenic plants. Since the gene of interest is 
incorporated in the genome, it is passed on to future generations. 
 
Figure 1.5 Agrobacterium-mediated transformation of plant cells (Gelvin, 
2005). In nature, A. tumefaciens transfers its T-DNA to the plant cell with the help 
of virulence proteins. Virulence proteins target the T-complex to the nucleus of the 
plant cell and mediate its integration into the plant genome. For genetic 
engineering applications, the Ti plasmid of Agrobacterium is modified so that it 
lacks the T-DNA region but still carries the virulence genes. Genes of interest are 
presented on another plasmid, called the binary plasmid.  
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Over time, a number of strategies have been devised by researchers to improve 
expression of recombinant proteins in plants. A successful approach to enhance 
both the yield and purity is sub-cellular compartmentalization of expressed 
proteins. Proteins can be expressed in plants with signals that target proteins to 
specific compartments of the cell, such as the vacuole, chloroplast or apoplast or to 
the endoplasmic reticulum (ER)-secretory pathway. Trafficking proteins to a 
secretary pathway not only allows complex post translational modifications but 
also often increases protein stability and hence their levels of accumulation (Desai 
et al., 2010; Fischer et al., 2004).  
Another approach to enhance protein expression in plants involves use of virus-
encoded proteins for suppression of post-transcriptional gene silencing (PTGS). 
PTGS is a well-known phenomenon in plants for regulation of gene expression at 
the post-transcriptional level. PTGS is triggered by presence of replicating viruses, 
transgenes and transposons. It is mediated by small RNAs that bind to mRNAs in a 
sequence-specific manner leading to their degradation, thus hampering foreign 
gene expression (Baulcombe, 2002).  
PTGS is thought to have evolved in plants as a mechanism for defence against 
viruses (Waterhouse et al., 2001). As counter-defence, viruses have evolved to 
express suppressors of silencing (Vance and Vaucheret, 2001; Voinnet et al., 1999). 
Viral suppressors of silencing are proteins that interfere with various steps of the 
silencing pathway leading to its suppression and hence, an up-regulation of gene 
expression. For this reason, suppressors of silencing are exploited in biotechnology 
for enhancement of expression. Suppressors of silencing that have been used to 
effectively prevent/reverse PTGS include HcPro from potyviruses (Anandalakshmi 
et al., 1998), P19 from tombusviruses (Voinnet et al., 2003) and 2b protein from 
cucumber mosaic virus (Brigneti et al., 1998). The work described in this thesis 
has been conducted using P19, where required, for enhancement of expression. 
1.7.1 Plant viral vectors  
Plant viral vectors exploit the natural ability of plant viruses to replicate and 
express proteins in plant cells. Such vectors deploy engineered viral genomes to 
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deliver genes to plants for transient expression of heterologous proteins, with or 
without causing an infection. The use of viruses has the advantage that any 
sequence inserted into a virus vector is highly amplified during replication. Also, 
because the gene does not get incorporated in the plant genome, it does not form a 
heritable trait and is thus contained.   
First-generation viral vectors were based on replication-competent full-size 
genomes, with the gene of interest being expressed in addition to all other genes of 
the functional virus. This ‘full-virus’ strategy had several limitations: (i) there were 
size limits on the sequences that could be inserted while retaining viability; (ii) the 
inserted sequences were susceptible to mutations during virus replication; and 
(iii) there were bio-containment concerns since the vectors encoded fully 
functional viruses. These limitations led to the design of second-generation viral 
vectors based on deconstructed viral genomes. These vectors only encoded viral 
elements essential for efficient expression of foreign sequences. Genes essential for 
virus replication, assembly and movement, if required, were supplied in trans 
(Gleba et al., 2007).  
Over the last two decades, CPMV has served as the basis for the development of a 
variety of replicating (based on the full-virus as well as the deconstructed virus 
strategy) and non-replicating virus vectors suitable for the production of 
heterologous proteins in plants (Sainsbury et al., 2010a). Significant milestones in 
its development as an expression vector have been summarized in the section 
below.  
1.7.2 CPMV-based plant expression systems 
CPMV-based expression systems initially focused on modifying the sequence of 
RNA-2 to express foreign genes along with full-length or deleted versions of RNA-2 
(Canizares et al., 2006; Sainsbury et al., 2008). To achieve amplification of 
expression, modified RNA-2 vectors were co-inoculated with wt RNA-1 (to provide 
the machinery for replication and polyprotein processing) and in case of vectors 
based on deleted RNA-2, also with a suppressor of silencing. The replicating viral-
vector approach led to high levels of expression but had several disadvantages. 
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Firstly, vectors based on full-length RNA-2 were capable of causing an infection 
thereby raising bio-containment issues. Secondly, inserted sequences were often 
lost upon systemic spread of the virus. In case of heteromeric proteins encoded on 
two separate RNA-2 vectors, segregation of vectors occurred upon systemic spread 
and hence, co-expression was restricted to the inoculated tissue (Sainsbury et al., 
2008).  
To overcome the above problems, vectors based on deleted RNA-2 were modified 
to abolish their replication by introducing two mutations in the 5’ UTR of RNA-2. 
Mutations of the start codon at position 161 (AUG161) and another out-of-frame 
start codon at position 115 (AUG115) destroyed the ability of the vector to 
replicate and unexpectedly, led to a massive increase in protein expression levels 
in transient expression studies (Sainsbury and Lomonossoff, 2008). Since high 
level expression was achieved due to enhanced translation, this system was named 
CPMV- ‘Hypertrans’ or CPMV-HT. The CPMV-HT system was subsequently refined 
through the creation of the ‘pEAQ’ series of expression plasmids (Sainsbury et al., 
2009). Using these plasmids, the gene of interest can be positioned between the 
modified 5’ UTR and the 3’ UTR of RNA-2 in a single step using either restriction 
enzyme-based cloning or GATEWAY® recombination.  
Today, the CPMV-HT system has been successfully used for high-level expression 
of a number of proteins, including single proteins (such as GFP), heterometric 
proteins (such as IgG antibodies), active enzymes (such as the human gastric 
lipase) and complex virus-like particles (such as bluetongue virus VLPs). While 
existing CPMV-HT vectors provide a quick, easy and inexpensive eukaryotic 
transient expression system, there is still a need to engineer this system for 
controlled simultaneous expression of multiple proteins in transient systems and 
stable expression of proteins in transgenic systems.   
Although CPMV eVLPs were first expressed in insect cell expression systems, 
higher expression levels were achieved in plants (Saunders et al., 2009). Therefore, 
subsequent production of eVLPs was carried out in plants by deploying the CPMV- 
HT expression system to achieve high-level expression of VP60 and 24K.  
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1.8 CPMV empty virus-like particles or eVLPs 
The availability of eVLPs has added a whole new dimension to applications of 
CPMV in nanotechnology since it is now possible to internally modify CPMV 
particles as well as modifying their external surface. eVLPs produced by co-
expression of VP60 and 24K (Section 1.4.6) have a number of advantages over wt 
CPMV:  
(i) There are no bio-safety concerns involved with the use of eVLPs since they 
are RNA-free. 
(ii) The space inside eVLPs is available for encapsulation of desired cargos, such 
as drug molecules, metal ions, nucleic acids, etc. 
(iii) eVLPs do not need to be functional viruses since they are not produced via an 
infection and are not required to spread, encapsidate nucleic acid or 
disaassemble. So, the range of modifications that can be introduced 
genetically to both its inner and outer surfaces is potentially greater, being 
limited only by the need to maintain particle assembly. 
The ability to both encapsulate material within eVLPs and to chemically or 
genetically modify the external surface of the capsid opens up the possibility for 
use of eVLPs in targeted delivery of therapeutic/diagnostic agents. Encapsulation 
of agents such as drugs would have the additional advantage of protection from 
breakdown in plasma.  
Since eVLPs have only recently been available, not much is known about the 
optimum methods for loading of eVLPs. From studies on wt CPMV, it is known that 
CPMV particles become permeable to caesium ions at pHs above 7.5 (Lin and 
Johnson, 2003). Penetration of Cs+ is thought to occur via funnel-shaped pores at 
each 5-fold axis of CPMV. The diameter of the pore at the narrow-end, which is at 
the outer surface of the particle, is about 7.5 Å (Lin et al., 1999). Current loading 
strategies rely on simple diffusion of molecules through this pore. However, 
studies on controlling permeability of eVLPs are on-going. 
The potential application of eVLPs in magnetic hyperthermia for treatment of 
cancer has been demonstrated by generation of iron oxide-eVLPs (Aljabali et al., 
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2010a). Incubation of eVLPs with ferrous and ferric ions, under reaction conditions 
that favour formation of iron oxide, generates eVLPs loaded with iron oxide, which 
can then be modified chemically by attachment of targeting peptides to the surface 
of the eVLP capsid (Figure 1.6). Thermal and magnetic properties of iron oxide-
eVLPs generated in this way, are being characterised with the objective of 
developing them for heat-induced destruction of cancerous cells. Using a similar 
approach, eVLPs are also being developed for drug targeting by loading eVLPs with 
the cancer drug gemcitabine and chemically or genetically attaching targeting 
peptides to surface of the eVLP capsid (A. Aljabali, pers. comm.).    
 
Figure 1.6 Schematic diagram depicting development of iron oxide-eVLPs 
(Aljabali et al., 2010a). Ferrous and ferric ions (Mn+) are loaded into eVLPs by 
diffusion through the pore at the 5-fold axis. Reaction conditions are changed to 
favour formation of iron oxide (shown in grey), which remains trapped within 
eVLPs. Iron oxide-loaded eVLPs are subsequently chemically modified for 
targeting to specific cells. 
1.9 Aims of this thesis 
Work presented in this thesis was undertaken with the general objective of 
developing CPMV eVLPs for various applications in nanotechnology.  During the 
course of this work, two fundamental processes in the CPMV lifecycle – viral 
replication and encapsidation, were also studied. This was followed by work on 
developing CPMV-based expression systems for stable expression of proteins, 
including CPMV eVLPs themselves. The aims of my thesis are as follows: 
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(1) Production and characterisation of CPMV eVLPs 
Methods for large-scale expression and purification of eVLPs will be 
described along with quantitative and qualitative characterisation of eVLPs. 
This will aid genetic and chemical modifications of eVLPs for various 
applications in bio-nanotechnology.   
 
(2) Study of replication and encapsidation of RNA in CPMV  
The requirements for RNA packaging in CPMV will be presented based on 
work done with various mutants. In addition to providing an insight into 
replication and encapsidation of RNA in wt CPMV, this will help develop 
methods to package nucleic acids of choice within eVLPs, thereby increasing 
the range of its applications. 
 
(3) Creation of transgenic plants producing eVLPs 
Attempts to create stable transgenic lines of N. benthamiana for large-scale 
production of eVLPs will be described. Initial work done with GFP will be 
presented followed by work on other pharmaceutically valuable proteins and 
eVLPs. 
 
(4) Development of plant expression vectors based on CPMV RNA-1 
For use in transient and transgenic expression systems, generation of plant 
expression vectors based on CPMV RNA-1 will be described, along with their 
comparison with previously existing CPMV-HT vectors.   
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Chapter 2: Materials and Methods 
2.1 Media, Buffers and Solutions 
Recipes of growth media, buffers and solutions used for the work described in this 
thesis are summarised in Table 2.1. All chemicals and reagents were purchased 
from Sigma Aldrich (Suffolk, U.K.). 
Name Recipe 
Luria-Bertani (LB) media 10 g/L Bacto-tryptone, 10 g/L NaCl, and 5 g/L Yeast 
extract, pH adjusted to7 
LB-agar As LB with 10 g/L agar added 
SOC 20 g/L tryptone, 5 g/L yeast extract, 0.58 g/L NaCl, 
0.19 g/L KCl, 2.03 g/L MgCl2, 2.46 g/L magnesium 
sulphate7-hydrate, 3.6 g glucose 
Murashige and Skoog (MS)- 
agar 
0.8% w/v agar, MS salts, 3% sucrose in 3 mM MES 
buffer, pH adjusted to 5.7 
Pre-callusing media MS-agar as above with the following additional 
ingredients:        
1 µg/ml BAP (benzyl aminopurine); 0.1 µg/ml NAA 
(naphthalene acetic acid) and organic supplements 
(0.5 µg/ml nicotinic acid, 0.5 µg/ml pyridoxine, 0.5 
µg/ml thiamine, 0.5 µg/ml glycine) 
Rooting media 
 
Pre-callusing media with appropriate antibiotic 
selection and without the hormones BAP and NAA 
Antibiotics  100 µg/ml Kanamycin (in water) 
50 µg /ml Rifampicin (in methanol) 
500 µg/ml Carbenicillin (in water)  
MMA 10 mM MES pH = 5.6, 10 mM MgCl2, 100 μM 
Acetosyringone 
1 x Tris-borate EDTA (TBE) 89 mM tris-HCl pH=7.6, 89 mM boric acid, 2mM 
EDTA 
TEN/NET buffer 100 mM NaCl, 10 mM Tris-HCl pH = 7.5, 1 mM EDTA 
Table 2.1 Recipes of media, buffers and solutions 
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5 x Formaldehyde gel 
running buffer (FGRB) 
100 mM MOPS, 40 mM sodium acetate, 5mM EDTA, 
pH adjusted to 7 with 2N NaOH 
Protein extraction buffer 50 mM tris-HCl pH = 7.25, 150 mM NaCl, 2 mM 
EDTA, protease inhibitor cocktail tablet 
0.1 M sodium phosphate 
buffer pH=7 
305 ml of 0.2 M Na2HPO4, 195 ml of 0.2 M NaH2PO4, 
500 ml of Milli–Q water  
1 x phosphate buffered 
saline (PBS) 
140 mM NaCl, 80 mM Na2HPO4 and 15 mM KH2PO4 , 
27 mM KCl, pH adjusted to 7.4 with HCl 
Western blot transfer buffer 120 mM Tris-HCl, 40 mM glycine, 0.1% (w/v) 
sodium dodecyl sulphate (SDS), 20% (v/v) 
methanol 
Western blot blocking 
solution 
5% (w/v) skimmed milk powder in 1x PBS; 0.05% 
(v/v) Tween-20 
6 x sample buffer for 
agarose gels 
0.025 g xylene cyanol, 0.025 g bromophenol blue, 
0.025 g orange-G dissolved in 60% (v/v) glycerol in 
1x TBE 
4 x sample buffer for 
protein gels 
NuPAGE® LDS sample buffer (Novex®) 
Coomassie staining solution 0.25% (w/v) Coomassie Brilliant Blue R, 40% (v/v) 
methanol, 7% (v/v) acetic acid  
Destaining solution 15% (v/v) methanol; 7.5% (v/v) acetic acid  
 Table 2.1 Recipes of media, buffers and solutions 
2.2 Vectors 
cDNA copies of full-length CPMV RNA-1 and RNA-2 were provided by constructs 
pBinPS-1-NT and pBinPS-2-NT respectively (Liu and Lomonossoff, 2002). For 
enhancing expression from vectors that did not encode a suppressor of silencing, 
P19 was co-expressed from pBIN61-P19 (Voinnet et al., 2003). 
For sub-cloning ‘genes of interest’, pM81-FSC-POW (Sainsbury et al., 2009) was 
used, which allows for expression of genes with the modified 5’ UTR and 3’UTR of 
RNA-2. For plant expression, the gene of interest was transferred to the 
appropriate ‘pEAQ’ vector (Sainsbury et al., 2009). pEAQ vectors are a series of 
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small binary vectors tailored for expression of proteins in plants. The various 
pEAQ vectors and their features are listed in Table 2.2.  
Plasmid Name Accession No. Features 
pEAQ-HT GQ497234 Designed for high-level expression of a ‘gene of 
interest’ in plants. Its T-DNA comprises: 
 the CPMV-HT expression cassette with a 
polylinker to insert the gene of interest;  
 the suppressor of gene silencing P19;  
 nptII to confer resistance to kanamycin. 
pEAQexpress GQ497230 
 
Designed for cloning multiple CPMV-HT 
expression cassettes in the same vector for 
transient expression in plants. Its T-DNA 
comprises: 
 a multiple cloning site  for insertion of 
multiple expression cassettes digested 
using enzymes PacI and AscI; 
 the suppressor of gene silencing P19. 
pEAQselectK GQ497231 
 
Designed for expression from a CPMV-HT 
expression cassette in the absence of a 
suppressor of silencing. Its T-DNA comprises: 
 a multiple cloning site for insertion of 
the expression cassette;  
 nptII to confer resistance to kanamycin. 
pEAQspecialK GQ497232 
 
Designed for expression from a CPMV-HT 
expression cassette in the presence of a 
suppressor of silencing. Its T-DNA comprises: 
 a multiple cloning site for insertion of 
the expression cassette;  
 the suppressor of gene silencing P19;  
 nptII to confer resistance to kanamycin. 
pEAQspecialKm GQ497233 
 
Best suited for stable expression of proteins in 
whole plants.  Same as pEAQspecialK apart 
from a mutation in suppressor of gene 
silencing: P19/R43W (Saxena et al., 2011). 
Table 2.2 pEAQ plasmids and their properties  
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2.3 Recombinant DNA methodology  
Standard molecular biology procedures, as described by Sambrook et al. (1989), 
were followed for cloning and the manufacturer’s instructions were followed 
wherever possible.  
2.3.1 Polymerase Chain Reaction (PCR) 
Primers for amplification of DNA (listed in Appendix I) were ordered from Sigma 
Aldrich. Reactions were set up using high-fidelity polymerase Phusion (New 
England Biolabs or NEB) as follows: 
Phusion HF buffer (5x)   4.0 µl 
dNTPs (10 mM)   0.5 µl 
Forward primer (10 µM)   1.0 µl 
Reverse primer (10 µM)   1.0 µl 
Template DNA (20-25 ng)   1.0 µl 
Phusion polymerase   0.2 µl 
Water 12.3 µl 
  20 µl 
 
The following program was run to amplify DNA: 
Step Setting Duration 
1 98 °C 2:00 mins 
2 98 °C 0:15 mins 
3 65 °C 0:30 mins 
4 72 °C 1:00 mins 
5 Go to step 2 24 times 
6 72 °C 5:00 mins 
7 10 °C Forever 
 
PCR products were analysed by agarose gel electrophoresis and purified using PCR 
clean up kits (Qiagen). Reactions for colony/plasmid screening were set up using 
the GoTaq® Green Master Mix (Promega). 
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2.3.2 Digestion  
For digestion of DNA fragments and plasmids, restriction enzymes supplied by 
NEB were used and digests were performed as per the manufacturer’s 
recommendations. In case of double digests with incompatible enzymes, the 
following universal digestion buffer was used: 
5x cuts all buffer: 100 mM Tris pH 7.5, 500 mM KCl, 35 mM MgCl2, 14.6 mM ß-
mercaptoethanol, 0.5 mg/ml BSA in 10 ml H2O 
2.3.3 Ligation 
DNA ligations were carried out using the Quick ligationTM kit (NEB) and reactions 
were set up as recommended by the manufacturer.  
2.3.4 Transformation 
 One Shot® TOP10 chemically competent E. coli (Invitrogen) was used for 
propagation of recombinant plasmids. E. coli was grown in LB media with 
appropriate antibiotic selection and transformed using heat shock.  
 A. tumefaciens strain LBA4404 (Hoekema et al., 1983) was used for plant 
transformation. A. tumefaciens was grown in LB with appropriate antibiotic 
selection and transformed by electroporation. 
2.3.5 Purification of plasmids 
For purification of plasmids from bacterial cultures, QIAprep spin Miniprep kits 
(Qiagen) were used. Plasmids were analysed by agarose gel electrophoresis.  
2.3.6 Sequencing 
Routine sequencing of plasmid DNA for verification of clones was done using the 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Reactions 
were set up according to the manufacturer’s instructions using the appropriate 
DNA template and primers and run in a thermal cycler. These ‘ready reactions’ 
were then sent for sequencing reads at the Genome Analysis Centre (TGAC), 
Norwich. Reads were analysed using Vector NTI version 11 (Invitrogen).   
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2.3.7 Site-directed mutagenesis (SDM) 
Point mutations in plasmids were introduced using Geneart® Site-directed 
mutagenesis system (Invitrogen) and the manufacturer’s instructions were 
followed closely.  
2.3.8 Agarose gel electrophoresis of DNA fragments 
For analysis of PCR products, digested DNA fragments and plasmids, DNA was 
separated on 0.8% (w/v) agarose gels in 1x TBE buffer. Routinely, samples were 
mixed with 6x loading buffer and migrated on gels at 70 V for 1 hour. 
HyperLadderTM I (Bioline) was used as the standard DNA marker in the range of 
0.2 – 10 kb.   DNA bands on gels were stained by placing the gel in a 0.5 µg/ml 
solution of ethidium bromide for 10 mins. Bands were visualised in UV light 
(wavelength = 302 nm) and imaged using Gene Snap (Syngene).  
2.4 Plant growth and transformation 
2.4.1 Plant growth 
N. benthamiana and V. unguiculata (cowpea) plants were grown in glasshouses 
maintained at 25°C with supplemental lighting to provide 16 hours of daylight. 
Plants were watered daily. 
2.4.2 Transient expression of proteins in plants (Agro-infiltration) 
A. tumefaciens suspensions were prepared by pelleting cells from an overnight 
culture and resuspending them in MMA buffer to make a solution of final optical 
density at 600 nm (OD600) = 0.4. For co-expression of two constructs, solutions of 
OD600 = 0.8 were prepared and mixed in 1:1 ratio to result in a final OD600 = 0.4 for 
each construct. The suspensions were left at room temperature for 0.5–3 hours 
prior to infiltration to allow acetosyringone in the buffer to induce virulence of 
agrobacteria.  
The agro-suspension was pressure-infiltrated into young fully expanded leaves of 
3-4 week old N. benthamiana plants with the help of a syringe (for small scale 
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expression; 1-10 plants) or a vacuum pump (for large scale expression; 10-100 
plants). For syringe infiltration, a sterile needle was used to wound the leaf surface 
followed by infiltration of the Agrobacterium-suspension into the leaf through the 
wound using a 1 ml sterile syringe. For vacuum infiltration, the plant was inverted 
into a beaker containing the agro-suspension and placed under negative pressure 
of 170 mbar (25 inches of Hg relative to atmospheric pressure) for 60 secs to suck 
air out of intracellular spaces. The vacuum was gently released allowing the 
solution to infiltrate leaves by occupying intracellular spaces. Infiltrated leaves 
were harvested from 1-12 days post infiltration (dpi), depending on the nature of 
the study. 
2.4.3 Stable expression of proteins in plants 
For integration of T-DNA from pEAQ vectors into the N. benthamiana genome for 
transgenic expression, leaf discs were transformed with A. tumefaciens cultures 
harbouring the desired pEAQ construct using the ‘leaf disc method’, first described 
by Horsch and Klee (1986).   
Briefly, young fully expanded leaves of N. benthamiana were rinsed in 5% (v/v) 
bleach and 70% (v/v) ethanol before punching out discs of about 1 cm diameter 
using a sterile cork borer. Leaf discs were placed on pre-callusing media in sterile 
plates sealed with micropore tape and transferred to a growth chamber. After 24 
hours, discs were dipped in appropriate A. tumefaciens cultures (freshly grown 
overnight without antibiotics) and placed back on pre-callusing plates in the 
growth chamber. After 48 hours, leaf discs were transferred to fresh plates with 
pre-callusing media, this time with 500 µg/ml carbenicillin and 100 µg/ml 
kanamycin for selection of transformed tissue. Shoots that appeared on calluses 
after 3-5 weeks were transferred to rooting media to allow roots to form. Once the 
roots developed, plantlets were moved to soil and placed in the glasshouse. Young 
leaves were harvested from regenerated plants for analysis of expressed proteins 
from time to time.  
To obtain subsequent generations of transgenic plants by self-fertilisation, flowers 
were taped just as they started developing and seeds were collected from the seed 
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pods that developed from the taped flowers. Transgenic seeds were plated on MS-
agar and placed in the growth chamber for 4-6 weeks to allow development of 
seedlings. Seedlings were subsequently transferred to soil for generation of plants. 
In some cases, antibiotic selection (100 µg/ml kanamycin) was used on MS-agar 
plates to select for the presence of the transgene (untransformed seedlings ‘bleach’ 
due to their sensitivity to kanamycin). In other cases, seedlings were grown in 
absence of antibiotic selection and screened subsequently for presence of the 
transgene using other methods, such as visualisation under UV light for detection 
of GFP or immunodetection of proteins.    
2.5 Production of wt CPMV 
2.5.1 Propagation  
To grow CPMV, 12 day old V. unguiculata plants were infected by mechanical 
inoculation of primary leaves with 5 µg of purified CPMV virions per leaf. Infected 
primary and trifoliate leaves were harvested on 12-15 dpi and frozen at -20 °C.  
2.5.2 Purification  
To purify virus from frozen leaf tissue, a method adapted from van Kammen 
(1967) was used. Briefly, frozen plant tissue was homogenised in 3 volumes of 0.1 
M sodium phosphate buffer pH 7.0. The homogenate was filtered through two 
layers of muslin and clarified by centrifugation at 13,000 g for 20 min at 4 °C. To 
the supernatant, 0.7 volumes of a 1:1 mixture of chloroform and butanol was 
added, mixed and centrifuged at 6000 g for 20 min at 4 °C. After centrifugation, the 
clear aqueous phase (containing CPMV) was carefully transferred to a glass beaker 
and particles were precipitated at 4 °C overnight by adding a solution of PEG 6000 
(final concentration of 4% (w/v)) and NaCl (final concentration of 0.2 M).  The PEG 
precipitate was obtained by centrifugation for 20 min at 13,000 g and resuspended 
thoroughly in 10 mM sodium phosphate buffer pH=7 (0.5 ml buffer per g of leaf 
tissue). CPMV was purified further by centrifugation at 27,000 g for 20 min to 
obtain the supernatant and then at 118,700 g for 2 hours and 15 mins to obtain a 
pellet of purified virions.  
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On most occasions, this was followed by an additional clearing spin at 16,000 g for 
15 mins using the bench-top centrifuge. For further purification of virions, Float-a-
lyzer® dialysis devices (Spectra/Por®) and/or PD-10 desalting columns 
(Amersham Biosciences) were used.  
2.5.3 Fractionation into Top, Middle and Bottom components 
Density gradient centrifugation was used to separate the different nucleoprotein 
components of CPMV on the basis of their buoyant density. The density gradient 
was prepared using 30%, 40%, 50% and 60% (w/v) solutions of Nycodenz® (Axis 
Shield) in 10 mM sodium phosphate buffer  pH=7.0. 2.5 ml of each Nycodenz® 
solution was layered in a thin-walled ultracentrifuge tube using the technique of 
under-layering (low density end first). 1 ml of the viral suspension (at 10 mg/ml 
CPMV) was layered on top of the gradient. The gradient was centrifuged at 
163,500 g for 23 hours to allow viral components to move down the gradient until 
the point was reached where density of the medium equalled density of the virus. 
The separated viral components were visualised by shining a beam of white light 
directly through the length of the tube (Figure 1.4) and Top, Middle and Bottom 
fractions were removed through the side of the tube using a syringe.  
Nycodenz® was removed from particle suspensions by ultracentrifugation of each 
fraction at 130,000 g for 3 hours followed by re-suspension of the pellet in 100 µl 
buffer (10 mM  sodium phosphate buffer pH = 7). This was repeated three times to 
remove all traces of Nycodenz®.  
2.6 Production of CPMV eVLPs 
2.6.1 Expression  
eVLPs were produced by co-expression of the CPMV coat protein precursor VP60 
and the viral proteinase 24K, either from constructs pEAQ-HT-VP60 and pEAQ-HT-
24K (Saunders et al., 2009) or from pEAQexpress-eVLP (described in Section 
3.3.1), using agro-infiltration (as per Section 2.4.2) in N. benthamiana. Leaves were 
harvested on 5-7 dpi and processed to obtain eVLPs.  
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2.6.2 Purification  
For purification of eVLPs from infiltrated N. benthamiana leaves, the method 
described in Section 2.5.2 for purification of wt CPMV was used with the following 
modifications: (i) Leaf tissue was processed fresh and not frozen; (ii) 2% (w/v) 
polyvinyl-polypyrrolidone (PVPP) was added to the 0.1 M sodium phosphate 
buffer used for homogenisation of leaves; (iii) the chloroform/butanol step was 
omitted; (iv) the ultra-centrifugation spin was done for 2.5 hours. The reasons 
behind each modification are explained in Section 3.2. 
 
2.7 Extraction and analysis of viral RNA 
2.7.1 Extraction of RNA from virus particles   
50-100 µg CPMV was purified in TEN/NET buffer and incubated at 60 °C for 5 mins 
in presence of 2% (w/v) SDS to denature the viral coat proteins. To the denatured 
sample, two volumes of a 1:1 mixture of phenol and chloroform was added and 
mixed by vortex. The mixture was centrifuged at 16,000 g in a bench-top 
centrifuge for 10 mins. After centrifugation, the aqueous layer was transferred 
carefully to a fresh tube and re-extracted using two volumes of phenol/chloroform. 
To precipitate RNA from the aqueous fraction, 0.2 volumes of 3 M sodium acetate 
at pH 5.5 and 2.5 volumes of ice-cold 100% ethanol were added and the sample 
was kept at -20 °C overnight. The sample was centrifuged at 16,000 g for 15 mins 
at 4 °C to recover the RNA pellet. The pellet was washed with 70% (v/v) ethanol, 
air-dried and resuspended in a small volume (5-10 µl) of sterile water.  
2.7.2 Electrophoresis of viral RNA 
Extracted RNA was analysed by agarose gel electrophoresis under denaturing 
conditions. A 1.2% agarose gel was prepared in 1x FGRB and 2.2 M formaldehyde. 
RNA samples were prepared as follows: 
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Extracted RNA (upto 30 µg)   4.5 µl 
5x FGRB   2.0 µl 
Deionised formamide 10.0 µl 
12.3 M Formaldehyde   3.5 µl 
  20 µl 
Samples were heated at 65 °C for 10 mins to denature RNA and placed on ice 
immediately. 0.5 µl of ethidium bromide (10 mg/ml) and 2 µl of Orange-G loading 
dye were added to the sample to enable detection of RNA and the sample was 
loaded on the gel. In parallel, 5 µl of Transcript RNA marker from Sigma was 
prepared as above and run as a standard. Samples were electrophoresed at 60 V 
for 1.5–2 hours. RNA bands were visualised under UV light (wavelength = 302 nm) 
and imaged using Gene Snap (Syngene).  
2.8 Analysis of protein expression  
2.8.1 Protein extraction and detection 
Infiltrated leaf tissue was homogenised in three volumes of protein extraction 
buffer. The lysate was clarified by centrifugation and proteins were separated by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under 
reducing or non-reducing conditions using 12% (w/v) Bis-Tris NuPAGE® gels 
(Invitrogen). Post electrophoresis, proteins were detected by one or both of these 
methods: 
 Coomassie staining 
To visualise separated proteins, Instant blue Coomassie stain (Expedeon) 
was applied to gels for 15 minutes followed by de-staining in sterile water 
for 1-2 hours. 
 Western blotting 
To detect specific proteins, gels were electro-blotted onto nitrocellulose 
membranes in transfer buffer. Target proteins were detected using 
antibodies raised against that specific protein (primary antibody) and a 
horseradish peroxidase (HRP)-conjugated antibody raised against the 
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primary antibody (secondary antibody). Non-specific sites on the 
membrane were blocked using blocking solution and binding of antibodies 
was detected using chemiluminescence. Table 2.3 lists primary and 
secondary antibodies used for work described in this thesis.   
 
Antigen Antibody  
CPMV coat protein Rabbit anti-CPMV polyclonal serum G49 
Human IgG Fc region Goat anti-human IgG (Fc specific)-HRP conjugate 
(Sigma) 
Rabbit IgG Goat anti-rabbit IgG-HRP conjugate  
(Amersham Biosciences) 
Table 2.3 Antibodies used for western blots 
2.8.2 Analysis of expression of GFP 
 Visualisation under UV light 
GFP expression in infiltrated and transformed N. benthamiana plants was 
monitored with a 100 AP handheld UV lamp (Blak Ray ®). 
 Fluorescence assay 
GFP fluorescence measurements were made using a protocol described by 
Richards et al. (2003). Soluble protein extracts were diluted 100-fold in 0.1 
M Na2CO3 and loaded onto a fluorescently neutral black 96-well plate 
(Greiner bio-one). Recombinant GFP from Clontech was used to generate 
standard curves. Excitation (395 nm) and emission (509 nm) maxima were 
matched to Clontech’s GFP and read using a SPECTRAmax 
spectrofluorometer (Molecular Devices). Measurements were done in 
triplicate to account for experimental variation and averaged to give a final 
value for each sample. 
2.8.3 Analysis of expression of VLPs 
 Transmission electron microscopy (TEM) 
TEM was routinely used to assess the integrity of VLPs. Samples were 
diluted to a conc. of approximately 0.1 mg/ml in sterile water (to dilute 
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phosphate in the sample buffer). Droplets of the sample were placed on 
carbon-coated copper grids (400 mesh; obtained from Agar Scientific). 
Grids were negatively stained by application of a droplet of 2% (w/v) 
uranyl acetate and dried after 20 secs using filter paper. Grids were 
visualized using a Technai F20 transmission electron microscope (FEI UK 
Ltd.) at 200 kV and imaged using a bottom-mounted AMT XR60 CCD camera 
(Deben UK Ltd.).  
 
 UV/Vis spectroscopy 
Photometric measurements of VLPs were made using either a Lambda 25 
UV-Vis spectrophotometer with UV WinLab software (Perkin Elmer) or a 
NanoVue spectrophotometer (GE Healthcare). The Beer-Lambert law was 
used to calculate VLP concentration from absorbance measurements, using 
molar extinction coefficients (Є) determined by van Kammen (1967) and 
shown in Table 2.4.  
 Absorbance maxima at 
wavelength (λ) 
Molar extinction  
coefficients (Є) 
wt CPMV 260 nm 8.1 ml mg-1 cm-1   
CPMV Bottom 260 nm 10.0 ml mg-1 cm-1   
CPMV Middle 260 nm 6.2 ml mg-1 cm-1   
CPMV Top or eVLPs 280 nm 1.28 ml mg-1 cm-1   
 Table 2.4 Molar extinction coefficients of wt CPMV and eVLPs 
 
 Bradford assays 
VLP concentrations were determined by a colorimetric protein assay using 
Bradford reagent (Sigma Aldrich). Bradford assays enable quantification of 
proteins in presence of nucleic acids and hence can be used to quantify both 
wt CPMV and eVLPs on the basis of coat proteins present in each sample. 
Serial dilutions of standards (wt CPMV in the range of 0.1-1.5 mg/ml) and 
the unknown samples were pipetted in a 96-well clear plate. To each well, 
250 µl of Bradford reagent was added, mixed and incubated at room 
temperature for 15 mins. Absorbance of the protein-dye complex was 
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measured at 595 nm using SPECTRAmax spectrophotometer (Molecular 
Devices). An absorbance versus concentration curve was plotted for wt 
CPMV standards and used for calculations of concentrations of unknown 
VLP samples.  
 
 Agarose gel electrophoresis of particles 
Intact VLPs were analysed on 1% (w/v) agarose gels in 1x TBE (pH=7.6) 
due to the fact that the CPMV capsid has a net negative charge at pH 7.6 
which causes particles to migrate towards the anode in an electric field 
(Steinmetz et al., 2007). Routinely, 5-10 µg VLPs were mixed with 6x 
loading buffer and electrophoresed at 60 V for 2.5 hours. To visualise 
particles, their coat proteins were fixed by placing the gel in Coomassie Blue 
staining solution for 20 mins followed by destaining overnight.  
Alternatively, to check for presence of nucleic acids within particles, the gel 
was placed in a 0.5 µg/ml solution of ethidium bromide for 10 mins and 
visualised in UV light (wavelength = 302 nm). 
 
 SDS-PAGE 
VLPs were prepared in LDS sample buffer and denatured by incubation at 
98 °C for 5 mins. Denatured samples were separated on 12% (w/v) Bis-Tris 
NuPAGE® gels (Invitrogen) according to the manufacturer’s instructions. 
Post electrophoresis, coat proteins from the VLPs were detected by staining 
with Coomassie blue or by western blotting, as described in Section 2.8.1. 
Known amounts of wt CPMV (usually 1 µg, 2 µg and 4 µg) were run in 
parallel and used as standards to quantify VLPs by eye or by densitometry. 
 
2.9 Photography 
A Nikon D700 digital camera with a 60 mm macro lens was used for image 
acquisition under visible light or, for the detection of GFP, under UV illumination. 
Images were edited using Photoshop CS4 (Adobe).    
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Chapter 3: Results I 
Production and Characterisation of CPMV eVLPs 
3.1 Introduction 
Production of apparently RNA-free particles of CPMV without an infection, as 
reported by Saunders et al. (2009), was a big leap for CPMV technology. Even 
though all evidence suggested that eVLPs thus produced were RNA-free versions of 
wt CPMV (which in a natural infection is the Top component of CPMV), conclusive 
experiments needed to be performed. It was important to establish that on the 
outside, the capsid of eVLPs was similar to wt CPMV and that inside, eVLPs were 
genuinely empty i.e. no heterologous RNA from the host cell got packaged within 
the capsid. The lack of any RNA within capsids is unusual as most VLPs are known 
to encapsidate random host nucleic acids if their own viral RNA is not available. 
The availability of potentially genuinely empty VLPs of CPMV was recognised as 
being very valuable for applications in nanotechnology and therefore, detailed 
studies on their production and characterisation were undertaken.  
Initial work showing that eVLPs can be produced in insect cells and plants 
(Saunders et al., 2009) looked promising in terms of the quality of eVLPs but their 
yield and purity was relatively low. eVLPs were produced in N. benthamiana by co-
expression of the coat protein precursor VP60 and the viral proteinase 24K by 
deploying the two constructs: pEAQ-HT-VP60 and pEAQ-HT-24K (Figure 3.1) and 
the yields obtained were estimated to be around 0.1-0.2 g/kg fresh weight tissue 
(FWT) (Saunders et al., 2009). This was found to be true when small-scale 
infiltrations were done (3-4 plants) but when production was scaled-up, yields 
dropped to as low as 0.01 g/kg FWT. In addition to the scale of the experiment, 
expression levels were seen to vary with the age of the plants, size of leaves and 
the time of the year. It was known that environmental factors affected expression 
levels of heterologous proteins in plants (K. Saunders and E. Thuenemann, pers. 
comm.) but parameters for optimal expression had not been established.  
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This chapter describes work aimed at defining the conditions for optimal 
expression and purification of eVLPs by working at three levels: particle 
purification, plant expression and scale of production. In addition, this chapter 
examines eVLPs on the basis of their structure and composition and compares and 
contrasts eVLPs to wt CPMV. Table 3.1 summarizes fundamental differences 
between wt CPMV and eVLPs, which have been exploited in characterisation of 
eVLPs described later in this chapter.       
 
 
 
Figure 3.1 Constructs used for expression of eVLPs in plants (Saunders et al., 
2009). Schematic diagrams of the T-DNA regions of constructs used for the 
expression of VP60 (a) and 24K (b) in N. benthamiana. RB and LB represent right 
and left borders respectively. Both constructs were harboured in agrobacteria and 
the two bacterial suspensions were mixed in 1:1 ratio prior to infiltration. Particles 
were extracted from infiltrated leaves on 6 dpi. 
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 wt CPMV eVLPs 
Host system Produced in cowpea Produced in N. benthamiana 
Method of 
expression  
Expressed by viral infection of 
plant 
Expressed by agro-infiltration of 
leaves 
Composition More than 90% of the particles 
contain RNA 
Particles don’t contain any 
nucleic acids 
Density Highly dense particles due to 
presence of RNA; high 
sedimentation coefficients 
Less dense due to absence of 
RNA; lower sedimentation 
coefficients 
Stability Very stable and compact as 
RNA makes stabilizing bonds 
with positively charged 
pockets in the capsid 
Less stable due to absence of 
negatively charged RNA 
Table 3.1 Fundamental differences between wt CPMV particles and eVLPs 
 
3.2 Optimisation of particle purification protocols 
The method for extraction of eVLPs from infiltrated N. benthamiana leaves was 
based on the protocol for extraction of wt CPMV from infected cowpea leaves (van 
Kammen, 1967; van Kammen and de Jager, 1978) as described in Section 2.5. 
However, since eVLPs differ from wt CPMV in a number of ways (as listed in Table 
3.1), including their stability, modifications to the extraction protocol were 
investigated. Samples at every stage of the extraction process were analysed by 
immunodetection to identify where particles were being lost (Figure 3.2) and 
changes were made to the protocol accordingly. Modifications made to the 
extraction protocol and specific reasons for each modification have been explained 
in Table 3.2. In summary, steps that led to degradation of eVLPs were omitted and 
steps that removed impurities from the extract were added to the protocol. 
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Figure 3.2 Immunodetection of eVLPs. 10 µl samples from each step of the 
extraction process were blotted on nitrocellulose and incubated with anti-CPMV 
antibody for immunodetection of CPMV coat proteins. Dots 1-8 correspond to 
fractions, as numbered in the flow-diagram. Dot 9 corresponds to 200 ng of 
purified eVLPs, used as the positive control. In particular, eVLPs were being lost in 
the pellet after the low-speed spin (Fraction 6).   
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Original protocol Modification  Reason  
Leaf tissue was 
harvested and frozen. 
Leaf tissue was 
processed fresh. 
eVLPs degrade upon 
freezing and thawing. 
Leaves were 
homogenised in 0.1 M 
sodium phosphate 
buffer. 
Leaves were 
homogenised in 0.1M 
sodium phosphate buffer 
with 2% PVPP 
(polyvinyl-
polypyrrolidone).   
PVPP binds to phenolics 
and polysaccharides from 
N. benthamiana, thereby 
reducing impurities in the 
prep. Since PVPP is 
insoluble in phosphate 
buffer, it pellets during the 
first spin and doesn’t 
affect subsequent steps.  
A 1:1 chloroform-
butanol mixture was 
used to remove 
chlorophyll and other 
plant proteins from the 
extract. 
This step was omitted.   Chloroform and butanol 
denature proteins 
including coat proteins 
from the eVLP capsid. wt 
CPMV survives this step 
due to the presence of 
RNA that stabilises the 
capsid.  
PEG precipitation was 
either done for 2 hours 
at room temperature or 
overnight in the cold 
room. 
PEG precipitation was 
always done in the cold 
room overnight (12-16 
hours). 
2 hours at room 
temperature was not 
enough to precipitate all 
eVLPs.  
After PEG precipitation, 
the pellet was quickly 
resuspended and spun at 
27,000 g to remove 
impurities from the 
sample.  
After PEG precipitation, 
the pellet was 
resuspended thoroughly 
by vortexing, shaking 
and vigorous pipetting 
before the 27,000 g spin. 
eVLPs were being lost in 
the pellet after the spin at 
27,000 g. This indicates 
that the PEG precipitate 
was not being 
resuspended completely 
prior to the spin. 
The ultra-centrifugation 
was done for 2 hrs and 
15 mins. 
The centrifugation time 
was increased to 2 hrs 
and 30 mins.  
The sedimentation co-
efficient of eVLPs (58 S) is 
lesser than that of the wt 
CPMV particles (115 S for 
CPMV-Bottom and 95 S for 
CPMV-Middle). 
Table 3.2 Modifications made to the original extraction protocol to enhance 
yield and purity. 
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By making all the changes listed in Table 3.2, loss of particles during extraction 
was minimised. In particular, omission of the protein denaturation step involving 
the chloroform/butanol treatment increased recovery of eVLPs by 50% (Figure 
3.3). This is consistent with work published on other viruses where the use of 
chloroform and butanol in virus purification caused loss of yield and affected 
relative amounts of virus components (Markham, 1962). Moreover, it is already 
known that in purification of wt CPMV, the chloroform and butanol step 
considerably decreases the proportion of empty particles (van Kammen, 1967).  
Some other modifications were made to the original protocol but these either did 
not improve the yield or even reduced it.  These modifications included: changes to 
PEG/NaCl concentration, centrifugation through a 40% (w/v) sucrose cushion and 
changes to the durations of incubations or several centrifuge spins.  
 
Figure 3.3 Effect of organic solvents on eVLP recovery. eVLPs extracted from 
the same amount of leaf tissue, with (Lane 1) and without (Lane 2) the organic 
clarification step, were denatured by heat-incubation and analysed by separation 
of coat proteins using SDS-PAGE and subsequent staining with Coomassie blue. 
Indicated amounts of wt CPMV were run as standards and the crude extract was 
run in Lane 3. Bands for L and S coat proteins have been indicated. Differences in 
the sizes of bands for S are due to differences in the processing of the C-terminus of 
the S coat protein which will be discussed in more detail in Section 3.6.1.      
CHAPTER 3 
 
  61 
 
3.3 Optimisation of the plant expression system 
3.3.1 Optimisation of expression constructs 
Originally, expression of eVLPs was achieved by co-infiltration of leaves with a 1:1 
mixture of two Agrobacterium strains, one harbouring the plasmid pEAQ-HT-VP60 
and the other pEAQ-HT-24K (Figure 3.1) (Saunders et al., 2009). To ensure 
efficient co-expression, each strain had to be infiltrated at an OD600 of at least 0.8 
so that the final OD600 of each construct in the mixture was 0.4. This made the 
inoculum dense and difficult to infiltrate. This also increased the amount of 
bacterial proteins being delivered to the plant, therefore putting the plant under 
greater stress and increasing contaminants in the host cell. Previous studies on co-
expression of proteins, conducted using the yellow fluorescent protein (YFP) and 
cyan fluorescent protein (CFP) (Montague et al., 2011), have shown that even by 
mixing equal amounts of two cultures, it cannot be guaranteed that every plant cell 
would receive both strains in sufficient amounts. Hence, there would always be a 
proportion of cells receiving only one strain resulting in production of only one of 
the two proteins (VP60 or 24K) but no eVLPs.  
To improve eVLP yields by solving the issues mentioned above, genes for VP60 and 
24K were cloned within the T-DNA of a single expression vector. pEAQexpress 
(Sainsbury et al., 2009) was modified to create pEAQexpress-eVLP (Figure 3.4) 
using a two-step cloning procedure. First, the expression cassette for 24K, 
consisting of the 35S promoter, the 5’ UTR, gene encoding VP60, the 3’ UTR and the 
nos terminator, was amplified from pEAQ-HT-24K and inserted in the restriction 
sites AsiSI and MluI of pEAQexpress. The plasmid thus generated was then 
modified further by insertion of the expression cassette for VP60 (amplified from 
pEAQ-HT-VP60) using the restriction sites PacI and AscI. The resultant plasmid, 
pEAQexpress-eVLP, was verified by sequencing and transformed into A. 
tumefaciens for subsequent expression in plants.  
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Figure 3.4 Schematic representation of the construct designed for eVLP 
expression. pEAQexpress-eVLP was constructed for expression of VP60 and 24K 
from a single T-DNA. RB and LB represent right and left borders respectively.  
To assess the eVLP yields obtained from expression with pEAQexpress-eVLP, 
agrobacteria cultures harbouring this construct were infiltrated at OD600 = 0.4 into 
N. benthamiana. In parallel, the original constructs, pEAQ-HT-VP60 and pEAQ-HT-
24K were co-expressed by syringe infiltration of plants from the same batch with a 
1:1 solution of agrobacteria harbouring each construct (at final OD600 = 0.4 each). 
Leaves from both sets of infiltrations were harvested on 6 dpi and the same 
amount of leaf tissue (in terms of FWT) was processed to obtain eVLPs in both 
cases. Analysis of purified particles using SDS-PAGE showed that infiltration of 
leaves with pEAQexpress-eVLP resulted in a remarkable increase in eVLP yield and 
a noticeable reduction of contaminants in the final prep. in comparison to co-
infiltrations conducted using two separate constructs (Figure 3.5). Therefore, 
pEAQexpress-eVLP was used for all subsequent expression of eVLPs.     
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Figure 3.5 Analysis of eVLP expression. Particles purified from same amounts of 
leaf tissue infiltrated with agrobacteria harbouring different constructs were 
analysed using SDS-PAGE. Samples were run as follows: 
wt: Indicated amounts of wt CPMV particles run as a standard 
1: eVLPs produced by co-expression of pEAQ-HT-VP60 and pEAQ-HT-24K; 
plants in small pots 
2: eVLPs produced by co-expression of pEAQ-HT-VP60 and pEAQ-HT-24K ; 
plants in big pots 
3: eVLPs produced by expression of  pEAQexpress-eVLP; plants in small 
pots 
4: eVLPs produced by expression of  pEAQexpress-eVLP; plants in big 
pots 
M: Protein Marker 
 
Bands for L and S are indicated. Differences in the sizes of bands for S in wt CPMV 
and eVLPs are due to differences in its processing and will be discussed later 
(Section 3.6.1). Expression levels were estimated from the intensity of bands. From 
this gel, comparisons can be made between constructs used (lane 1 compared with 
lane 3; lane 2 compared with lane 4) and sizes of pots used (lane 1 compared with 
lane 2; lane 3 compared with lane 4).   
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3.3.2 Optimisation of plants used for infiltration 
Expression of eVLPs in different N. benthamiana plants was monitored and it was 
found that the youngest fully expanded leaves of 4-week old plants express best. 
Agrobacterium suspensions diluted to an OD600 of 0.4 for infiltration gave the best 
yields with the least agrobacterial contaminants in the prep. Plants that were 
grown in bigger pots showed better expression levels (Figure 3.5). In general, 
healthier plants yielded more eVLPs since their leaves were bigger and thicker. 
Expression levels decreased as plants went into flowering and dropped 
dramatically at plant senescence.     
Expression of eVLPs in cowpea was investigated since wt CPMV naturally infects 
cowpea and grows to high titres (usually 1 g/kg FWT) in cowpea. It was found that 
eVLP expression in cowpea by agro-infiltration was almost a tenth of the 
expression achieved in N. benthamiana. This is likely to be due to the reduced 
ability of agrobacteria to transform cowpea (Bakshi et al., 2011). In addition, 
syringe infiltration of cowpea leaves was harder as they are thicker and waxier.  
3.3.3 Optimisation of time of harvest 
To determine the time after infiltration required for optimal expression of eVLPs, a 
time-course was conducted over 12 days. To this end, three leaves each of twelve   
N. benthamiana plants were infiltrated with pEAQexpress-eVLP. As controls, two 
plants were infiltrated with the empty vector pEAQexpress. From 1-12 dpi, three 
independent leaves (approximately 3 g FWT), each from different infiltrated plants 
selected randomly, were harvested daily and processed using the standard 
protocol for particle purification. Purified samples were stored at 4°C and 
subsequently analysed using SDS-PAGE (Figure 3.6). Detectable levels of eVLPs 
were found from 4 dpi onwards and levels were observed to increase steadily until 
day 7. Optimal expression was achieved from 6-10 dpi and the same level of 
expression was maintained until plant senescence. 
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Figure 3.6 eVLP expression over time. (a) eVLPs purified from leaf tissue 
harvested daily from 1-12 dpi (Lanes 1-12) were denatured by heat-incubation 
and separated using SDS-PAGE. Amounts of wt CPMV run as standards and bands 
obtained for L and S have been indicated. (b) Relative expression levels, estimated 
from intensity of bands on the gel using GS-800 calibrated densitometer (Bio-Rad), 
are shown. Results shown are combined results from measurements of all the 
bands for L and S and show expression relative to 4 µg wt CPMV loaded on the 
same gel.  
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3.4 Scale-up of production 
Large-scale production of proteins involves infiltration of hundreds of grams of 
leaf tissue. Although syringe infiltration is an effective method for infiltration of N. 
benthamiana, it is too labour-intensive. Hence, the alternative approach of vacuum-
mediated infiltration was adopted for large-scale production of eVLPs. The idea 
behind this approach was to use negative pressure to draw air out of intra-cellular 
spaces in leaves, making agro-infiltration easy and quick. By using this system, 
whole plants could be infiltrated in under two minutes.   
To ensure plant health and expression levels were not compromised by vacuum 
infiltration as compared to syringe infiltration, the two methods were initially 
compared for using GFP expression. Agrobacterium cultures harbouring the 
plasmid pEAQ-HT-GFP (Sainsbury et al., 2009) were infiltrated both using a 
syringe and using the vacuum system and plants were compared. It was found that 
neither plant health nor expression levels were affected by the use of vacuum. In 
fact, the area of leaves infiltrated with culture was greater when the vacuum 
system was used (Figure 3.7). In addition, vacuum infiltration was quicker and less 
tedious enabling infiltration of more tissue in less time. Vacuum infiltration was 
then extended to eVLPs enabling production of milligram quantities of eVLPs from 
infiltration of 10-100 plants with ease.     
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Figure 3.7 Syringe vs. vacuum-infiltration of GFP. Expression of GFP in 4-week 
old N. benthamiana plants infiltrated with the vector pEAQ-HT-GFP (Sainsbury et 
al., 2009) using a syringe (left column) and vacuum (right column).  
 
In another approach to scale-up eVLP production, N. benthamiana callus was 
grown in specialized immersion bio-reactors (Michoux et al., 2011) and vacuum-
infiltrated with Agrobacterium cultures harbouring construct pEAQexpress-eVLP 
for eVLP expression (Figure 3.8). Preliminary results on expression of eVLPs 
looked promising. Plant growth conditions and precise eVLP expression levels are 
currently being characterized by Mr. Sherwin Barretto and Dr. Franck Michoux at 
the Imperial College, London. This method has the potential to be used for 
infiltration of hundreds of grams of N. benthamiana tissue in one go. 
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Figure 3.8 Vacuum infiltration of N. benthamiana biomass. Around 100 g of N. 
benthamiana tissue was grown in specialized bio-reactors (shown above) under 
sterile conditions and infiltrated with Agrobacterium cultures harbouring 
pEAQexpress-eVLP using vacuum infiltration techniques. Analysis of levels of eVLP 
expression and feasibility of this approach is being conducted at the Imperial 
College, London.  
 
3.5 Current eVLP yields 
Upon expression using the new construct pEAQexpress-eVLP (Section 3.3) and 
vacuum infiltration methods (Section 3.4) and subsequent purification using the 
modified protocol (Section 3.2), eVLP yields in excess of 0.3 g/kg FWT were 
achieved. This is at least 2-fold more than what was previously reported (Saunders 
et al., 2009). On some occasions, eVLP yields of up to 0.5 g/kg FWT have also been 
obtained owing to healthier plants. This is nearly half of the average titre obtained 
from a natural virus infection in cowpea and therefore very impressive for 
expression from a non-replicative vector.  
Currently, eVLP expression is carried out on a scale of 30-40 plants (approximately 
100-150 g FWT) resulting in generation of 20-40 mgs of eVLPs per batch. 
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3.6 Characterisation of eVLPs 
3.6.1 SDS-PAGE  
As a routine technique to examine particles, wt CPMV and eVLP particles were 
denatured by incubation at 98°C for 5 mins and separated on polyacrylamide gels. 
Bands of approximately 39 and 22-25 kDa were seen corresponding to the L and S 
coat proteins respectively (Figure 3.9). The intensity of both bands was similar 
showing that both L and S were present in equal amounts. 
The L coat protein generated two bands of similar size upon SDS-PAGE (Figure 
3.9). This was surprizing as differently processed forms of L had never been 
previously observed. To investigate this further, both bands were analysed by 
mass spectrometry which identified both bands to be the L coat protein and 100% 
identical to each other. Subsequently, SDS-PAGE was done in presence of reducing 
agents, such as beta-mercaptoethanol in the samples and now only one band was 
detected for L. So, it was concluded that, unlike the two forms of S generated by 
differential processing of the protein, the two bands for L are seen on the gel due to 
the presence/absence of disulphide bonds between cysteine residues of the L coat 
protein. 
Slow (Ss) and fast (Sf) electrophoretic forms of S coat protein (described in Section 
1.4.2) produced distinct bands upon separation by SDS-PAGE due to differences in 
their molecular weights. In wt CPMV, the S coat protein was seen to be present in 
its fast-migrating form producing a band of approximately 22 kDa whereas in 
eVLPs, the S coat protein was predominantly in the slow-migrating form producing 
a band of approximately 25 kDa (Figure 3.9). The reason for this difference is 
attributed to the age of the sample. It is known that S coat protein gets converted 
from Ss to Sf during the course of a natural infection (Niblett and Semancik, 1969). 
Since wt CPMV was harvested from infected leaf tissue during the late stages of 
infection, the S coat protein was only present in its fast-migrating form in wt 
particles. 
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Figure 3.9 SDS-PAGE of wt CPMV and eVLPs. Indicated amounts of wt CPMV and 
eVLPs were denatured by heat-incubation and separated on polyacrylamide gels 
using SDS-PAGE. Two bands of approx. 39 kDa were seen for the L coat protein. 
The S coat protein was predominantly seen in its fast-migrating form Sf (approx. 
22kDa) in wt CPMV and in its slow-migrating form Ss (approx. 25 kDa) in eVLPs. 
3.6.2 UV-Vis spectrophotometry 
Analysis of the UV/Vis spectrum of wt CPMV shows absorption at 260 nm due to 
the presence of RNA. In absence of RNA, as in the case of eVLPs, a peak is produced 
at 280 nm due to the absorbance of aromatic amino acids such as tyrosine, 
tryptophan and phenylalanine present in the coat proteins of CPMV. An additional 
shoulder at 292 nm is seen in eVLPs due to the absorption profile of tryptophan 
residues (Figure 3.10).  
Absorbance measurements at 280 nm were routinely used for calculations of eVLP 
concentrations using the molar extinction coefficient for CPMV-Top (1.28 ml mg-1 
cm-1). However, this method had the limitation that measurements could not be 
taken for very dilute eVLP samples. Also, the presence of other protein impurities 
in the sample influenced absorption and concentration calculations.  
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Figure 3.10 UV/Vis spectrophotometry. UV-Vis spectra of wt CPMV and eVLPs 
are shown in blue and red respectively.  
3.6.3 Native gel electrophoresis 
Native gel electrophoresis of virus particles in an agarose matrix is a technique 
routinely used for characterization of chemically-modified virus particles 
(Steinmetz et al., 2007) as this compares intact virus particles on the basis of their 
size and charge. Particles are electrophoresed on agarose under native conditions 
and analysed by either coomassie-staining (to detect the viral coat proteins) or 
ethidium bromide-staining (to intercalate any encapsulated RNA) as described in 
Section 2.8.3. Here, native gel electrophoresis was used to compare and contrast 
wt CPMV and eVLPs. 
For consistency, the results shown in this section were obtained using 
preparations of wt CPMV and eVLPs that only contained the fast form of CPMV, i.e. 
C-terminally processed form of the S coat protein. In all the preparations used, the 
C-terminal peptide was cleaved off, either naturally by ageing or by proteolysis 
using chymotrypsin (Niblett and Semancik, 1969). 
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3.6.3.1 Coomassie-staining of wt CPMV and eVLPs 
When separated on agarose gels and stained with Coomassie blue, wt CPMV 
generated three bands for Bottom, Middle and Top components due to differences 
in each component’s mass and charge. On the other hand, eVLPs generated a single 
band showing homogeneity between eVLPs (Figure 3.11a). The migration of Top 
component of wt CPMV appeared slightly retarded as compared to eVLPs even 
though CPMV-Top and eVLPs have the same mass and charge. This difference in 
migration is believed to be due to the presence of Bottom and Middle components 
in the wt CPMV mixture. When purified Top component is run in parallel, it 
migrates exactly like eVLPs. 
3.6.3.2 Ethidium bromide-staining of wt CPMV and eVLPs 
When particles were separated on agarose and stained with ethidium bromide for 
identification of nucleic acids, two bands were seen in the wt CPMV sample, for 
RNA-1 and RNA-2 in Bottom and Middle fractions respectively. No band was seen 
in case of eVLPs reiterating the absence of RNA from eVLP capsids (Figure 3.11b). 
                  
Figure 3.11 Native gel electrophoresis of wt CPMV and eVLPs. Approximately 
10 µgs each of wt CPMV and eVLPs were separated on 1% agarose gels and stained 
with Coomassie blue (a) or ethidium bromide (b). Both gels were imaged under UV 
light.   
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3.6.4 TEM 
eVLPs were visualised under the TEM to assess their integrity, appearance and 
approximate size. TEM imaging of eVLPs showed intact monodisperse particles of 
28-30 nm in diameter. At a magnification of 50000x, the appearance of eVLPs was 
very similar to wt CPMV apart from one obvious difference: there were dark spots 
in the middle of some eVLPs (Figure 3.12). This is because the negative stain 
penetrates and accumulates in empty eVLPs whereas in wt CPMV, dense RNA 
occupies the capsid preventing accumulation of negative stain.  
 
Figure 3.12 TEM of wt CPMV and eVLPs. wt CPMV (left) and eVLPs (right) were 
negatively-stained and visualised by TEM at a magnification of 29000x (top row) 
and 50000x (bottom row).  
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Recent studies on eVLPs possessing the processed and unprocessed forms of S 
have shown that the presence of the C-terminal peptide influences particle 
permeability by blocking access to the pore at the 5-fold axis (Sainsbury et al., 
2011). This may explain why penetration of the negative stain is only seen in a few 
eVLPs, given that a majority of the eVLPs possess the unprocessed form of S.  
3.6.5 Cryo-electron microscopy (cryo-EM) 
Cryo-EM on wt CPMV and eVLP particles was performed by Mr. Kyle Dent and Dr. 
Neil Ranson at the University of Leeds, UK using material prepared at the John 
Innes Centre. 3D reconstructions of wt CPMV and eVLPs showed that both species 
possessed identical capsids. Computational analysis of the interior of capsids 
showed eVLPs to be RNA-free, as density attributable to RNA could not be 
observed in any of the recorded eVLP images (Figure 3.13). 
 
Figure 3.13 Three-dimensional reconstructions of wt CPMV and eVLPs. wt 
CPMV (left) and eVLPs (right) were loaded on copper grids, frozen rapidly by 
plunging into liquid ethane and imaged at a magnification of 84900x. 3D 
reconstructions of recorded images were done by iterative-projection-matching 
using a spherical starting model and the published crystal structure of CPMV (Lin 
et al., 1999). Surface view (a) and cut-away view (b) of particles is shown.  
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The above cryo-EM studies represent the first time RNA has been visualised within 
a CPMV particle and therefore present an opportunity for analysing the structure 
of RNA within the particles. However, the wt CPMV preparation used for this work 
was from a natural infection and hence, contained a mixture of Bottom, Middle and 
Top particles. Though Top component can be easily distinguished on frozen grids, 
Middle and Bottom components cannot. Thus, any data obtained on the RNA 
structure would be an average of the structures adopted by RNA-1 and RNA-2. To 
obtain high-resolution data on the structures adopted by either RNA within the 
particles, it was necessary to fractionate a CPMV preparation so that Middle and 
Bottom components could be analysed separately. To this end, a 30 mg sample of 
wt CPMV was applied to a Nycodenz® gradient (as described in Section 2.5.3) and 
fractionated on the basis of particle density. Upon fractionation, 3, 4.5 and 0.2 mgs 
of Bottom, Middle and Top components, respectively, were recovered and these 
were sent for further cryo-EM.  
Cryo-EM on the Bottom component of wt CPMV generated preliminary data on the 
secondary structure of encapsidated RNA, which suggested that RNA-1 adopts the 
structure of a dodecahedral cage (Figure 3.14). The structures of the Middle and 
Bottom components, as well as the eVLPs, continue to be refined and should 
provide insights on interactions between RNA and coat proteins in wt CPMV.   
 
Figure 3.14 Three-dimensional reconstructions of CPMV-Bottom. Exclusively 
RNA-1 containing particles (CPMV-Bottom) were analysed by cryo-EM. 3D 
reconstructions at 7.5 Å show presence of highly dense RNA within the capsid. The 
coat proteins are depicted in blue and encapsulated RNA is shown in yellow. 
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Close comparison of surfaces of CPMV-Bottom and eVLPs using data generated by 
cryo-EM revealed one difference between the two species: some extra density was 
seen around the five-fold axis in eVLPs (Figure 3.15). This mapped to the C-
terminus of the S coat protein and is thought to result from the presence of the 
slow rather than the fast form of the S coat protein in eVLPs, as seen previously on 
SDS-PAGE gels (Section 3.6.1). The fact that at least some of the C-terminal 24 
amino acids from the S protein can be seen in the cryo-EM reconstructions 
suggested that it may be possible to obtain some structural information on this 
previously unresolved aspect in the structure of CPMV. To investigate this, fresh 
preparations of eVLPs with and without the C-terminal peptide were recently sent 
to the University of Leeds for cryo-EM.   
 
Figure 3.15 Comparison of CPMV-Bottom and eVLPs around the 5-fold axis. 
The red box highlights the differences between the Bottom component (left) and 
eVLPs (right) around the 5-fold axis. 
3.6.6 Neutron scattering studies  
The internal dynamics of eVLP capsids were compared to wt CPMV using neutron 
spin echo experiments conducted by Dr. Simon Titmuss at the University of 
Edinburgh. Clear differences were observed in the effective diffusion coefficients 
for the empty and filled capsids, at a length-scale corresponding to the overall 
diameter of the capsid. The analysis of this data is on-going, but suggests that there 
are differences in the elastic properties of wt CPMV and eVLPs, that could be due to 
the presence and absence of favourable interactions between the capsids and the 
RNA, respectively.  
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3.7 Discussion  
One of the main criteria for a reagent to be chosen for development as a 
nanoparticle is its ease of production. Therefore, for development of eVLPs as 
potential reagents for application in nanotechnology, it was important that 
methods for its large-scale production and purification were established. This 
chapter presented ways to produce milligram quantities of eVLPs from transiently-
infiltrated leaves. Every step in the production pipeline was analysed and 
optimised resulting in an overall increase in eVLP yield.  
Despite various levels of purification, some contaminants, albeit in small amounts, 
were seen to be present in standard eVLP preps. (Figure 3.5). Using mass 
spectrometry, the contaminants were mainly identified to be the large and small 
subunits of the plant protein RuBisCo. The level of purity attained was sufficient 
for all the work described in this thesis and other preliminary experiments in the 
lab. However if desired, eVLPs can be purified further using downstream 
purification techniques such as desalting columns, centrifugal devices and 
incubation in a selection of buffers at different pH.  
Starting from average eVLP yields of 0.05 g/kg FWT, the expression and 
purification system was optimised to deliver yields in excess of 0.3 g/kg FWT. This 
not only helped conduct experiments that involved the use of eVLPs by providing 
abundant starting material, but also threw light on various steps of the production 
pathway making it easier to design purification protocols for genetically and 
chemically modified versions of eVLPs. The average yields currently achieved for 
eVLPs are comparable to yields for other VLPs expressed transiently in N. 
benthamiana. For instance, Norwalk virus VLPs are expressed at 0.4 g/kg FWT (Lai 
and Chen, 2012) and for Hepatitis B VLPs, average expression levels of 0.25-0.3 
g/kg FWT are attained (pers. comm., Alberto Berardi).  
Using a selection of techniques, namely, gel electrophoresis, TEM, cryo-EM and 
neutron scattering studies, it was concluded that eVLPs possessed capsids 
identical to wt CPMV and that eVLPs were genuinely empty. This also confirmed 
similarities between eVLPs and natural Top component.  
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eVLPs were generally found to possess the slow form of the S coat protein since 
eVLPs were routinely harvested after 5-6 dpi. Analysis of particles over time using 
SDS-PAGE (Figure 3.6a) showed that the S coat protein pre-dominantly remains in 
its slow form until 5 dpi, after which it undergoes natural proteolysis to generate 
Sfast. Analysis of native particles on agarose is a quick and easy method for 
detection of C-terminal processing of CPMV. Particles possessing Sslow show 
retarded mobility on agarose in comparison to CPMV possessing the processed 
form of S. This is due to two reasons: 
(i) Presence of two lysine and four arginine residues in the C-terminal peptide 
confers an overall positive charge to the peptide, thereby retarding its 
mobility towards the anode; 
(ii) Presence of sixty copies of the 24 amino acid peptide adds approximately 160 
kDa to the mass of each CPMV capsid. 
Repeated analysis of CPMVslow particles showed that their pattern of migration in 
agarose is not always the same. This raises questions about the efficiency of 
proteolytic processing of the S coat protein. It is not known if the 24 amino acid 
peptide simultaneously cleaves from all sixty S coat proteins in a particle. Kridl and 
Bruening (1983) suggest that even after proteolysis, the peptide may remain 
attached   to the capsid via non-covalent bonds until all sixty S coat proteins are 
processed to generate Sf. Processing of the C-terminal peptide is still not 
completely understood. 
The fact that eVLPs can be readily generated by co-expression of VP60 and 24K 
proves that presence of RNA is not a pre-requisite for capsid formation. However, 
it is still not understood why empty particles, albeit in small amounts, are naturally 
produced in an infection (as Top component). It is not known whether empty 
particles of CPMV provide any benefit to the virus or if they are just produced as a 
bi-product of RNA-containing virions. Production of empty particles could be a 
strategy of the virus to regulate expression levels by depleting unassembled coat 
proteins in the host cell.  
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Following production and characterisation of eVLPs, the focus of the work shifted 
to development of eVLPs for various applications. In parallel to chemical 
modification of eVLPs, attempts were made to genetically fuse peptides to (i) the 
exterior surface of eVLPs for cell-specific targeting and (ii) the interior surface of 
eVLPs for promoting mineralization.  
A 20 amino acid peptide from the foot-and-mouth disease virus (FMDV) was 
selected for expression on the exterior surface of the eVLP capsid since this 
peptide contains an arginine-glycine-aspartate (RGD) motif that mediates specific 
binding to integrin αvβ6 (DiCara et al., 2008). Integrin αvβ6 is an epithelial-specific 
integrin expressed at undetectable levels in healthy cells but is up-regulated 
during tissue remodelling, as in the case of wound healing, inflammation and 
cancer (Caswell and Norman, 2008). So, eVLPs displaying the FMDV peptide on 
their surface would specifically bind to cells expressing integrin αvβ6, i.e. 
cancerous cells.  
To generate chimeric eVLPs, the FMDV peptide was fused to the C-terminus of the 
S coat protein by genetic modification of the plasmid encoding the coat proteins. 
The C-terminus of the S coat protein was chosen because it was expected that upon 
assembly, sixty copies of the peptide would be exposed on the surface of the eVLP 
capsid. However, it was found that modifications to the peptide at the C-terminus 
increased its tendency to cleave and resulted in particles with the processed form 
of the S coat protein. Even though particles were extracted at 5 dpi and analysed 
straightaway, the C-terminus peptide was found to be absent from all particles.  
Attempts were also made to introduce peptides on the interior surface of eVLPs by 
genetic modification of the sequence encoding the N-terminus of the L coat 
protein. The peptides chosen for this purpose were peptides that promote 
mineralization of materials such as metals, metal oxides and alloys (Seker and 
Demir, 2011). In particular, a 13 amino acid peptide that specifically promotes 
mineralization of iron and platinum was chosen (Reiss et al., 2004). Upon genetic 
modification of plasmids and their expression in plants, it was seen that particles 
could not be generated in presence of the N-terminally modified form of the L coat 
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protein, suggesting that modifications to the N-terminus of the large coat protein 
affected particle assembly. 
Other potential sites for modification of eVLPs, identified using literature on 
modified wt CPMV (Porta et al., 2003) and the crystal structure of wt CPMV (Lin 
and Johnson, 2003), continue to be investigated. Internal labelling of eVLPs with 
dyes, such as Oregon Green 488 and Rhodamine Red, has been successfully 
achieved by conjugation of dyes to available lysines on the interior surface of 
eVLPs (Wen et al., 2012). Labelled eVLPs are being developed for studies on the 
uptake of CPMV in mammalian cells.    
The availability of eVLPs has opened opportunities for novel applications of CPMV 
due to reduced bio-safety issues and their ability to encapsulate. One such 
application is the use of eVLPs as a delivery vehicle for nucleic acids and this idea 
has been explored in the following chapter.  
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Chapter 4: Results II 
Study of replication and encapsidation of RNA in CPMV  
4.1 Introduction 
The fact that empty particles of CPMV can be generated, both during an infection as 
the Top component and without an infection by co-expression of VP60 and 24K, 
demonstrates two things: first, that presence of RNA is not a pre-requisite for 
particle assembly in CPMV and second, that cellular RNAs of the host are excluded 
from the capsid during assembly. This makes CPMV different from other viruses, 
such as turnip crinkle virus (TCV) or Hepatitis B virus (HBV), which package 
random host nucleic acids if their own genomic DNA/RNA is not available. This 
ability of CPMV to specifically package RNA makes it a good candidate for use as a 
delivery vehicle for specific nucleic acids, such as antisense oligonucleotides and 
small interfering RNA (siRNA), for research and therapeutic applications. 
siRNAs are being developed to target therapeutically important genes involved in 
cancer, viral infections, autoimmune and neurodegenerative diseases (Tokatlian 
and Segura, 2010). Although siRNA therapy has the potential to be a powerful 
therapeutic drug, its delivery remains a major limitation (Kesharwani et al., 2012). 
There is a requirement for vehicles that can offer protection to siRNA while 
circulating in the body of the host, target siRNA to the desired tissue in the body 
and subsequently upon internalization, release encapsulated siRNA in the 
cytoplasm. Since viruses are designed to protect their genomic nucleic acids in 
harsh environments and release encapsulated material upon internalisation, they 
make ideal candidates for this application.  
This chapter explores the idea of developing CPMV eVLPs for delivery of nucleic 
acids of choice. Preliminary experiments on loading eVLPs with small nucleic acids 
through the five-fold axis pore suggested that loading via simple diffusion into 
particles was not a viable approach. The size and secondary structure of nucleic 
acids made it very difficult to direct short nucleic acids towards the pore and 
thread them into the particle (M. Nelson and P. Saxena, unpublished results). So, it 
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was concluded that methods for packaging DNA or RNA within eVLPs would have 
to involve assembly of the coat proteins around the desired cargo. To develop such 
methods, an understanding of the process of encapsidation in CPMV was needed. 
The work described in this chapter is aimed at defining the elements required for 
packaging of RNA in CPMV with the intention of exploiting the findings to develop 
CPMV eVLPs as carriers of DNA or RNA of choice. Once the requirements for 
packaging nucleic acids within eVLPs are established, methods for the 
incorporation of desired nucleic acids within eVLPs could be developed. Combined 
with previously established methods for the modification of the outer particle 
surface, this could lead to the development of methods for the targeting of specific 
nucleic acids to particular cells.    
Saunders et al. (2009) showed that CPMV eVLPs are formed in absence of wt RNA-
1 and wt RNA-2 by co-expression of VP60 and 24K. A point to note here is that the 
mRNAs which direct the synthesis of VP60 and 24K contain viral sequences yet do 
not get packaged within eVLPs. By contrast, when wt RNA-1 is expressed in 
presence of VP60, particles are generated with RNA-1 packaged within them 
(Figure 4.1). This shows that in CPMV, presence of partial sequences from wt RNA-
1 or RNA-2 is not sufficient for packaging. The reason could simply be that they are 
too small to be efficiently packaged (mRNAs for VP60 and 24K are 2.5 kb and 1.3 
kb long respectively) or that they lack specific recognition sequences needed for 
encapsidation. An alternative hypothesis could be that RNA replication and 
packaging are coupled and only replicating RNAs can be packaged as found with 
picornaviruses (Nugent et al., 1999).  
To investigate the requirements for packaging further, several mutants of RNA-1 
and RNA-2 were generated and their translation, replication and encapsidation 
were studied. The results were consistent with replication being required for the 
packaging of RNAs. 
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Figure 4.1 Analysis of RNA within particles (Saunders et al., 2009). RNA was 
extracted from VLPs (generated as below) using phenol/chloroform and analysed 
on a 1.2% formaldehyde gel. Bands obtained for RNA-1 and RNA-2 have been 
indicated. Samples were run as follows: 
Lane 1: RNA from particles generated by co-expression of 24K and VP60 
Lane 2: RNA from particles generated by co-expression of RNA-1 and VP60  
Lane 3: RNA from particles generated by co-expression of RNA-1 and RNA-2 
 
4.2 Study of encapsidation of a replication-deficient mutant of RNA-1  
A previously generated mutant of RNA-1 called 32E (Liu et al., 2004) was deployed 
to investigate the dependency of RNA encapsidation on RNA replication in CPMV. 
The plasmid for expression of 32E, named pBinPS-32E-NT, was originally designed 
to study the replication of RNA-1 where it was shown that 32E can neither self-
replicate nor support the replication of RNA-2 (Liu et al., 2005; Liu et al., 2004). 
This is because 32E was engineered to lack the 5’ UTR of RNA-1 (Figure 4.2).  
The accuracy of pBinPS-32E-NT was verified by sequencing and the plasmid was 
used in the study described below to compare the abilities of 32E and wt RNA-1 to 
be encapsidated and to support the encapsidation of RNA-2. 
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Figure 4.2 Schematic diagrams of constructs expressing RNA-1 and 32E. 
Relevant sections of pBinPS-1-NT and pBinP-32E-NT (Liu et al., 2004), deployed 
for expression of wt RNA-1 and 32E respectively, are shown. The green arrow and 
red box represent the CaMV 35S promoter and nos terminator respectively. The 
indicated sizes correspond to the length of the transcribed RNA and do not include 
the size of the promoter and terminator.  
The constructs pBinPS-1-NT and pBinP-32E-NT were each co-infiltrated into 
plants with either pBinPS-2-NT (Liu and Lomonossoff, 2002) for expression of wt 
RNA-2 (samples 1 and 3) or pEAQ-HT-VP60 for expression for VP60 (samples 2 
and 4). While pEAQ-HT-VP60 encoded P19 for enhancement of expression, in case 
of pBinPlus-based constructs, P19 was supplied by co-infiltration with pBIN61-P19 
(Voinnet et al., 2003). In parallel, pEAQ-HT-VP60 was infiltrated as a control 
(sample 5). Details of all sets of infiltrations are presented in Table 4.1. 
Sample Infiltrated constructs 
1 pBinPS-1-NT + pBinPS-2-NT + pBIN61-P19  
2 pBinPS-1-NT + pEAQ-HT-VP60 
3 pBinPS-32E-NT + pBinPS-2-NT + pBIN61-P19 
4 pBinPS-32E-NT + pEAQ-HT-VP60 
5 pEAQ-HT-VP60 
Table 4.1 Combinations of constructs infiltrated into N. benthamiana leaves for 
comparative analysis of RNA-1 and 32E.  
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For all combinations of constructs, 10-12 g of infiltrated leaf tissue was harvested 
after 6 dpi and subjected to the standard protocol for particle purification. The 
purified samples were analysed by TEM, which confirmed the presence of 
particles, similar to CPMV in morphology, in samples 1-4. In line with expectation, 
sample 5 did not yield viral particles due to absence of 24K for processing of VP60. 
To further characterise the particles obtained in samples 1-4, 4 µl of each purified 
sample was separated using SDS-PAGE. Bands corresponding to L and S coat 
proteins were observed in samples 1-4 demonstrating that the constructs were 
being translated to generate VP60 and 24K, and that VP60 was being processed to 
yield L and S (Figure 4.3). Particle yield was estimated to be in the range of 0.4-0.5 
g/kg FWT based on the intensities of bands on the gel. The fact that similar yields 
of L and S were obtained in all four samples provided some evidence that even in 
the absence of replication, coat proteins were being translated at levels similar to 
those in presence of replication. 
 
Figure 4.3 SDS-PAGE analysis of particles. 4 µl of samples 1-5 were denatured 
by heat-incubation and separated using SDS-PAGE. The number of the lane 
corresponds to the number of the sample, as per Table 4.1. The standard protein 
marker was run in lane M. Bands observed for L and S upon staining of the gel with 
Coomassie blue are indicated.   
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Particles purified from samples 1-4 were then subjected to native agarose gel 
electrophoresis to verify the presence of intact particles by staining with 
Coomassie blue and to assess the presence of encapsulated RNA within particles by 
staining with ethidium bromide. Approximately 10 µg of particles per sample were 
electrophoresed on agarose. It was observed that in all four samples, particles 
were a mixture of CPMVfast and CPMVslow, i.e. particles possessing the processed 
and unprocessed forms of the C-terminus of the S coat protein, resulting in 
separate bands on agarose (Figure 4.4). Staining with Coomassie blue showed 
presence of particles in all four lanes, while staining of the agarose gel with 
ethidium bromide revealed presence of RNA within particles generated using wt 
RNA-1 (samples 1 and 2) but not within particles generated using 32E constructs 
(samples 3 and 4) (Figure 4.4).  
Figure 4.4 Particle analysis using agarose gel electrophoresis. Particles 
generated by co-expression of various combinations of constructs (as per Table 
4.1) were analysed on agarose by staining with Coomassie blue (left) or ethidium 
bromide (right). The number of the lane corresponds to sample number. The two 
bands seen are due to differentially processed forms of the S coat protein in 
particles, thereby generating CPMVslow and CPMVfast .  
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RNA within particles in samples 1-4 was subsequently extracted and analysed by 
denaturing gel electrophoresis. It was found that either RNA-1 or RNA-2 was 
present within particles from sample 1 while only RNA-1 was detected in particles 
from sample 2, consistent with results shown in Figure 4.1. No RNA was detected 
within particles in samples 3 and 4 showing lack of encapsidation in presence of 
32E. 
The finding that co-infiltration with wt RNA-1 but not 32E results in RNA 
encapsidation points to replication and packaging being coupled.  Infiltration with 
32E clearly resulted in the production of RNA since this was subsequently 
translated to produce the 24K proteinase essential for the generation of particles. 
Yet, no RNA transcripts were packaged within capsids in the presence of the non-
replication competent 32E transcripts. While the lack of packaging of 32E 
transcripts could be explained if the deletion of the 5’ UTR resulted in the 
elimination of a packaging signal, the lack of packaging of wt RNA-2 constructs co-
infiltrated with 32E (Sample 3) cannot be explained this way.  The wt RNA-2 
expressed was not genetically manipulated in any way and was therefore expected 
to contain any packaging signals; furthermore the RNA-2 produced from the same 
construct pBinPS-2-NT was packaged in the presence of wt RNA-1 (sample 1) 
showing that it is potentially fully competent for packaging. The only difference 
between the RNA-2 molecules produced in the presence of wt RNA-1 and 32E is 
that they will be replicated in the former but not the latter situation. Overall, the 
results suggest that the requirement for packaging in CPMV is more than just the 
presence of a sequence or secondary structure within the RNA with the simplest 
explanation being that only replicating RNAs can be packaged.  
To obtain further evidence that replication was necessary for encapsidation, it was 
decided to create other replication-incompetent versions of RNA-1, this time with 
minimal changes to the wt sequence. It was decided to create point mutations in 
the active site of the 87K replicase encoded by RNA-1 such that the mutations 
abolished the ability of the replicase to function. CPMV shares sequence homology 
with other RNA polymerases around a motif in the 87K replicase that contains the 
amino acids: glycine-aspartate-aspartate (GDD). The GDD motif is known to be 
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important for RNA polymerase activity since the first aspartate co-ordinates 
magnesium divalent (Mg2+) cations during RNA synthesis thereby stabilizing the 
leaving pyrophosphate group (Delarue et al., 1990). Mutations within the GDD 
motif, especially of the first aspartate residue, result in loss of enzyme function 
(Jablonski and Morrow, 1995; Kim et al., 2007; Shwed et al., 2002; Vazquez et al., 
2000; Wang and Gillam, 2001; Wang et al., 2007). Hence, a point mutation in the 
GDD motif of CPMV RNA-1 would knock-out replicase activity without any 
substantial changes to the sequence of RNA-1.  
Primers (listed in Appendix I) were designed to separately introduce the following 
mutations in the replicase: 
(1) G389A – to change glycine to alanine, i.e. GDD to ADD 
(2) D390A – to change aspartate to alanine, i.e. GDD to GAD 
(3) D390E – to change aspartate to glutamine, i.e. GDD to GED 
G389A and D390E were chosen since substitution of glycine with alanine or 
aspartate with glutamate was expected to cause minimal changes to the structure 
of the replicase due to similarities in the properties of these amino acids. On the 
other hand, D390A was expected to completely disrupt the structure of the 
replicase. Either way, all three mutations were expected to knock-out replicase 
activity without affecting the expression and activity of the other proteins encoded 
by RNA-1.  
In order to introduce the above mutations, plasmid pBinPS-1-NT (Liu and 
Lomonossoff, 2002) was subjected to SDM and potential mutant colonies were 
transferred to liquid media to obtain plasmid for analysis by sequencing. It was 
found that a majority of colonies obtained on plates did not grow in liquid media 
suggesting that the bacteria had lost viability. Amongst the few that grew, 
substantial rearrangements were found in the sequences of their plasmids. The 
desired mutations in the GDD motif were detected in some of these plasmids but 
the presence of other sequence rearrangements meant that the plasmids no longer 
encoded wt RNA-1 from CPMV with just one amino acid substitution.  
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Either loss of viability or sequence rearrangements upon propagation of wt RNA-1 
in E. coli has previously been observed during manipulation of RNA-1 sequences 
(G. P. Lomonossoff, pers. comm.). In addition, the vast amount of literature 
available on RNA-2 as compared to RNA-1 also shows that in the past, most work 
has concentrated on manipulation of RNA-2 sequences, suggesting difficulties in 
manipulation of RNA-1. This is likely to be due to leaky promotion of RNA-1 
leading to accumulation of viral proteins with catalytic activities, such as the 
helicase, the proteinase and the replicase, in the bacterial cell. Such proteins are 
capable of acting on bacterial nucleic acids and therefore, possibly interfere with 
housekeeping processes in E. coli.  
One of the ways to combat problems with bacterial expression of toxic proteins is 
to slow down the rate of growth of the bacteria to suppress basal expression of 
toxic genes. This approach was tried by incubating E. coli colonies transformed 
with RNA-1 constructs at 28°C instead of the optimum growth temperature of 
37°C. In addition, 2% glucose was added to the media since it mediates catabolic 
repression thereby reducing basal expression levels in bacteria leading to reduced 
growth rates (Saida, 2007). However, RNA-1 mutants could still not be obtained.    
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4.3 Study of encapsidation of a non-replicatable mutant of RNA-2 
After several failed attempts at creation of GDD mutants of RNA-1 to study the 
possible coupling of replication and packaging, an alternative approach was 
adopted. This involved the creation of a non-replicatable form of RNA-2 that could 
still be translated to generate all RNA-2-encoded proteins. The question was asked 
whether this mutant RNA-2, that did not replicate, would be encapsidated in 
presence of RNA-1.  
To this end, a version of RNA-2  with HT mutations in its 5’ UTR was created using 
the vector pEAQ-HT (Sainsbury et al., 2009). The sequence of RNA-2 starting from 
AUG 512 was amplified from the plasmid bearing wt RNA-2, namely pBinPS-2-NT 
(Liu and Lomonossoff, 2002), and cloned in pEAQ-HT using the restriction sites 
AgeI and StuI in its polylinker. As mentioned previously, the HT mutations 
eliminate the start codon at position 161 (AUG161) and another out-of-frame start 
codon at position 115 (AUG115) in the 5’ UTR (Sainsbury and Lomonossoff, 2008). 
Based on previous studies (Holness et al., 1989; Rohll et al., 1993; Wellink et al., 
1993), these mutations, as well as enhancing translation, would be expected to 
abolish replication of any RNA-2-based construct bearing them.  So pEAQ-HT-RNA-
2 (Figure 4.5), thus generated was not expected to replicate and hence, was ideal 
for investigation of the link between replication and encapsidation.  
At the same time, another version of RNA-2 was created by amplifying the entire 
coding region of RNA-2 (starting from AUG 161) from the plasmid pBinPS-2-NT 
and inserting it downstream of the HT 5’ UTR in the vector pEAQ-HT using sites 
AgeI and StuI. The construct thus generated, named pEAQ-HT-full length RNA-2 
(Figure 4.5), contained a repeat of the region between AUG161 and AUG512. This 
construct was produced to determine whether the presence of both AUGs and the 
maintenance of their frame relationship positioned downstream of the HT leader 
would restore the ability of HT-full length RNA-2 to be replicated.  
 
 
 CHAPTER 4 
  91 
 
 
 
 
Figure 4.5 Schematic diagrams of constructs expressing mutants of RNA-2. wt 
RNA-2 was expressed from pBinPS-2-NT (Liu and Lomonossoff, 2002) while the 
RNA-2 mutants were encoded in pEAQ-HT-based vectors (Sainsbury et al., 2009). 
HT-RNA-2 is a mutant of RNA-2 with two point mutations in its 5’ UTR (HT 
mutations; represented by an asterisk). HT-full length RNA-2 is a mutant of RNA-2 
containing both the HT mutations as well as the full-length coding sequence of 
RNA-2.  HT-VP60 also contains the HT mutations and encodes the L and S coat 
proteins. The green arrow and red box represent the CaMV 35S promoter and nos 
terminator respectively. The indicated sizes correspond to the length of the 
transcribed RNA and do not include the size of the promoter and terminator.  
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The mutants of RNA-2, defined in Figure 4.5, were each infiltrated into N. 
benthamiana leaves in presence of wt RNA-1 (from pBinPS-1-NT). Since pEAQ-HT-
based vectors encoded P19 for enhancement of expression, in case of non-pEAQ 
vectors, P19 was supplied by co-infiltration of pBIN61-P19 (Voinnet et al., 2003). 
Details of the different sets of infiltrations are presented in Table 4.2. 
 
Sample Infiltrated constructs 
1 pBinPS-1-NT + pBinPS-2-NT + pBIN61-P19  
2 pBinPS-1-NT + pEAQ-HT-full length RNA-2 
3 pBinPS-1-NT + pEAQ-HT-RNA-2 
4 pBinPS-1NT + pEAQ-HT-VP60 
Table 4.2 Combinations of constructs infiltrated into N. benthamiana leaves for 
analysis of replication and encapsidation of different versions of RNA-2.  
 
At 12-15 dpi, plants infiltrated with construct combinations 1 and 2 showed 
symptoms characteristic of a CPMV infection, such as crinkling of leaves and vein 
clearing in upper leaves. By contrast, no such symptoms were observed in plants 
infiltrated with construct combinations 3 and 4 (Figure 4.6). The same results 
were observed in four independent plants infiltrated with each of the above 
combinations of constructs. This provided evidence that wt RNA-2 (sample 1) and 
HT-full length RNA-2 (sample 2) were being replicated, encapsidated and 
systemically moved through the plant. On the other hand, HT-RNA-2 (sample 3) 
and HT-VP60 (sample 4) were neither being replicated nor packaged, limiting their 
expression to the infiltrated tissue. 
The appearance of symptoms in plants infiltrated with wt RNA-1 and HT-full 
length RNA-2 (sample 2) was indistinguishable from symptoms in plants 
infiltrated with wt RNA-1 and wt RNA-2 (sample 1).   
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Figure 4.6 Symptoms in the upper leaves of plants upon expression of RNA-2 
mutants in presence of wt RNA-1. wt RNA-1 co-expressed with HT-RNA-2 (left) 
did not result in symptoms characteristic of a viral infection in the upper leaves of 
N. benthamiana. Co-expression of HT-full length RNA-2 and wt RNA-1 (right) 
resulted in systemic movement of particles resulting in viral symptoms. Plants 
were photographed on 18 dpi. 
 
Infiltrations listed in Table 4.2 were repeated for further analysis of the expression 
of the constructs and the particles thereby produced. The infiltrated leaves were 
harvested at 6 dpi and subject to the standard protocol for particle purification. 
Separation of purified extract using SDS-PAGE confirmed presence of particles in 
all four samples. This showed that all constructs were functional and coat proteins 
were being produced from all versions of RNA-2, regardless of their ability to be 
replicated.  
Approximately 100 µg of particles from each sample were used for extraction of 
RNA encapsidated within them. RNA-1 was expected to be replicated and packaged 
in each case but encapsidation of the RNA-2 mutants was questionable. Analysis of 
extracted RNA on denaturing agarose gels showed that versions of RNA-2 that 
could be replicated were packaged and others that could not be replicated were 
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not packaged (Figure 4.5). In other words, wt RNA-2 and HT-full length RNA-2 
were packaged in presence of RNA-1, whereas HT-RNA-2 and HT-VP60 were not.  
 
 
Figure 4.7 Analysis of RNA within capsids generated by co-expression of 
mutant versions of RNA-2 and wt RNA-1. RNA extracted from particles (as 
below) electrophoresed on denaturing agarose gels to resolve RNA on the basis of 
its size and imaged after 1 hour (a) and after 2 hours (b). Bands for wt RNA-1 and 
RNA-2 have been indicated. 
Lane1: RNA from particles generated by co-expression of RNA-1 and RNA-2  
Lane 2: RNA from particles generated by co-expression of RNA-1 and HT-full 
length RNA-2  
Lane 3: RNA from particles generated by co-expression of RNA-1 and HT- RNA-2 
Lane 4: RNA from particles generated by co-expression of RNA-1 and HT- VP60 
Lane M: RNA marker  
 
The 2.5-3 kb band observed in Lane 4 of Figure 4.7 is likely to be due to 
degradation of RNA-1. The band was not seen in previous and subsequent RNA 
extractions from particles generated using the same combinations of constructs, 
i.e.  pBinPS-1NT + pEAQ-HT-VP60.  
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Further experiments on RNA-2 mutants were hampered due to the fact that during 
design of primers for generation of construct pEAQ-HT-RNA-2, two extra bases 
were inadvertently incorporated upstream of the start codon (AUG 512). Although 
this did not affect results that have been reported, it made it cumbersome to 
generate a construct encoding wt RNA-2 in the vector pEAQ-HT. This aspect 
continues to be worked upon. 
 
4.4 Discussion  
The specific recognition of viral genomic RNA for encapsidation is a critical event 
in the infection cycle of plant viruses from the Comoviridae family since 
encapsidation of RNA is essential for systemic spread of the infection and cell-to-
cell movement of the virus. In natural infections of most viruses, viral RNA 
encapsidation is seen to be highly specific and cellular RNAs are only rarely 
packaged into virions (Rochon and Siegel, 1984). In CPMV, even in the absence of 
the viral RNAs, cellular RNAs are not encapsidated suggesting particularly high 
specificity in its packaging. 
Different viruses adopt different mechanisms to achieve specificity in recognition 
of RNA by their coat proteins. The presence of a specific packaging signal or origin 
of assembly within the RNA has been well characterised for viruses such as TMV  
(Turner et al., 1988; Zimmern, 1977) and TCV (Qu and Morris, 1997). Similar 
packaging signals have been observed to be present on the genomes of  HBV 
(Junker-Niepmann et al., 1990), Sindbis virus (Weiss et al., 1994) and cucumber 
necrosis virus (Reade et al., 2010). However, no such packaging signal has been 
identified on the RNAs of CPMV. The only homology that exists between RNA-1 and 
RNA-2 of CPMV lies in their 5’ and 3’ UTRs and there has been speculation that 
these might contain packaging signals (Verver et al., 1998; Wellink et al., 1994). 
However, experiments described in this chapter involving expression of wt RNA-2 
in a non-replicating system (Section 4.2) showed that the presence of the 5’ and 3’ 
UTRs was not sufficient for encapsidation.  
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Studies using replication-deficient mutants of CPMV RNA-1 and RNA-2, presented 
in this chapter and summarized in Figure 4.8, show that encapsidation of an RNA 
molecule only occurs when it is replicating, suggesting coupling of RNA replication 
and encapsidation. However, the underlying mechanism whereby a replicating but 
not a non-replicating version of the same RNA molecule is packaged (for instance 
the RNA-2 molecules in Fig. 4.4) is not clear.  
One of the factors that might play a role in determining RNA that gets encapsidated 
in CPMV is the presence of the genome-linked viral protein VPg. All newly 
synthesised RNAs emerging from a replication complex possess a VPg covalently-
bound to their 5’ end, which is thought to act as a primer for RNA synthesis 
(Lomonossoff et al., 1985; Wimmer, 1982). On the other hand, non-replicating 
RNAs, expressed using Agrobacterium-mediated expression vectors, are 
transcribed from their DNA complement in the nucleus of the plant cell and 
therefore, possibly possess a 5’ 7-methylguanosine cap structure, as commonly 
observed in eukaryotic mRNAs originating from the nucleus (Kapp and Lorsch, 
2004). This may influence recognition of the RNA by coat proteins for 
encapsidation. In addition, the proximity of RNA and coat proteins may affect RNA 
encapsidation; in a replicating system, translation of coat proteins and replication 
of RNA occurs close to one another in the cytoplasm.      
Another possibility that cannot be ruled out is that the lack of packaging of RNA in 
the non-replicating system was due to the lack of availability of RNA transcripts. 
Although an unlikely possibility, it is required to demonstrate that, for instance in 
case of experiments with 32E, wt RNA-1 and 32E were both present in sufficient 
amounts in the host cell despite differences in their method and location of 
production (RNA-1 transcripts were synthesised by replication in the cytoplasm; 
32E transcripts were produced by transcription of its DNA complement in the 
nucleus). Studies for quantification of RNA could not be undertaken due to time 
constraints but are recognised as being essential for culmination of this work. 
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Figure 4.8 Summary. Species of virus-like particles obtained upon co-expression 
of various constructs (as listed in the first column).  
 
 CHAPTER 4 
  98 
 
Functional coupling between replication and packaging of RNA has been 
previously demonstrated in positive-strand viruses of diverse origins. In 
poliovirus, a member of Picornaviridae family, coupling of RNA packaging to 
replication and of replication to translation has been shown (Novak and 
Kirkegaard, 1994). The observed coupling is thought to be a result of direct 
interactions between the RNA replication machinery and the capsid proteins, so 
that only newly synthesised RNAs emerging from the replication complex get 
packaged (Nugent et al., 1999). Coupling between replication and packaging in the 
Flaviviridae family has also been shown using Kunjin virus (Khromykh et al., 
2001).  
Coupling of translation and packaging in viruses makes evolutionary sense as this 
ensures that only those genomes capable of translating a full complement of 
functional proteins get packaged. Consequently, other genomes with mutations, 
which abolish their ability to produce functional proteins, do not get packaged. 
Also, since a majority of the RNA viruses are assembled in the cytoplasm, it is 
economical for the virus to replicate and encapsidate RNA simultaneously.  
A similar coupling between replication-dependent translation and encapsidation 
has been observed in brome mosaic virus (BMV) from the Bromoviridae family 
(Annamalai and Rao, 2006) and flock house virus (FHV) from the Nodaviridae 
family (Venter et al., 2005). In FHV, the requirement of a physical interaction 
between the viral replicase and capsid proteins for specificity in packaging has also 
been demonstrated (Seo et al., 2012). An interesting observation in FHV was that 
uncoupling of viral protein synthesis from RNA replication affected packaging of 
RNA. It was seen that neither RNA-1 nor RNA-2 of FHV, which were both being 
replicated,  were packaged when the capsid protein was supplied in trans from 
non-replicating RNA (Venter et al., 2005). The situation in CPMV, however, is 
different since it has been shown that CPMV RNA-1 is packaged by capsid proteins 
supplied in trans from a non-replicating vector (pEAQ-HT-VP60) (Saunders et al., 
2009). The ability of capsid proteins to package RNA-1 in trans suggest that 
efficient packaging of any replicating RNA is likely to be achieved by the coat 
proteins supplied using pEAQ-HT-VP60.  
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Based on the above hypothesis and the observation that RNA replication is needed 
for encapsidation, I wish to propose a tripartite system for packaging ‘RNA of 
choice’ in CPMV capsids (Figure 4.9). To package any desired RNA within CPMV, 
using this system, three species of RNA will need to be co-expressed:  
(i) wt RNA-1 to provide the replication machinery;  
(ii) RNA encoding VP60 to supply the coat proteins;  
(iii) modified RNA-2 which could contain any RNA sequence along with the 
minimum sequence recognised as being essential for replication in CPMV 
(Canizares et al., 2006).  
This would be expected to result in replication of (i) and (iii) followed by their 
encapsidation in separate particles using coat proteins supplied in trans by (ii). 
Capsids containing the modified RNA-2 could be purified using a density gradient 
and used for the delivery of the RNA, probably after modification of the outer 
capsid surface. 
 
 
Figure 4.9 Proposed model for co-expression and encapsidation of modified 
RNA-2. Expression of a replication competent mutant of RNA-2 encoding the ‘RNA 
of choice’, in presence of wt RNA-1 and VP60 will result in formation of the three 
kinds of particles shown above.  
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Chapter 5: Results III 
Creation of transgenic plants producing eVLPs 
5.1 Introduction 
Stable transgenic plants are an attractive alternative to transient protein 
expression systems in situations where continuous production of a defined 
product is required. Though creation of a transgenic line requires considerable 
initial effort, once a stable line has been generated by transformation of leaf tissue 
and self-fertilised to obtain transgenic seeds, large-scale protein expression can be 
achieved with little further effort. Transgenic seeds can be stored for years and are 
easy to transport. They can be sown on any desired scale and plants can be 
harvested as per convenience since transgenes are constitutively expressed 
throughout the lifetime of the plant. This is a complete contrast to transiently-
infiltrated leaf tissue where optimal expression is achieved on a certain day post-
infiltration and only in the infiltrated region of the leaf. In addition, transient 
infiltration requires a higher degree of containment since live Agrobacterium 
cultures are infiltrated into plants. Moreover, delivery of concentrated solutions of 
agrobacteria puts host plant cells under unnatural stress, often leading to 
degradation of expressed proteins. The great advantage of transient expression is 
its speed and flexibility which enables a wide variety of different constructs to be 
expressed and the properties of the resultant proteins analysed. However, once a 
construct expressing a product with the required properties has been identified 
using this approach, it may be advantageous to express it continuously using stable 
transformation. Indeed, the optimum approach may be to use transient expression 
for initial studies followed by the generation of stable transformants for long-term 
production, ideally using exactly the same construct.     
For all the above reasons, it was decided to investigate the possibility of creating 
transgenic lines of N. benthamiana for continuous production of eVLPs since there 
appears to be a considerable, on-going demand for this material. However, it is 
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generally the case that the levels of expression achieved from transient expression 
are much higher than those from plants transformed with conventional binary 
vectors. So, prior to creation of eVLP transgenic lines, I wished to create an 
expression system for transgenic plants which incorporates the features of the 
CPMV-HT system with the aim of achieving high levels of expression from stably 
integrated transgenes. Such a system would be extremely valuable not only for the 
production of eVLPs but also for many other proteins where continuous 
production is required. 
One of the factors that contributes to high levels of expression obtainable with the 
CPMV-HT system is the use of the suppressor of silencing P19 from the tomato 
bushy stunt virus (TBSV) (Voinnet et al., 2003).  P19 is a 19 kDa protein which self-
interacts to form homodimers that specifically sequester 21 nucleotide siRNAs 
regardless of their sequence (Omarov et al., 2006; Ye et al., 2003). Binding of P19 
to siRNAs blocks post-transcriptional gene silencing and leads to up-regulation of 
protein expression. When co-expressed with GFP, P19 leads to as much as 50-fold 
increase in GFP expression (Voinnet et al., 2003). However, when used in 
transgenic systems, P19 was found to inhibit plant regeneration, though it can be 
used in transgenic cell cultures (Sun et al., 2011). Published studies report that leaf 
discs transformed with P19 do not regenerate and the only transformants that 
survive are ones with negligible levels of P19 (Scholthof et al., 1995). This is not 
surprising as it has now been demonstrated that P19 interferes with miRNA 
pathways involved in growth and development by binding to miRNA duplexes 
thereby making it impossible to regenerate plants from transformed leaf discs 
(Chapman et al., 2004; Dunoyer et al., 2004). Hence, P19 cannot be deployed in 
stably transformed plants for enhancement of expression. Inability of leaf discs to 
regenerate and other severe developmental defects have also been found with 
transgenic expression of other silencing suppressors such as HcPro of tobacco etch 
virus, HcPro of potato virus Y and AC2 of African cassava mosaic virus (Mallory et 
al., 2002; Siddiqui et al., 2008; Soitamo et al., 2011). 
This chapter investigates the use of a previously characterized mutant of P19, 
P19/R43W, to suppress virus-induced RNA silencing without the concomitant 
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developmental effects. P19/R43W was first identified in an attenuated strain of 
TBSV where it was found to prevent the onset of systemic lethal necrosis in N. 
benthamiana (Chu et al., 2000) while maintaining some ability to bind siRNAs 
(Omarov et al., 2006). Sequestration of siRNAs by P19 is modulated by a central 
region of P19 that is positioned at the inner core of the dimer whereas R43 is 
located on the periphery of each monomer (Scholthof, 2006). So, the single amino 
acid substitution of arginine at position 43 with tryptophan still allows P19 to bind 
siRNA duplexes but the binding is weaker. The crystal structure of P19 bound to a 
21 nt siRNA duplex suggests that the R43W mutation destabilizes the interaction 
of a tryptophan residue (W39) in each P19 monomer with the 3’ end of siRNA 
(Figure 5.1) (Xia et al., 2009; Ye et al., 2003). This makes the binding of P19/R43W 
with siRNA duplexes unstable, resulting in reduced suppression of RNA silencing. 
 
Figure 5.1 Location of R43 in P19-siRNA duplex complex. (Xia et al., 2009). 
Structural diagram of a P19 dimer (green) bound to a helical 21 bp siRNA duplex 
(purple). R43 is located on the periphery of the P19 dimer and makes indirect 
contacts with the siRNA duplex.  
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Even though it had been demonstrated that P19/R43W had reduced but sufficient 
ability to sequester virus-derived siRNAs and suppress virus-induced RNA 
silencing in the context of a viral infection (Omarov et al., 2007; Qiu et al., 2002), no 
evidence was available that P19/R43W would effectively suppress RNA silencing 
of heterologous genes outside the context of a viral infection. The results in this 
chapter demonstrate the effectiveness of P19/R43W in enhancement of expression 
of foreign genes in transiently-infiltrated as well as permitting the regeneration of 
homozygous transgenic plants. GFP was used for proof-of-principle studies 
followed by expression of pharmaceutically valuable proteins, such as human anti-
HIV antibody 2G12 and the human gastric lipase (hGL). Finally, these results were 
used to design constructs for creation of transgenic N. bethamiana lines expressing 
high levels of eVLPs. 
Generation of constructs and regeneration of leaf discs for the hGL transgenics 
(described in Section 5.3.2) and for the eVLP transgenics (Section 5.4) was done 
with the help of two rotation students in the lab, Mr. Hadrien Peyret and Miss Tilly 
Eldridge. 
5.2 Creation of lines transgenic for GFP 
5.2.1 Generation of constructs 
To test expression of GFP in presence of P19/R43W, pEAQspecialKm-GFP-HT 
(Figure 5.2a) was generated by SDM of pEAQspecialK-GFP-HT (Sainsbury et al., 
2009). Primers P19-R43W-SDM-F and P19-R43W-SDM-R (Appendix I) were used 
to change nts. ‘CGG’ (encoding arginine) to ‘TGG’ (encoding tryptophan) in order to 
introduce the point mutation R43W in wt P19 encoded by pEAQspecialK-GFP-HT. 
After verification of the mutation by sequencing, pEAQspecialKm-GFP-HT was 
transformed into agrobacteria for expression in plants.  
In parallel, the expression cassette for GFP in the above vectors was replaced with 
a multiple cloning site to generate plasmids pEAQspecialK and pEAQspecialKm, 
which were used for expression of 2G12 described in Section 5.3.1.  
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Figure 5.2 Schematic diagrams of constructs used for expression of GFP.       
(a) pEAQspecialKm-GFP-HT was created by SDM of pEAQspecialK-GFP-HT 
(Sainsbury et al., 2009) to introduce the R43W mutation in P19. The mutation is 
represented by an asterisk. LB and RB represent left and right borders 
respectively. (b) T-DNA regions of the plasmids used in this study for comparison. 
The main difference is the presence/absence of the P19 expression cassette. 
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5.2.2 Transient expression of GFP in presence of P19/R43W  
Before proceeding with leaf disc transformation experiments to create transgenic 
plants, constructs pEAQspecialK-GFP-HT and pEAQspecialKm-GFP-HT were tested 
by transient expression in plants. pEAQselectK-GFP-HT (Sainsbury et al., 2009) 
was used as a control since the T-DNA of this vector does not encode any 
suppressor of silencing. Agrobacteria cultures, separately harbouring the three 
vectors (Figure 5.2b), were infiltrated into N. benthamiana leaves for comparison 
of GFP expression. At 6 dpi, the expression levels of GFP were assessed visually by 
the illumination of the infiltrated leaves in UV light and by spectrofluorometry 
(Figure 5.3).  
                     
Figure 5.3 Transient expression of GFP in presence of wt P19 and P19/R43W. 
(a) Leaves expressing GFP from plasmids pEAQselectK-GFP-HT (no P19), 
pEAQspecialK-GFP-HT (wt P19) and pEAQspecialKm-GFP-HT (P19/R43W) were 
photographed on 6 dpi under UV light. (b) Infiltrated leaves were harvested and 
processed for quantification of fluorescence. Yield calculations based on 
spectrofluorometry readings are shown above. Values are averages of expression 
levels of three biological replicates.  
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As seen in Figure 5.3, in the absence of any suppressor of silencing (pEAQselectK-
GFP-HT), GFP expression levels of 0.1 g/kg FWT were obtained while 
pEAQspecialK-GFP-HT (encoding wt P19) gave GFP levels of 1.4 g/kg of FWT, a 
result similar to that reported previously (Sainsbury et al., 2009). In the case of 
pEAQspecialKm-GFP-HT, harbouring P19/R43W, GFP levels of 0.7 g/kg of FWT 
were achieved, approximately half that observed when the wt P19 was used and 
about 7-fold greater than those obtained in the absence of any suppressor. This 
demonstrates the reduced, though still substantial, ability of P19/R43W to 
enhance expression of a transiently expressed gene. 
5.2.3 Stable integration of GFP and P19/R43 in N. benthamiana  
Once transient studies confirmed that P19/R43W retained a substantial ability to 
enhance the expression of a heterologous gene, the next step was to determine its 
ability to allow the regeneration of stably transformed N. benthamiana and, if this 
proved possible, to determine its ability to enhance gene expression. To this end, 
leaf discs were separately transformed with the three vectors described in Figure 
5.2b using the method described in Section 2.4.3. In 3-4 weeks, formation of callus 
was observed in transformed leaf discs and calli were moved to fresh media for 
development of shoots.  While a number of primary transformants (T0) could be 
isolated when pEAQspecialKm-GFP-HT or pEAQselectK-GFP-HT were used for 
transformation, no plants could be regenerated when pEAQspecialK-GFP-HT, 
expressing wt P19, was used. This is consistent with previously reported toxigenic 
properties of wt P19 (Scholthof, 2006). By contrast, primary transformants 
suggested that P19/R43W was being tolerated within the plant.  
One plant each from the T0 population generated upon transformation with 
pEAQselectK-GFP-HT (expressing no suppressor of silencing; referred to as Line 3) 
and with pEAQspecialKm-GFP-HT (expressing P19/R43W; referred to as Line 5) 
was selected for analysis of GFP expression. Both T0 plants grew normally and 
fluoresced under UV light showing successful integration of the GFP gene (Figure 
5.4). Upon visualization under UV light, Line 5 appeared to give higher 
fluorescence that Line 3. However, assays for quantification of GFP needed to be 
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undertaken before any conclusions could be drawn. The plants were self-fertilized 
and the resultant seeds were sown on MS agar (without any antibiotic selection) to 
generate a T1 population of around 50 plants from each line. None of the T1 plants 
from Line 3 or Line 5 showed any obvious developmental defects.  
 
Figure 5.4 Phenotype of plants transgenic for GFP and P19/R43W. T0 plants 
of Line 3 and Line 5 were brought to flower to illustrate their normal development 
independent of the presence of P19/R43W. Under UV light, GFP fluorescence is 
evident in transgenic plants in comparison to a non-transformed plant which 
appears red due to the fluorescence of leaf chlorophyll in UV light.  
5.2.4 Analysis of GFP expression levels in transgenic N. benthamiana  
Initial characterization of GFP expression was performed by visually scoring each 
T1 plant for green fluorescence under UV light followed by verification using 
spectrofluorometry. T1 plants from both Line 3 and Line 5 appeared to give three 
distinct levels of GFP fluorescence, with the ratio of plants showing high, medium 
and no fluorescence being approximately 1:2:1 (Figure 5.5). Even though a strict 
correlation between zygosity and level of expression cannot be assumed, these 
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results fit with the occurrence of a single integration event in both cases, where the 
ratio 1:2:1 corresponds to homozygotes : heterozygotes : null segregants.  
 
Figure 5.5 GFP expression levels in T1 populations of Line 3 and Line 5.  Bars 
show the percentage of plants expressing high levels of GFP (bright green bars), 
medium levels of GFP (dark green bars) and no GFP (red bars) amongst the T1 
population of Line 3 and Line 5, as judged by visualisation of leaves under UV light. 
The ratio is roughly 1:2:1. 
For detailed quantitative analysis of GFP expression, the fifteen highest expressing 
plants were chosen from Line 3 and Line 5 each based on the initial 
spectrofluorometry results. This selection was done to reduce the number of 
plants to be analysed over generations. Moreover, I was interested in finding 
plants homozygous for P19/R43W and the fifteen highest expressing plants (top-
third of the T1 population) had the highest probability of being homozygous for 
the transgene.    
Leaf tissue was harvested from all fifteen plants of Line 3 and Line 5 and GFP 
fluorescence was quantified by spectrofluorometry. Although there was 
considerable variation in the levels of GFP in T1 plants from the same line, overall, 
GFP expression levels were higher in plants of Line 5 in comparison with those of 
Line 3 (Figure 5.6). For Line 3, the average level of GFP expression was 48 mg/kg 
FWT whereas that the average level of GFP expression in Line 5 was 66 mg/kg 
FWT, which is an increase of almost 40%. This shows that the chances of getting a 
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high-expressing transgenic line for GFP are much higher if P19/R43W is co-
expressed with GFP.  
 
Figure 5.6 Comparison of expression levels of GFP in Line 3 and Line 5. Fifteen 
plants (numbers along the X-axis) from the T1 population of Line 3 (blue bars) and 
Line 5 (red bars) have been arranged in increasing order of GFP expression. 
Although the difference between the highest expressor of both lines is only 4.3 
mg/kg FWT, the average level of expression is higher in Line 5, i.e. in presence of 
P19/R43W. Plants subsequently identified as homozygotes (details in Section 
5.2.5) have been marked with an asterisk (*). 
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5.2.5 Identification and analysis of plants homozygous for P19/R43W 
If transformation with P19/R43W was to be used as a practical method of 
enhancing transgene expression, it was essential to determine if plants 
homozygous for P19/R43W could be made since the ability to produce 
homozygous plants is a pre-requisite for the creation of a true-breeding line. 
Previous attempts to produce transgenic plants homozygous for other suppressors 
of silencing have been unsuccessful  (Mallory et al., 2002).  
To identify homozygotes among the fifteen T1 plants of Line 3 and Line 5, each 
plant was self-fertilised and seeds were collected. These were then germinated on 
agar in the absence of any antibiotic selection in the media to enable growth of the 
null segregants in addition to the transgenic seedlings. After 3-4 weeks, the 
seedlings were scored for GFP expression by visualisation under UV light. In the 
majority of cases, only 50-75% of the T2 seedlings expressed GFP showing that 
there was a proportion of null segregants in the T2 generation, indicating that 
selfed T1 parent was heterozygous. However, for plant 3.26 of Line 3 and plants 
5.5, 5.10, and 5.12 of Line 5, 100% of the T2 seedlings expressed GFP 
demonstrating that their parent plant was homozygous for GFP (Figure 5.7). Since 
P19/R43W was encoded on the same T-DNA as GFP, it was very likely that plants 
homozygous for GFP were also homozygous for P19/R43W.  
Plants identified to be homozygous for GFP and P19/R43W in this way have been 
marked with an asterisk in Figure 5.6. As expected, these homozygotes were found 
to be amongst the highest expressors for each line. On comparing the average yield 
of homozygous plants of Line 3 and Line 5, the presence of P19/R43W appears to 
enhance expression of GFP approximately 1.7 fold. All homozygous individuals of 
Line 3 and Line 5 were phenotypically normal which demonstrated that even when 
expressed from two alleles, P19/R43W did not interfere with growth and 
development in N. benthamiana.  
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Figure 5.7 GFP expression in the T2 generation of Line 3 and Line 5. Seeds of 
T1 plants (numbered on the top-left corner of each picture) from Line 3 and Line 5 
were germinated on agar to assess GFP expression and four-week old seedlings 
were photographed under UV light. Section (a) shows plates where 100% of the 
seedlings expressed GFP showing that their parent plant was homozygous for GFP. 
Section (b) shows plates where around 75% of the seedlings expressed GFP 
indicating that their parent plant was heterozygous for GFP. 
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5.3 Creation of lines transgenic for pharmaceutically valuable proteins 
Following promising results achieved with GFP, the P19/R43W-based expression 
system was extended to two pharmaceutically valuable proteins: a human IgG 
antibody named 2G12 and the human gastric lipase.  
5.3.1 Human HIV-1 antibody 2G12  
2G12 is a human monoclonal antibody to a surface glycoprotein (gp120) of human 
immunodeficiency virus type 1 (HIV-1) (Buchacher et al., 1994). 2G12 is a good 
candidate for treatment of HIV-1 infections by passive immunization since it 
possesses potent and broad neutralizing activity against primary strains of HIV-1 
(Trkola et al., 1996).  In addition, recent studies in primates have demonstrated the 
ability of 2G12 to prevent HIV-1 transmission when supplied through mucosal 
tissue (Mascola et al., 1999; Mascola et al., 2000). However in all these cases, 
multiple high doses of 2G12 are needed for effective treatment. Currently 
produced using Chinese Hamster Ovary (CHO) cell lines, there is a clear demand 
for a low-cost high-level production method for 2G12 and a transgenic plant 
expression system would be a good option.  
Plant production of 2G12 involves co-expression of heavy and light chains of 2G12 
and purification under non-reducing conditions. 2G12 was chosen for this work 
since it had previously been produced in N. benthamiana leaves by transient 
infiltration and preliminary studies suggested that the binding and neutralization 
properties of plant-produced 2G12 were generally similar to that of CHO cell-
produced 2G12 (Sainsbury et al., 2010b). In addition, the approval for Phase I 
clinical trials of 2G12 produced in transgenic tobacco (Fox, 2011) encouraged 
further research on methods for its large-scale production in plants. 
5.3.1.1 Transient expression of 2G12 and P19/R43W 
The cassettes for expression of the heavy and light chains of 2G12, consisting of the 
35S promoter, the HT 5’ UTR, the gene encoding the heavy/light chain, the 3’ UTR 
and the nos terminator, were amplified from plasmids pBD2G12HE-HT and 
pBD2G12L-HT (Sainsbury et al., 2010b) respectively. In addition, pBD2G12HE-HT 
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encoded an ER-retention signal at the 5’ end of the gene encoding the heavy chain 
to target the protein to the ER for higher expression levels (Sainsbury and 
Lomonossoff, 2008). Post amplification, the expression cassette for the light chain 
was cloned within the AscI sites of the vectors pEAQspecialK and pEAQspecialKm 
(Section 5.2.1), followed by cloning of the heavy chain within the PacI sites of both 
the above vectors. The resultant vectors were named pEAQspecialK-HEL and 
pEAQspecialKm-HEL (Figure 5.8).   
 
 
 
Figure 5.8 Design of constructs used for expression of 2G12. Schematic 
representation of the T-DNA regions of vectors pEAQspecialK-HEL and 
pEAQspecialKm-HEL. LB and RB represent left and right borders respectively. The 
asterisk denotes the R43W mutation in P19. 
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pEAQspecialK-HEL and pEAQspecialKm-HEL were tested by transient infiltration 
of agrobacteria harbouring each construct into N. benthamiana plants followed by 
separation of crude extracts of infiltrated leaves on SDS-PAGE gels. Under reducing 
conditions, bands of about 50 kDa and 25 kDa were obtained in both samples, 
corresponding to heavy and light chains of 2G12 respectively; thereby confirming 
expression of constructs. Under non-reducing conditions, a band of about 220 kDa 
was obtained confirming assembly of the heavy and light chains into an IgG protein 
(Figure 5.9). The unexpectedly high molecular weight of the fully assembled 
antibody (220 kDa instead of 150 kDa) is commonly observed for antibodies when 
analysed by electrophoresis using Tris-glycine running buffers (Sainsbury et al., 
2008).  
 
 
Figure 5.9 Analysis of 2G12 expression by SDS-PAGE. Total protein extracts of 
infiltrated leaves were separated on polyacrylamide gels under reducing and non-
reducing conditions and visualized by staining with Coomassie blue. Samples were 
run as follows: Lane (1) Extract from plant infiltrated with empty vector pEAQ-HT, 
(2) extract from plant infiltrated with pEAQspecialK-HEL, (3) extract from plant 
infiltrated with pEAQspecialKm-HEL, (4) 1 µg of CHO-produced 2G12, (5) 2 µg of 
CHO-produced 2G12 and (M) standard protein marker.  
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Known amounts of CHO-produced 2G12 were run in parallel as standards and used 
to estimate expression levels. In presence of wt P19 (pEAQspecialK-HEL), 2G12 
expression levels approaching 400 mg/kg FWT were attained, while in presence of 
P19/R43W (pEAQspecialKm-HEL), 2G12 expression levels appeared to be 
approximately half as much. This is consistent with the results obtained with GFP 
expression and reiterates that P19/R43W retains a reduced but significant ability 
to enhance expression.       
Presence of the heavy and light chains of 2G12 within the same T-DNA, as in the 
case of pEAQspecialK-HEL and pEAQspecialKm-HEL, was essential since the 
constructs were ultimately designed for transgenic expression of 2G12 and 
simultaneous integration of the genes encoding the heavy chain and the light chain 
into the genome of the plant was a pre-requisite for transgenic expression of 2G12.   
5.3.1.2 Transgenic expression of 2G12 and P19/R43W 
After confirming that pEAQspecialKm-HEL was a functional clone from transient 
studies, A. tumefaciens harbouring pEAQspecialKm-HEL was used to transform 20-
25 N. benthamiana leaf discs. Plantlets regenerated from discs were transferred to 
soil and five T0 transgenic plants were subsequently obtained. However, all five 
plants came from different sections of the same disc, so it was possible that all of 
these were generated from the same transformation event. A number of 
transformed leaf discs were lost due to contamination and other technical 
problems with the growth chamber. Nonetheless, the five plants obtained were 
analysed independently for 2G12 expression. At this stage, plants grew normally 
and showed no obvious morphological defects (Figure 5.10).  
Crude leaf extracts from the five T0 plants were separated using SDS-PAGE and 
analysed for presence of 2G12 using the technique of western blotting. Bands for 
IgG heavy chains were detected in extracts from all five plants confirming 
successful integration of the T-DNA and expression of 2G12 (Figure 5.11).  On 
comparison of the intensities of bands with known standards, the five T0 plants 
were estimated to express levels of 2G12 in the range of 40-60 mg/kg FWT.  
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Figure 5.10 T0 transgenic plants expressing 2G12 and P19/R43W. 8-week old 
plants regenerated from leaf discs transformed with pEAQspecialKm-HEL, showed 
no morphological defects. 
 
 
Figure 5.11 Detection of 2G12 in T0 transgenic plants. Using anti-human IgG 
(Fc specific) antibody, bands for the 2G12 heavy chain were detected in all five 
transgenic plants (Lanes 4-8). Extracts from plants transiently infiltrated with 
2G12 constructs were analysed in parallel (Lanes 2-3). Extract from a healthy plant 
was run in Lane 1 and 200 ng of CHO cell-produced 2G12 was run in Lane 9. 
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T0 plants expressing 2G12 were allowed to flower and self-fertilized to obtain the 
T1 generation. However, despite several normal-looking flowers developing on 
each plant, none set seed. Flowers were taped at different stages of their 
development to avoid putting the plant under any kind of stress but seed pods did 
not develop in any of the flowers under any of the conditions examined. This 
suggests that during genome integration of T-DNA, functional genes of the plant 
were disrupted and as a consequence, the plants could not produce seeds. 
However, the precise reason for this is unclear. Since all transformed discs were 
likely to be a result of the same transformation event, it was not surprising that all 
plants displayed the same phenotype. Due to lack of seed, this work could not be 
taken any further as time did not permit the production of additional primary 
transformants. Nevertheless, T0 plants of 2G12 provided further evidence that 
P19/R43W was tolerated in plants and could enhance transgene expression.  
5.3.2 Human gastric lipase 
Human gastric lipase (hGL) is a member of the family of preduodenal lipases, 
primarily responsible for initiation of lipolysis of dietary fats, such as triglycerides 
in the gastrointestinal tract (Carriere et al., 1993). It is a candidate for treatment of 
pancreatic enzyme insufficiency, as a superior substitute for the current treatment 
that uses enzyme obtained from porcine pancreatic extract (DiMagno et al., 1977). 
Recently, it was demonstrated that active recombinant hGL can be produced in N. 
benthamiana by transient expression using the CPMV-HT system (Vardakou et al., 
2012). Given the demand for a reliable hGL production system and promising 
results obtained from transient expression studies, it was decided to attempt 
creation of transgenic plants producing hGL. 
5.3.2.1 Transgenic expression of hGL and P19/R43W 
Transgenic plants expressing hGL in presence of P19/R43W were created by Mr. 
Hadrien Peyret by transformation of N. benthamiana leaf discs with the vector 
pEAQspecialKm-hGL, generated by replacement of the gene for GFP in 
pEAQspecialKm-GFP-HT with the gene encoding hGL. Phenotypically normal T0 
plants expressing active hGL were obtained. These were selfed to produce the T1 
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generation of plants transgenic for hGL. While active hGL was obtained from a 
majority of the T1 plants, it was observed that seed production was significantly 
reduced amongst the T1 population. For every 10 developing flowers that were 
taped, 2-3 produced seeds. Nonetheless, resultant seeds were analysed to identify 
homozygotes amongst the T1 population. Homozygotes grew normally and 
expressed high levels of active hGL, averaging around 0.3 mg/kg FWT.  Although 
further work needs to be done on purification of plant produced- hGL, this 
promises to be a cheap and reliable production system and continues to be worked 
upon in the lab.   
5.4 Creation of lines transgenic for eVLPs 
Following the success of P19/R43W in enhancement of transgenic expression of 
GFP, 2G12 and hGL, the prospect of creating a transgenic line of N. benthamiana 
that constitutively produced high levels of eVLPs was considered. A transgenic 
eVLP-producing line would be an efficient way of obtaining a regular supply of 
eVLPs for their further characterization and their use in nanotechnology.  
Creation of a line transgenic for eVLPs would involve stable transformation of leaf 
discs with a plasmid encoding VP60 (coat protein precursor), 24K (viral 
proteinase) and P19/R43W (suppressor of silencing) within its T-DNA region. This 
section describes the creation of this plasmid and attempts to transform leaf discs 
with it. 
5.4.1 Generation of the construct 
To generate a construct for transgenic expression of eVLPs in presence of 
P19/R43W, three fragments of DNA, namely, the VP60 expression cassette, the 
24K expression cassette and the pEAQspecialKm vector backbone, were combined 
using a three-part ligation reaction. First, the VP60 expression cassette was 
amplified from pEAQ-HT-VP60 (Saunders et al., 2009) using primers FSC2-F and 
FSC5-R (Appendix I) which resulted in introduction of the restriction sites PacI and 
SbfI on either side of the expression cassette. In parallel, the 24K expression 
cassette was amplified from pEAQ-HT-24K (Saunders et al., 2009) using primers 
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FSC6-F and FSC2-R (Appendix I) which introduced the restriction sites SbfI and 
AscI on either side of the expression cassette. The amplified fragments and the 
vector pEAQspecialKm were then digested as follows: 
(i) Amplified VP60 expression cassette was digested with PacI and SbfI; 
(ii) Amplified 24K expression cassette was digested with SbfI and AscI; 
(iii) Vector backbone pEAQspecialKm was digested with PacI and AscI.  
The digested fragments were ligated together using standard ligation protocols 
(Section 2.3.3) to generate pEAQspecialKm-eVLP (Figure 5.12). 
 
 
Figure 5.12 Schematic diagram of the construct used for expression of eVLPs. 
The plasmid map of pEAQspecialKm-eVLP is shown. LB and RB represent left and 
right borders respectively. The asterisk denotes the R43W mutation in P19.  
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5.4.2 Transient expression of eVLPs and P19/R43W 
pEAQspecialKm-eVLP was initially tested for its ability to direct the synthesis of 
eVLPs by transient expression in N. benthamiana leaves. pEAQexpress-eVLP, 
described previously in Section 3.3.1,  was used for comparison since it expresses 
eVLPs in presence of wt P19. An empty pEAQ vector was used as the negative 
control for transient expression of eVLPs. Leaves infiltrated with either of the eVLP 
constructs or with the empty pEAQ vector were harvested on 6 dpi and the crude 
leaf extracts were subjected to the standard eVLP purification protocol (Section 
2.6.2). The resulting proteins were analysed by SDS-PAGE.  
Prominent bands were seen for L and S coat proteins from denatured eVLPs in the 
extracts from plants inoculated with either pEAQexpress-eVLP or pEAQspecialKm-
eVLP, while no proteins of the size of L and S were seen in the extract from leaves 
infiltrated with the empty pEAQ vector (Figure 5.13). On the basis of the intensity 
of the bands on the gel, it was estimated that expression of eVLPs from 
pEAQspecialKm-eVLP was higher than that from pEAQexpress-eVLP. This was 
unexpected as the latter encoded wt P19 which, from previous results, is known to 
enhance expression 2-fold more than the P19/R43W encoded by the former. This 
observation could not really be explained and was attributed to differences in 
infiltration technique, health of plants, health of agrobacteria, etc. Nonetheless, 
these transient infiltration studies confirmed that pEAQspecialKm-eVLP was a 
functional clone and could be taken forward for stable transformation of leaf discs.  
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Figure 5.13 Analysis of eVLP expression by SDS-PAGE. Proteins purified from 
crude extracts of infiltrated leaves were denatured by heat-incubation and 
separated on polyacrylamide gels. The gel was stained with Coomassie blue for 
detection of proteins. Samples were run as follows: Lane (1) extract from leaves 
infiltrated with an empty pEAQ vector (2) extract from leaves infiltrated with 
pEAQspecialKm-eVLP, (3) extract from leaves infiltrated with pEAQexpress-eVLP, 
(4) 2 µg of purified eVLPs, (5) 4 µg of purified eVLPs and (M) standard protein 
marker. Bands for L and S are indicated. 
5.4.3 Transgenic expression of eVLPs and P19/R43W 
Leaf discs were transformed with pEAQspecialKm-eVLP using the standard 
protocol for stable transformation of tissue (Section 2.4.3). This resulted in the 
regeneration of six primary transformants out of which four were from 
independent leaf discs. All six plants developed normally and showed no 
morphological defects. About eight weeks after regenerated primary 
transformants were transferred to soil, leaf tissue from each T0 plant was analysed 
for eVLP expression. 4-5 leaves (5 g FWT) were harvested from each of the T0 
plants and subjected to the standard particle purification protocol. Analysis of 
purified extracts from infiltrated leaves using TEM and SDS-PAGE showed the 
absence of particles in all T0 plants.  
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Integration of the T-DNA into the plant genome was confirmed by PCR, using 
primers C1 and C3 (Appendix I) that bind to the HT UTRs, on genomic DNA 
extracted from the leaves of T0 plants (H. Peyret, pers. comm). Moreover, since the 
entire T0 population was germinated on agar plates containing kanamycin, the 
expression of the gene for kanamycin resistance was confirmed. This implied that 
it was likely that VP60 and 24K, encoded on the same T-DNA, were being 
expressed but were either aggregating due to their insolubility or getting degraded 
by the host cell machinery.  
To investigate this further, a western blot was conducted on the crude leaf extracts 
of the T0 plants using the anti-CPMV antibody G49 (Table 2.3) which specifically 
recognizes the coat proteins of CPMV. To prepare each sample for blotting, 4-5 leaf 
discs (150 mg FWT) from each T0 plant were homogenized in three volumes of 0.1 
M sodium phosphate buffer (pH=7). As a control, leaf extracts from plants 
transiently infiltrated with the constructs pEAQ-HT-VP60 and pEAQ-specialKm-
eVLP were used. The homogenized extracts were heat-denatured and subjected to 
SDS-PAGE, followed by their transfer to a nitrocellulose membrane. The levels of 
expression in the transgenic plants were expected to be lower than those achieved 
from transiently-infiltrated plants and therefore, higher amounts of the crude 
extracts from the transgenic plants were loaded on the gel. The membrane was 
probed with anti-CPMV antibody G49 and its binding was subsequently detected 
using a secondary antibody and chemiluminescence. Results showed that neither 
VP60 nor L and S coat proteins were present in the transgenic tissue (Figure 5.14). 
A band for VP60 was detected in the leaf extract of the plant transiently-infiltrated 
with pEAQ-HT-VP60 and bands for L and S were detected in the leaf extract of the 
plant infiltrated with pEAQspecialKm-eVLP.  
The western blot confirmed the absence of VP60 in all transgenic lines and it was 
recognized that the method for expression of VP60 would need to be refined 
further to achieve transgenic expression of eVLPs. Expression of 24K could not be 
verified since no antibodies against it were available.  
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Figure 5.14 Immunodetection of CPMV coat protein. Leaf extracts of selected 
T0 transgenic plants (Lanes 1-3) and of plants transiently infiltrated with pEAQ-
HT-VP60 (Lane 4) and pEAQspecialKm-eVLP (Lane 5) were analysed by western 
blotting using the anti-CPMV antibody G49. Bands for VP60, L and S have been 
indicated. The high molecular weight bands (over 100 kDa) are aggregates of VP60 
or L and S coat proteins.  
 
5.5 Discussion  
A novel system for stable expression of foreign genes in plants has been presented 
in this chapter. In this system, the modified suppressor of silencing P19/R43W was 
deployed to enhance expression of heterologous genes in transient and transgenic 
systems. Initial studies were undertaken with GFP, followed by their validation by 
expression of two pharmaceutically valuable proteins and finally, the system was 
used in an attempt to produce lines of plants for the stable expression of eVLPs.  
In parallel to our studies with GFP and P19/R43W, N. benthamiana plants 
transgenic solely for P19/R43W were created by our collaborators, Dr. Yi-Cheng 
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Hsieh and Prof. Herman Scholthof at Texas A&M University. Out of fourteen 
regenerated transformants, three were confirmed to be transgenic for P19/R43W 
by western blot analysis of leaf tissue (Saxena et al., 2011). All fourteen T0 plants 
developed normally, flowered and set fertile seed. The phenotype of the three 
plants accumulating detectable levels of P19/R43W was not very different from 
the rest apart from some evidence of cup shaped leaves and mild blistering (Figure 
5.15). These results provided evidence that P19/R43W can accumulate at 
detectable levels in transgenic N. benthamiana with minimal effects on plant 
morphology, growth and development. This encouraged further work on the 
assessment of the effect of P19/R43W on expression levels of other heterologous 
proteins in the plant.   
 
Figure 5.15 Phenotype of plants transgenic for P19/R43W. Plants transgenic 
for P19/R43W developed normally and only upon close inspection, displayed mild 
morphological features such as cupping of leaves and blistering (Data from Dr. Yi-
Cheng Hsieh and Prof. Herman Scholthof, Texas A&M University). 
Proof-of-principle studies undertaken with GFP showed that P19/R43W can be 
used to boost expression of GFP in plants, without deleterious effects on plant 
growth and development. Transient expression of GFP in presence of P19/R43W 
was seen to be half of that in presence of wt P19, but this was still significantly 
more than the expression in the absence of any suppressor. Plants transgenic for 
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GFP and P19/R43W also showed elevated levels of GFP expression (an average 
enhancement of 40% over expression seen in the absence of a suppressor). Since 
the emphasis of this study was to assess if P19/R43W could be tolerated within 
stably transformed plants and not the absolute expression levels achieved, no 
attempts were made to boost GFP expression levels further. However, if desired, 
the system can be optimized to achieve maximal expression of transgenes. One of 
the ways to maximize expression would be to boost the expression of P19/R43W 
itself by expressing it with CPMV-HT UTRs. This is expected to lead to increased 
RNA suppression activity and in turn, enhanced transgene expression. The use of 
different promoters and terminators for every expression cassette may also 
enhance expression levels. However, increasing the levels of P19/R43W could also 
adversely affect plant regeneration. 
Studies on GFP were limited to one line each for expression in absence of any 
suppressor (Line 3) and for expression in presence of P19/R43W (Line 5). While 
this was enough to establish that P19/R43W does not affect growth and 
development of plants and contributes to elevated expression levels, more lines 
should be generated and analysed to obtain homozygotes with maximally 
enhanced expression. This would be critical if a line was to be used commercially 
as a source for a particular heterologous protein. In that case, detailed analysis of 
the site of integration and the copy number of the transgene would also be needed.  
After success with GFP expression, the P19/R43W system was modified to 
enhance expression of an antibody (2G12), an enzyme (hGL) and virus-like 
particles (eVLPs). Work done with GFP, 2G12 and hGL demonstrated that the 
highly efficient transient expression system, CPMV-HT, can be adapted for stable 
transformation. However, plants transgenic for eVLPs could not be generated. 
Expression of neither VP60 nor 24K could be confirmed in any of the regenerated 
plants and due to time constraints, regeneration of further lines could not be 
undertaken. This continues to be worked upon in the lab. In addition, attempts to 
solubilize VP60 in vivo are being made. Once the issue of solubility of VP60 is 
resolved, other factors like accessibility of VP60 to 24K, stoichiometry of both 
proteins and the stability of both proteins will also need to be considered. Overall, 
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on-going work on generation of plants transgenic for eVLPs promises to deliver an 
easy and reliable method for high-level production of eVLPs.   
The work presented in this chapter is the first study to report the accumulation of 
readily detectable levels of a constitutively expressed suppressor of silencing in 
transgenic plants without severe morphological defects. However, although the 
plant grows and develops normally, P19/R43W may have an effect on plant fitness, 
for instance on the defense response of the plant or its resistance to pathogens. 
Also, since the main problem observed in plants transgenic for 2G12 and hGL was a 
reduction in their ability to develop seeds, it may be possible that P19/R43W 
interferes with the development of the ovum or pollen or with the process of 
fertilization in N. benthamiana. This is because the underlying principle of 
enhancement of expression by P19/R43W is inhibition of RNA silencing in a non-
specific manner and hence, in addition to the gene of interest, expression of other 
housekeeping genes in the host cell is also affected. From a biotechnological 
perspective, a reduction in plant fitness is a small price to pay to gain high yields. 
Use of suppressors of silencing such as wt P19 in transient expression is common 
practice and reduction in plant fitness has never been a problem in transient 
systems.  
Since the CPMV-HT vectors are designed for easy and quick expression of proteins, 
a number of constructs can be generated and screened by transient-expression in 
plants in a matter of days and then, selected constructs can be taken forward for 
stable transformation, if required. However, a point to bear in mind while using 
CPMV-HT vectors in transgenic expression is that for every expression cassette in 
the vector, there will be present a 35S promoter, a nos terminator and CPMV-HT 
UTRs. Repetitive use of the same sequences encoding the promoters, terminators 
or UTRs increase the chances of homologous recombination within the T-DNA 
which can result in loss of the transgene(s). Although this was not found to be the 
case with GFP transgenic plants (selfed to two generations) and with hGL 
transgenic plants (selfed to three generations), it is a potential source of concern. A 
solution to this potential problem could be the use of different promoters and 
terminators for different expression cassettes.  However, since the CPMV-HT 
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system is optimized for best expression levels, a change in its components may 
negatively affect transgene expression.  
Published studies report expression of transgenes in stable transgenic plants to be 
around a tenth of the expression achieved using a transient expression system 
(Rybicki, 2010). As demonstrated by results shown in this chapter, the use of 
P19/R43W has the potential to enhance expression to almost half the levels 
obtained with transient expression. Thus, P19/R43W is a useful addition to the 
toolbox for high-level expression of heterologous proteins in plants.   
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Chapter 6: Results IV 
Development of expression vectors based on CPMV RNA-1  
6.1 Introduction 
Work towards development of a system for transgenic expression of eVLPs 
highlighted two limitations of the current CPMV-HT expression system. First, that 
the high levels of expression obtained using CPMV-HT can lead to deleterious 
effects on the plant due to accumulation of proteins, as seen with the plants 
transgenic for 2G12 (Section 5.3.1.2). Also, in situations such as expression of 
metabolites in an enzymatic pathway, low levels of a certain substrate may be 
needed; or in expression of virus-like particles such as eVLPs, different 
components may be required in different amounts. Secondly, multiple copies of the 
same expression cassette, i.e. the promoter, terminator and the UTRs are used for 
co-expression of multiple proteins using the CPMV-HT system. While the repetitive 
use of the same sequences does not matter in transient expression, in transgenic 
expression systems, it increases the chances of homologous recombination, 
thereby risking loss of transgenes in subsequent generations.  
To overcome the above limitations and to increase the range of CPMV-based 
expression vectors available, the possibility of creating expression vectors based 
on sequences derived from CPMV RNA-1 was explored. All CPMV-based expression 
systems developed to date have been based on modified versions of RNA-2 
(Sainsbury et al., 2010a). This is because RNA-2 encodes the viral coat proteins (L 
and S) which are present in 60 copies each per virus particle and so RNA-2 is 
believed to be translated at high levels. By contrast, RNA-1 encodes proteins with 
catalytic activities (such as the 24K proteinase and RNA polymerase) which need 
to be present in much lower amounts and it has therefore been assumed that the 
translational efficiency of RNA-1 is likely to be lower than RNA-2. In addition, 
manipulation of RNA-1 sequences in bacterial systems has proved to be difficult 
leading to sequence rearrangements and loss of viability of the host (Section 4.2).  
CHAPTER 6 
 
  129 
 
Work presented in this chapter demonstrates the use of the 5’ and 3’ UTRs of RNA-
1 for transient expression of proteins. 5’ and 3’ UTRs have been shown to be 
important for efficient translation of mRNA in a number of viruses (Karetnikov and 
Lehto, 2008; Kneller et al., 2006; Sarawaneeyaruk et al., 2009; van Lipzig et al., 
2002) and the ability of the UTRs to form secondary and higher-order structures 
has been recognised as one of the main reasons for their function (Liu et al., 2009). 
Although precise mechanisms remain unknown, one can speculate the reasons for 
elevation of expression in the presence of UTRs to be (i) increased stability of 
mRNA in presence of the UTRs; and (ii) improved translational efficiency by easier 
access and improved binding of ribosomes to the mRNA for translation.  
The use of only the UTRs circumvents the problem with toxicity of wt RNA-1 since 
the UTRs do not code for any proteins. Also, since CPMV is a bipartite virus 
requiring co-expression of RNA-1 and RNA-2 for an infection, both RNAs are 
inherently non-competitive with each other. This implies that vectors based on 
UTRs from RNA-1 can be used in parallel with vectors based on UTRs from RNA-2, 
such as the CPMV-HT vectors. 
Vectors based on the UTRs of RNA-1 were examined using GFP and it was found 
that GFP expression using these vectors was more rapid than the expression 
achieved using other available expression systems, including the HT system based 
on the UTRs of RNA-2 (Sainsbury and Lomonossoff, 2008). For this reason, the 
RNA-1 based expression system was named ‘Rapid-Trans’ or RT. 
6.2 Generation of expression vectors based on RNA-1 
A basic RNA-1-based expression vector similar to pEAQ-HT (Sainsbury et al., 2009) 
was designed for expression of genes of interest flanked by  the 5’ and 3’ UTRs of 
RNA-1. The RNA-1-based expression cassette of 924 bp in length, consisting of the 
CaMV 35S promoter, the 5’ UTR of RNA-1, a multiple cloning site, the 3’ UTR of 
RNA-1 and the nos terminator in that order (Figure 6.1), was ordered from 
Geneart ® and cloned in the T-DNA region of binary plasmid pEAQexpress 
(Sainsbury et al., 2009) using the restriction sites PacI and AscI. The vector thus 
generated was named pEAQexpress-RT.  
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Subsequently, the gene for reporter protein GFP was amplified using primers GFP-
start-XhoI-F and GFP-stop-XmaI-R (Appendix I) and cloned within the multiple 
cloning site of pEAQexpress-RT using the restriction sites XhoI and XmaI to 
generate pEAQexpress-RT-GFP (Figure 6.2) for expression of GFP with RNA-1 
UTRs, referred to as RT-GFP.  
 
 
 
Figure 6.1 The RT expression cassette. A schematic diagram of the DNA 
synthesised by Geneart® for creation of pEAQexpress-RT is shown. The green 
arrow and the red box represent the CaMV 35S promoter and the nos terminator 
respectively. Sequences encoding the 5’ UTR of 206 bp and the 3’ UTR of 82 bp of 
RNA-1 are coloured in brown. Some restriction sites in the multiple cloning site 
(MCS) have also been shown.   
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6.3 Analysis of expression from RT vectors 
To assess the performance of the RT cassette in promoting translation, N. 
benthamiana leaves were infiltrated with pEAQexpress-RT-GFP and the expression 
of GFP was monitored from 1-11 dpi by visualisation of the leaves under UV light. 
Expression of GFP was observed in leaves from 2 dpi onwards and expression 
seemed to increase remarkably by 3 dpi. Leaf samples were collected each day and 
frozen for quantification of expression.  Separation of crude leaf extract using SDS-
PAGE and measurement of fluorescence using spectrofluorometry (Figure 6.3) 
confirmed that GFP from pEAQ-RT-GFP was being expressed from 2 dpi, after 
which levels rapidly increased until 4 dpi. At 4 dpi, GFP expression levels of up to 
0.5-0.6 g/kg FWT were attained. A similar level of expression was maintained until 
7 dpi after which it declined.  
                               
Figure 6.2 Schematic diagram of pEAQexpress-RT–GFP. The plasmid generated 
for expression of GFP with the 5’ and 3’ UTRs of RNA-1 has been shown. 
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Figure 6.3 Expression of RT-GFP over time. (a) SDS-PAGE separation of proteins 
from leaf tissue infiltrated with pEAQ-RT-GFP and harvested on 1-11 dpi. Extract 
from a plant infiltrated with the empty vector (pEAQexpress-RT) was used as a 
negative control (-). 500 ng of commercially available recombinant GFP was used 
as the positive control (+). A 27 kDa band for GFP has been highlighted.                  
(b) Expression levels of RT-GFP based on spectrofluorometry on leaf extracts from 
1-11 dpi. Values are averages of expression levels of three biological replicates.  
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6.4 Comparison of RNA-1 and RNA-2 based expression systems 
To assess the RT expression system in relation with the previously existing RNA-2-
based HT system, expression from the construct pEAQexpress-RT-GFP was 
compared to expression from pEAQexpress-HT-GFP (Sainsbury et al., 2009) over a 
period of 12 days. The only difference in the T-DNA of the above vectors was in the 
sequences of the 5’ UTR and 3’ UTR flanking the gene for expression of GFP, as 
shown in Figure 6.4. N. benthamiana leaves were infiltrated with both constructs 
and GFP expression was monitored by visualisation of leaves under UV light 
(Figure 6.5) and analysis of crude leaf extracts using SDS-PAGE and 
spectrophotometry (Figure 6.6). On 3 dpi, expression of RT-GFP was observed to 
be very similar to that of HT-GFP. From 4 dpi onwards, expression of RT-GFP 
declined while the expression of HT-GFP was sustained over the period of 12 days. 
This shows the ability of the HT UTRs to enhance expression of GFP over a longer 
period, possibly by enhancing mRNA stability.     
 
 
 
Figure 6.4 Schematic diagrams of constructs. T-DNA regions of constructs used 
for expression of GFP using the RT system (pEAQexpress-RT-GFP) and the HT 
system (pEAQexpress-HT-GFP) are shown. RT-GFP is expressed with the RNA-1 5’ 
UTR of 206 nts and 3’ UTR of 82 nts. HT-GFP is expressed with the RNA-2 5’ UTR of 
511 nts and 3’ UTR of 184 nts.   
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Figure 6.5 Expression of RT-GFP and HT-GFP. Leaves were photographed under 
UV light on 3, 6, 9 and 12 dpi. Each leaf has been infiltrated with four constructs for 
comparison: pEAQexpress-RT-GFP (top left); pEAQexpress-HT-GFP (top right) and 
empty vectors pEAQexpress-RT (bottom left) and pEAQexpress-HT (bottom right).   
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Figure 6.6 Expression of RT-GFP and HT-GFP over time. (a) The gel shows SDS-
PAGE separation of proteins from leaf tissue expressing RT-GFP and HT-GFP 
harvested on 3, 6, 9 and 12 dpi. Extract from a plant infiltrated with the empty 
vector (pEAQexpress-RT) was used as a negative control (-) and 500 ng of 
commercially available recombinant GFP was used as the positive control (+). The 
band for GFP has been highlighted. (b) Expression levels of GFP in the RT system 
(brown bars) and the HT system (blue bars) based on spectrofluorometric analysis 
of extracts from leaves harvested on 3, 6, 9 and 12 dpi are shown. Values are 
averages of expression levels of three biological replicates. 
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6.5 Expression using a combination of RNA-1 and RNA-2 sequences 
After establishing that the expression profile achieved using UTRs from RNA-1 was 
different to that achieved using RNA-2 UTRs, expression in presence of various 
combinations of sequences from RNA-1 and RNA-2 was investigated. It was 
recognised that the use of different combinations of 5’ and 3’ UTRs of RNA-1 and 
RNA-2 would enable the creation of expression vectors with varying translational 
strengths. This work was done in collaboration with Dr. Yulia Meshcheriakova who 
was undertaking detailed studies on the role of the 3’ UTR of RNA-2 in enhancing 
expression in the CPMV-HT system. These studies indicated that the 3’ UTR of 
RNA-2 plays a significant role in stabilising the mRNA produced during transient 
expression.  
6.5.1 Generation of constructs 
To assess the role of the 3’ UTR, if any, in enhancement of translation in the RT 
expression system, deletion mutants were generated for expression of GFP in the 
absence of the 3’ UTR. pEAQexpress-RT-GFP was modified to delete the entire 82 
bp sequence encoding the 3’ UTR of RNA-1. This was done by amplifying the 
segment immediately downstream of the 3’ UTR in this vector using primers RT-
del3’UTR-F and RT-del3’UTR-R (Appendix I) and inserting the amplified DNA 
fragment back in the same vector using the XmaI and BamHI sites as shown in  
Figure 6.7a. The vector thus generated lacked the 3’ UTR and was named 
pEAQexpress-RT-GFP-del3’UTR. In a similar fashion, construct pEAQexpress-HT-
GFP-del3’UTR was created by deletion of the 184 bp-long 3’ UTR in pEAQexpress-
HT-GFP (Y. Meshcheriakova, unpublished results).  
Another construct was generated by replacing the 3’ UTR of RNA-1 with the 3’ UTR 
of RNA-2. To this end, a segment containing the 3’ UTR of RNA-2 was amplified 
from pEAQexpress-HT-GFP using primers RT-HT3’UTR-F and RT-del3’UTR-R 
(Appendix I) and cloned into the XmaI and BamHI sites of pEAQexpress-RT-GFP as 
shown in Figure 6.7b. The vector thus generated was named pEAQexpress-RT-GFP-
HT3’UTR.  
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Figure 6.7 Schematic diagrams of constructs generated for expression of 
mutants of the 3’ UTR of pEAQexpress-RT-GFP. Relevant sections of the 
plasmids generated by (a) deletion of the 3’ UTR of pEAQexpress-RT-GFP (RT-GFP-
del3’UTR) and (b) replacement of the 3’ UTR of pEAQexpress-RT-GFP with the HT-
3’ UTR (RT-GFP-HT3’UTR) are shown.  
6.5.2 Expression of GFP in the absence of the 3’ UTR  
Agrobacteria harbouring the two deletion constructs: pEAQexpress-RT-GFP-
del3’UTR and pEAQexpress-HT-GFP-del3’UTR were infiltrated into plants to assess 
the impact of the deletion of the 3’ UTR on the transient expression of GFP. It was 
found that in both the RT and HT systems, expression of GFP dropped significantly 
in the absence of the 3’ UTR. At 6 dpi, expression of GFP in absence of the 3’ UTR of 
RNA-1 was only 0.13 g/kg FWT, approximately one third of the level achieved in 
presence of the 3’ UTR (Figure 6.8). A similar decline in expression was observed 
in the HT system where expression levels dropped from 0.5 g/kg FWT to 0.15 g/kg 
FWT in absence of the 3’ UTR. These results show that the 3’ UTRs play a 
significant role in enhancement of translation of RNA-1 and RNA-2. 
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Figure 6.8 Expression of RT-GFP and HT-GFP in the absence of their 3’ UTRs.     
(a) Different sections of the leaf were infiltrated with four different constructs (as 
indicated) for comparison. The leaf was photographed on 6 dpi under UV light.   
(b) Expression of GFP as quantified by spectrofluorometry. ‘RT del3’ and ‘HT del 3’ 
correspond to expression of GFP using pEAQexpress-RT-GFP-del3’UTR and 
pEAQexpress-HT-GFP-del3’UTR respectively. Values are averages of expression 
levels of three biological replicates. The error bars denote standard error of mean. 
The error bar for HT-GFP suggests significant variations between the individual 
readings recorded for its three biological replicates in this experiment. 
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6.5.3 Expression of GFP using the 5’ UTR of RNA-1 and the 3’ UTR of RNA-2  
Following experiments involving the deletion of the entire 3’ UTR of RNA-1, the 
level of translation achievable from a construct using a combination of the 5’ UTR 
of RNA-1 and the 3’ UTR of RNA-2 was investigated. A new construct named 
pEAQexpress-RT-GFP-HT3’UTR was generated by replacing the 3’ UTR of RNA-1 in 
pEAQexpress-RT-GFP with the 3’ UTR of RNA-2, as described in Section 6.5.1.  
Leaves were infiltrated with this new construct and GFP expression was monitored 
over a period of 10 days. In parallel, pEAQexpress-RT-GFP and pEAQexpress-HT-
GFP were also infiltrated into leaves for comparison. At 6 dpi, GFP expression 
achieved with pEAQexpress-RT-GFP-HT3’UTR was 0.67 g/kg FWT, which was 
more than the levels achieved separately using the RT and HT systems (Figure 6.9). 
This unexpected observation suggested that the 3’ UTR of RNA-2 could not only 
fully complement the deletion of the 3’ UTR of RNA-1, but also enhance translation 
of GFP mRNA even further.  
 
 
Figure 6.9 (a) Expression of RT-GFP in presence of the 3’ UTR from RNA-2. 
Leaf infiltrated with pEAQexpress-RT-GFP (left) and pEAQexpress-RT-GFP-
HT3’UTR (right) is shown above for comparison of GFP expression in presence of 
the 3’ UTR from RNA-1 with that in presence of the 3’ UTR from RNA-2. The leaf 
was photographed on 6 dpi under UV light.  
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Figure 6.9 (b) Expression of RT-GFP in presence of the 3’ UTR from RNA-2. 
Expression of GFP as quantified by spectrofluorometry. ‘RT-GFP HT3’’ refers to 
expression of GFP from pEAQexpress-RT-GFP-HT3’UTR. Values are averages of 
expression levels of three biological replicates. The error bars denote standard 
error of mean. The error bar for HT-GFP suggests significant variations between 
the individual readings recorded for its three biological replicates in this 
experiment. 
6.6 Discussion 
The work described in this chapter exploits differences in the expression profiles 
of CPMV RNA-1 and RNA-2 for development of expression vectors based on RNA-1, 
to complement the existing CPMV-HT vectors based on RNA-2. It was observed 
that inserting a sequence between the 5’ and 3’ UTRs of RNA-1 can lead to rapid 
synthesis of proteins in transient systems. In view of the kinetics of protein 
synthesis, which differ from that seen with the CPMV-HT system, the RNA-1-based 
expression system was named Rapid-Trans (RT). The rapid rise and decline in 
expression seen with the RT system could be particularly beneficial in achieving 
expression of a protein that is unstable or has toxic effects on the plant. The 
availability of two compatible expression systems with different strengths may be 
beneficial in circumstances where differing levels of expression are desired, for 
instance in metabolic pathways or to create complexes in which protein sub-units 
are required in different amounts. 
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In contrast to the HT system which deploys the 5’ UTR from RNA-2 with two point 
mutations engineered within its sequence, the RT system deploys wt sequences of 
the UTRs of RNA-1. The presence of multiple sites for initiation of translation in 
RNA-2 (AUG 115, AUG 161 and AUG 512) and a 10-fold increase in translation 
upon deletion of the sites upstream of AUG 512 (Sainsbury and Lomonossoff, 
2008) suggests a somewhat-complicated mechanism for translational regulation of 
RNA-2. No such mechanism seems to exist for translation of RNA-1 where protein 
synthesis initiates at the first AUG encountered (Wellink et al., 1986).   
The differences observed in expression using the RT and HT expression systems 
throw light on potential differences in the timings and levels of translation of RNA-
1 and RNA-2 during the course of a natural viral infection. RNA-1 is expected to be 
translated first to provide proteins for replication and hence, expression with the 
RNA-1 UTRs is expected to be rapid; levels of proteins produced are expected to be 
lower as compared to RNA-2; and the levels of translation are expected to drop 
once the replication machinery has been generated. By contrast, RNA-2 is expected 
to be translated at high levels once replication of RNA-1 has commenced and the 
expression is expected to be sustained over a longer period to ensure availability 
of adequate coat proteins for packaging of replicating RNA and spread of infection. 
This fits with the expression profiles achieved with the RT and HT systems 
demonstrating the critical role played by the 5’ and 3’ UTRs in controlling 
expression levels.    
In CPMV, studies on various mutants of the 3’ UTR of RNA-2 have shown that the 3’ 
UTR of RNA-2 enhances expression by improving mRNA stability and that direct 
contacts between the 5’ UTR and the 3’ UTR are unlikely (Y. Meshcheriakova, 
unpublished results). This was confirmed when the combinations of UTRs from 
RNA-1 and RNA-2 were used. Based on the results with the combinatorial 
constructs, it can be speculated that the 5’ and 3’ UTRs work independent of 
eachother. The 5’ UTR is likely to work by enhancing the efficiency of translation 
while the 3’ UTR has been shown to work by enhancing mRNA stability.  
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Demonstration of the requirement of 3’ UTRs for the maximum enhancement of 
expression in both CPMV-RT and -HT systems prompted an investigation into the 
specificity of the sequence, specifically whether 5’ and 3’ UTRs from the same RNA 
had to be used to achieve maximum expression. To this end, the 3’ UTRs of RNA-1 
and RNA-2 were interchanged and its effect on GFP expression was monitored. 
GFP expression using the combination of the 5’ UTR of RNA-1 with the 3’ UTR of 
RNA-2, unexpectedly, led to higher expression levels than achieved with the 
individual RT or HT systems. On the other hand, the reverse combination, i.e. 5’ 
UTR of RNA-2 and the 3’ UTR of RNA-1 led to a 50% decline in expression levels 
compared to levels achieved with the HT system which deploys the cognate 5’ and 
3’ UTRs of RNA-2 (Y. Meshcheriakova, unpublished results). These results suggest 
the possibility of the creation of different expression systems, using combinations 
of RNA-1 and RNA-2 sequences, to achieve a wide-range of controlled expression 
levels.  They also indicate that the RNA-2 3’ UTR is superior to that from RNA-1 in 
enhancing expression, most probably through a superior ability to stabilise 
mRNAs, regardless of the origin of the 5’ UTR. 
The superior performance of the 3’ UTR of RNA-2 to enhance expression can be 
partially explained on the basis of predicted secondary structures of both 3’ UTRs. 
Predictions of the secondary structures (Gruber et al., 2008) of the 3’ UTRs of RNA-
1 and RNA-2 reveal the presence of a ‘Y-shaped’ structure in both cases (Figure 
6.10). This ‘Y-shaped’ structure has previously been shown to be important for 
enhancement of expression in the HT system, since mutations that disrupted the 
formation of this structure led to a decline in GFP expression (Y. Meshcheriakova, 
unpublished results).  The exact function of this ‘Y-shaped’ structure is not known 
although it can be thought to be involved in enhancement of mRNA stability. 
Complementation of the ‘Y-shaped’ structure of the 3’ UTR of RNA-1 by the 3’ UTR 
of RNA-2 restores expression, while in the reverse situation, the 82 nt long 3’ UTR 
of RNA-1 is not sufficient for complementation of the much longer, 3’ UTR of RNA-
2 of 184 bases. Overall, the results suggest that the Y-shaped structure of the 3’ 
UTRs of RNA-1 and RNA-2 is important for mRNA stability but that its context also 
has an influence on its ability to enhance expression.  
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Figure 6.10 Predicted secondary structures of the 3’ UTRs of RNA-1 and RNA-
2 generated using the software ‘RNAfold’ (Gruber et al., 2008).  
While further research into the role of the UTRs in translation is on-going, recent 
work on CPMV UTRs provides approaches to exploit sequences in the UTRs of 
RNA-1 and RNA-2 for control of gene expression for applications in biotechnology.  
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Chapter 7: Conclusions and Outlook 
Today, CPMV is one of the best-studied plant viruses due to its diverse applications 
in biotechnology and nanotechnology. In the last twenty years, the CPMV particle 
has been exploited for applications such as epitope presentation or as a building 
block for supramolecular assemblies, while the CPMV genome has been exploited 
for expression of heterologous proteins in plants. The two aspects were brought 
together when an expression system based on the CPMV genome (CPMV-HT) was 
deployed for expression of its own coat proteins resulting in the generation of 
CPMV eVLPs (Saunders et al., 2009).  
The availability of eVLPs took CPMV particle technology to another level since it 
was now possible both to use eVLPs for all the applications for which wt CPMV 
particles, containing RNA, had previously been used, with reduced bio-safety 
concerns, and for additional applications which make use of the space now 
available inside the capsid. The overall objective of this thesis was to advance this 
new eVLP technology through the complete characterisation of eVLPs and 
development of methods for applications in nanotechnology. In addition, the 
expression system based on CPMV RNA-2, CPMV-HT was further developed for 
stable expression of heterologous proteins in plants and a new transient 
expression system based on the UTRs of RNA-1 was created. 
eVLPs were initially expected to be less stable as compared to wt CPMV since it 
was believed that generally, RNA makes a contribution to particle stability (Fisher 
and Johnson, 1993). This was found to be true in case of CPMV and hence the 
protocols for production and purification of eVLPs had to be optimised to account 
for their reduced stability and absence of RNA. Analysis of the structure of eVLPs 
using TEM and cryo-EM revealed that all protein-protein contacts were conserved 
in eVLPs and that the capsids were identical to wt CPMV. This was very valuable as 
it meant that published literature on the structure and modifications of wt CPMV 
could be applied to eVLPs. During the course of cryo-EM studies to gain further 
information about the structure of eVLPs in comparison to wt CPMV, insights were 
gained on two previously unexplored aspects of the CPMV structure.  
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Firstly, at least some of the 24 amino acid peptide at the C-terminus of the S coat 
protein was observed in cryo-EM images. No structural information has previously 
been available on this peptide due to its absence from the crystallographic 
structure of CPMV owing to a combination of its high mobility and susceptibility to 
proteolysis (Lin et al., 1999). The C-terminal peptide has been shown to be 
important for packaging of RNA (Taylor et al., 1999) and for suppression of virus-
induced silencing (Canizares et al., 2004), both of which are important during the 
early stages of viral infection. Recent studies have shown that this peptide has a 
role in controlling the permeability of CPMV as particles possessing the intact 
peptide cannot be internally mineralised (Sainsbury et al., 2011). The reason for 
this is thought to lie in the location and structure of this peptide which enables it to 
block access to the pore at the 5-fold axis. So, any understanding of the structure or 
the precise location of the C-terminal peptide will provide methods to control the 
permeability of CPMV particles, a valuable trait for applications of eVLPs as nano-
containers, and provide information about the role of this peptide in the virus 
replication cycle.  
Secondly, preliminary data on the secondary structure adopted by RNA-1 and 
RNA-2 within capsids in CPMV has been obtained from cryo-EM of purified Bottom 
and Middle components respectively. Further results will help identify RNA-
binding sites in the interior of the CPMV capsid. This information can then be used 
to genetically modify of the interior of eVLPs for its application as a carrier for 
nucleic acids. Data generated by cryo-EM on residues that bind to RNA will also 
help in understanding the processes of RNA encapsidation and coat protein 
assembly in CPMV. 
The three-dimensional structure of the protein component of the capsids of many 
non-enveloped spherical RNA viruses has been determined in great detail, mainly 
using X-ray crystallography. However, much less is known about the secondary 
and tertiary structure of the RNA within the capsid, due to a number of 
methodological problems (Bink and Pleij, 2002). Therefore, any structural data 
obtained from cryo-EM of CPMV will be useful to all spherical viruses to some 
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extent and certainly to picornaviruses, given the high degree of similarity in the 
genomes of CPMV and picornaviruses (Franssen et al., 1984).  
Methods for high-level production of eVLPs using transient expression techniques 
have been described, resulting in average eVLP expression levels in excess of 0.3 g/ 
kg FWT. However, approaches for transgenic expression of eVLPs continue to be 
developed. It is not clear why the expression of eVLPs was not achieved in plants 
generated from leaf tissue transformed with pEAQspecialKm-eVLP, given that the 
construct was functional in transient expression systems. This aspect will have to 
be investigated further. In particular, the stoichiometry and the solubility of VP60 
and 24K will need to be taken into consideration. VP60 is likely to be required in 
higher amounts since one CPMV particle comprises sixty copies of VP60. On the 
other hand, the same molecule of the 24K proteinase could potentially be used for 
proteolytic processing of more than one VP60 molecule. Thus, the solution for 
transgenic expression of eVLPs may lie in expression of low levels of 24K, possibly 
by deploying the RNA-1-based RT system, along with expression of VP60 using the 
HT system. This would mimic the situation in a natural infection where 24K is 
translated from RNA-1 and expressed as a part of a polyprotein with the UTRs of 
RNA-1. The insolubility of VP60, as observed by Saunders et al (2009), will also 
need to be addressed for transgenic expression of VP60. This would involve 
optimisation of buffers for extraction of VP60 and possibly genetic modification of 
VP60.  
The prospect of an in vitro assembly system for CPMV can be considered once the 
issue of insolubility of VP60 is resolved. Such in vitro assembly systems have been 
successfully used for other icosahedral viruses such as CCMV (Bancroft and 
Hiebert, 1967) and BMV (Chaturvedi et al., 2012). Moreover, the fact that eVLPs 
have been successfully generated in two very different expression systems, namely 
in insect cells and in plants (Saunders et al., 2009), suggests that the requirement 
of host proteins for assembly in CPMV is unlikely and that in vitro assembly can be 
achieved simply by making VP60 and 24K available. The specificity in packaging 
exhibited by CPMV combined with its potential to assemble in vitro makes it an 
attractive candidate for applications as delivery vehicles for nucleic acids.   
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Although the objective of the creation of transgenic plants producing eVLPs was 
not achieved during this thesis, demonstration that P19/R43W can be successfully 
deployed in a transgenic expression system to express diverse proteins, from 
enzymes to antibodies, is a valuable achievement in biotechnology.  Studies with 
P19/R43W so far have only been undertaken in N. benthamiana but its use can 
easily be extended to other plant hosts since P19 is a protein from TBSV which has 
a broad host range of over a hundred plants in 20 families of mono- and 
dicotyledonous plants (Russo et al., 1994). Furthermore, the development of the 
pEAQspecialKm series of vectors encoding the CPMV-HT cassette provides a 
system for quick and efficient cloning for transient and transgenic expression. 
pEAQspecialKm has been tailored in such a way that once the gene of interest is 
cloned in this vector, it can be tested by transient expression in N. benthamiana 
and then the same vector can be used for leaf disc transformation.  
A number of published studies report the high levels of expression achieved by 
deploying the pEAQ-HT system to express a variety of proteins and multi-protein 
complexes. These include the human gastric lipase (Vardakou et al., 2012), 
sesquiterpene synthases (Kanagarajan et al., 2012a), a rice chitinase (Miyamoto et 
al., 2012), human papillomavirus (Matic et al., 2011), human IgG 2G12 (Sainsbury 
et al., 2010b) and the hemagglutinin antigen H7N7 (Kanagarajan et al., 2012b). 
However, limited success has been achieved with the expression of membrane-
bound proteins using this system since high levels of these proteins result in 
necrosis of the infiltrated tissue (P. Lenzi and L. Schellenberg, unpublished results). 
One solution to this problem has been to harvest tissue before necrosis has had 
time to develop. The development of expression vectors that deploy sequences 
from RNA-1 may prove to be useful in the expression of such proteins since the 
expression achieved in the RT system is rapid and lower than the levels achieved in 
the HT system. In fact, for the expression of a heterologous protein, the best 
approach would be to clone the gene of interest simultaneously with the RT and 
the HT UTRs in different pEAQ vectors and test expression by transient-infiltration 
of the constructs. Eventually, the expression cassette can be moved to 
CHAPTER 7 
 
  148 
 
pEAQspecialKm in one-step using restriction enzyme-based cloning for stable 
expression of the gene of interest. 
Overall, the work presented in this thesis has enabled sufficient quantities of 
purified eVLPs to be obtained for their detailed characterisation by a number of 
techniques and for investigations into their potential uses as a nanoparticle. CPMV 
eVLPs are currently being developed for applications in magnetic hyperthermia, as 
contrast agents for imaging, as vehicles for targeted drug delivery, as reaction 
vessels and as carriers for nucleic acids of choice. For the last application, the 
results reported in this thesis regarding the link between replication and 
encapsidation are of critical importance. A recent review by Mark Young et al. 
(2008) lists three main hurdles in the use of plant viruses in nanotechnology: (i) 
stability; (ii) efficacy and safety and (iii) production and costs. CPMV eVLPs have 
the potential to overcome all of these hurdles and the work described in this thesis 
is certainly a step in that direction.  
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Appendix I: List of Primers 
Details of the primers used for amplification of inserts, verification of clones and 
introduction of mutations in the work described in this thesis are presented below. 
For convenience, restriction sites have been coloured in blue and start and stop 
codons are in green and red respectively. 
For amplification of the VP60 expression cassette from pEAQ-HT-VP60 
VP60-PacI-F GCCAGTGAATTGTTAATTAAGAATTCGAGC 
VP60-SbfI-R TATACCTGCAGGCTTGAGACTCTAGAGATCTAG 
FSC2-F CCGCTTAATTAAGAATTCGAGCTCCACCGCGGAAACC 
FSC5-R AGTCTACGCGTTGGCCCTGCAGGGCTTGAGACTCTAGAGATCTAG 
 
For amplification of the 24K expression cassette from pEAQ-HT-24K 
24K-XmaI-F TATTCCCGGGTTCGAGCTCCACCGCGGAAACC 
24K-AscI-R TTAAGCTGGCGCGCCAAGCTTGAGACTCTAGAG 
FSC6-F AAACGCGATCGCTCCTGCAGGTATTCGAGCTCCACCGCGGAAACC 
FSC2-R AAGCTGGCGCGCCAAGCTTGAAACTCTA 
 
For SDM of the GDD motif of CPMV RNA-1 
GDD-ADD F GGTGACTTATGCTGATGATAATCTGATTTCAG 
GDD-ADD R CTGAAATCAGATTATCATCAGCATAAGTCACC 
GDD-GAD F GGTGACTTATGGTGCTGATAATCTGATTTCAG 
GDD-GAD R CTGAAATCAGATTATCAGCACCATAAGTCACC 
GDD-GED F GGTGACTTATGGTGAAGATAATCTGATTTCAG 
GDD-GED R CTGAAATCAGATTATCTTCACCATAAGTCACC 
 
For verification of the GDD mutants of RNA-1  
GDD check F 2 GCCAATGGAATATAATTTGGTCG 
GDD check R 2 CGCTTCTTTCTCAAAAGACAAAGG 
 
For verification of inserts cloned in between the 5’UTR and 3’ UTR of HT 
C1   AACGTTGTCAGATCGTGCTTCGGCACC 
C3 CTGAAGGGACGACCTGCTAAACAGGAG 
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For amplification of RNA-2 from AUG 512 to the end of the vp60 gene 
48K-AgeI-F GTTGACCGGTCGATGGAAAGCATTATGAG 
48K-SbfI-F TGTCCTGCAGGCGATGGAAAGCATTATGAG 
VP60-StuI-R AATAGGCCTACCTAAGCAGCAGTAGC 
VP60-XmaI-R ATACCCGGGACCTAAGCAGCAGTAGC 
 
For amplification of RNA-2 from AUG 161 to the end of the vp60 gene 
58K-AgeI-F GTTGACCGGTCGATGTTTTCTTTCACTG 
58K-SbfI-F TGTCCTGCAGGCGATGTTTTCTTTCACTG 
VP60-StuI-R AATAGGCCTACCTAAGCAGCAGTAGC 
VP60-XmaI-R ATACCCGGGACCTAAGCAGCAGTAGC 
 
For introduction of peptides at the N-terminus of CPMV-L for mineralization  
FePt-blunt/start/XmaI-F ATGCATAATAAACATTTGCCTTCTACTCAACCTTTGG
CTC 
FePt-blunt/start/XmaI-R CCGGGAGCCAAAGGTTGAGTAGAAGGCAAATGTTTAT
TATGCAT 
 
For introduction of the RGD peptide at the C-terminus of S for targeting  
RGD-XmaI/ blunt-F CCGGGAATGCTGTTCCTAATTTGAGAGGTGATTTGCA
AGTTTTGGCTCAAAAAGTTGCTAGAACTTAG 
RGD-XmaI/ blunt-R CTAAGTTCTAGCAACTTTTTGAGCCAAAACTTGCAAA
TCACCTCTCAAATTAGGAACAGCATTC 
 
For SDM of P19 to generate pEAQspecialKm-based plasmids  
P19-R43W-SDM-F CGAGTTGGACTGAGTGGTGGCTACATAACGATGAG 
P19-R43W-SDM-R CTCATCGTTATGTAGCCACCACTCAGTCCAACTCG 
 
For amplification of the gene encoding GFP 
GFP-start-XhoI-F GACTCGAGCTATGACTAGCAAAGGG 
GFP-stop-XmaI-R GATCCCGGGTATTATTTGTATAGTTCATCC 
 
For creation of the 3’ UTR mutants of pEAQexpress-RT-GFP  
RT-del3’UTR-F CGATCCCGGGTTGATCGTTCAAACATTTGG 
RT-del3’UTR-R GACTCTAGAGGATCCCCTTAAATCGATATGG 
RT-HT3’UTR-F CGATCCCGGGCTTAACTCTGGTTTCATTAA 
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Appendix II: List of Vectors 
The T-DNA regions of all vectors used for the work described in this thesis are 
shown below. Key elements have been labelled in each figure. Other elements are 
represented as follows: 
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Summary
Endeavours to obtain elevated and prolonged levels of foreign gene expression in plants are
often hampered by the onset of RNA silencing that negatively affects target gene expression.
Plant virus–encoded suppressors of RNA silencing are useful tools for counteracting silencing
but their wide applicability in transgenic plants is limited because their expression often causes
harmful developmental effects. We hypothesized that a previously characterized tombusvirus
P19 mutant (P19 ⁄ R43W), typified by reduced symptomatic effects while maintaining the abil-
ity to sequester short-interfering RNAs, could be used to suppress virus-induced RNA silencing
without the concomitant developmental effects. To investigate this, transient expression in
Nicotiana benthamiana was used to evaluate the ability of P19 ⁄ R43W to enhance heterolo-
gous gene expression. Although less potent than wt-P19, P19 ⁄ R43W was an effective sup-
pressor when used to enhance protein expression from either a traditional T-DNA expression
cassette or using the CPMV-HT expression system. Stable transformation of N. benthamiana
yielded plants that expressed detectable levels of P19 ⁄ R43W that was functional as a suppres-
sor. Transgenic co-expression of green fluorescent protein (GFP) and P19 ⁄ R43W also showed
elevated accumulation of GFP compared with the levels found in the absence of a suppressor.
In all cases, transgenic expression of P19 ⁄ R43W caused no or minimal morphological defects
and plants produced normal-looking flowers and fertile seed. We conclude that the expres-
sion of P19 ⁄ R43W is developmentally harmless to plants while providing a suitable platform
for transient or transgenic overexpression of value-added genes in plants with reduced
hindrance by RNA silencing.
Introduction
In applied biological plant sciences and biotechnology, there is
an increasing demand for gene expression systems that allow
for high levels of foreign protein production in plants, whether
transgenically, transiently or by means of a virus vector (Scholt-
hof et al., 2002; Can˜izares et al., 2005). However, irrespective
of the system, optimum expression is often not achieved or
maintained because of the onset of RNA silencing (Scholthof,
2007). Therefore, it is highly desirable to establish a high-level
expression platform in plants that is not subject to deleterious
effects of RNA silencing.
Many plant viruses are known to encode one or more sup-
pressors of RNA silencing (Voinnet, 2005), and these have been
successfully used to enhance transient gene expression of
co-expressed genes (Johansen and Carrington, 2001; Voinnet
et al., 2003; Sainsbury and Lomonossoff, 2008). An example of
such a suppressor is the Tomato bushy stunt virus (TBSV)-
encoded P19 that suppresses RNA silencing of foreign genes by
sequestering short-interfering RNAs (siRNAs) in a manner that
is neither sequence-specific nor organism-dependent (Scholthof,
2006). However, the toxigenic effect associated with expression
of P19 in plants (Scholthof et al., 1995) results in the situation
that the only transformants that survive accumulate poor levels
of P19 (Silhavy et al., 2002; Papp et al., 2003; Dunoyer et al.,
2004; Alvarez et al., 2008; Siddiqui et al., 2008). Still, in these
cases, severe negative consequences on plant performance and
development occur, which may be associated with the binding
of P19 to microRNAs (miRNAs) (Papp et al., 2003; Chapman
et al., 2004). A similar problem has also been found with the
transgenic expression of other silencing suppressors (Mallory
et al., 2002; Siddiqui et al., 2008). In the current study, we
aimed to develop and test a system in which desirable traits of
P19 with respect to enhancing gene expression are uncoupled
from unwanted side effects.
TBSV P19 is an intriguing multifunctional pathogenicity pro-
tein because it is a very critical host-range determinant, as well
as an important contributor to viral symptoms, and it has host-
dependent effects on virus invasion (Chu et al., 2000). Many of
these biological effects are related to the activity of P19 as a
suppressor of virus-induced RNA silencing (Silhavy et al., 2002;
Lakatos et al., 2004; Park et al., 2004; Omarov et al., 2006). To
enable this suppression function, P19 self-interacts to form
dimers that specifically sequester 21 nucleotide (nt) siRNAs in a
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sequence-nonspecific manner (Vargason et al., 2003; Ye et al.,
2003). This prevents the programming of a RNA interference-
associated RNA-induced silencing complex, thereby blocking the
antiviral RNA silencing and consequently protecting viral RNA
from degradation during infection (Omarov et al., 2007;
Pantaleo et al., 2007).
Our previous studies showed that the different host-depen-
dent biological activities and sequestration of siRNAs are all
structurally modulated by the same central region on P19 that
is positioned at the inner core of the dimer (Chu et al., 2000;
Scholthof, 2006). One mutation at amino acid 43 of the P19
protein [P19 ⁄ R43W; substitution of Arg43 (R43) with Trp (W)]
that is located more at the periphery of each monomer in the
dimer (Fig. 1a) strongly reduces the symptoms of TBSV infection
(Chu et al., 2000) while maintaining the ability to bind siRNAs
(Omarov et al., 2006). We have demonstrated that P19 ⁄ R43W
prevents virus-induced silencing (Qiu et al., 2002) and thus pro-
tects TBSV RNA from silencing-mediated degradation during
invasion of plants (Omarov et al., 2006). This outcome, in com-
bination with the absence of severe symptoms, suggests that
P19 ⁄ R43W is an active suppressor that, compared with wt-P19,
interferes far less with endogenous events, possibly including
miRNA function.
Based on the aforementioned observations, we hypothesized
that the nontoxic P19 ⁄ R43W suppressor would represent a bio-
technological tool to enhance foreign gene expression in plants
while minimizing negative effects on plant development and
performance. To examine this, we used three different methods
to illustrate the biotechnological potential of the mutant sup-
pressor: (i) transient expression of P19 ⁄ R43W along with target
constructs [green fluorescent protein (GFP) and the pharmaceu-
tically valuable human anti-HIV-1 IgG antibody 2G12], (ii) trans-
genic expression of P19 ⁄ R43W to test its effect on plant
development and to allow transient introduction of test con-
structs and (iii) transgenic co-expression of P19 ⁄ R43W with GFP
using the versatile and highly expressing CPMV-HT system
(Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2009).
Collectively, the results showed that even though P19 ⁄ R43W
was not quite as potent a suppressor as wild-type P19, its tran-
sient or transgenic expression yielded detectable levels of pro-
tein that did not negatively affect Nicotiana benthamiana
plants, as evidenced by the absence of severe deformations and
GFP
GFP
pEAQ-selectK-GFP-HT
pEAQ-specialKm-GFP-HT
GFPNPT
RB
35S 
promoter
Nos 
terminator
LB
pGFP
pKYLX-R43W
P19m
R43W  
P19m
35S 
terminator
(a)
(b)
Figure 1 P19 ⁄ R43W. (a) Three-dimensional
views of the location of R43 in the P19 ⁄ siRNA
structure. The red and green regions indicate the
amino acids in two P19 monomers important for
siRNA sequestration. The yellow balls on the P19
dimer indicate the location of P19 ⁄ R43 that is
close to the Trp reading head of P19 that mea-
sures 21-nt siRNAs. The blue ribbon represents
the backbone of the P19 dimer, and the siRNA
duplex is shown as the gold chain. The protein
structure profile was downloaded from the NCBI
protein structure database and viewed ⁄modified
by DeepView ⁄ Swiss-PdbViewer v3.7. (b) Sche-
matic representation of select T-DNA expression
cassettes used in this study. LB and RB represent
left and right border, respectively, and other
expression elements are described within the dia-
gram. Abbreviations are as follows: 35S pro-
moter = Cauliflower mosaic virus 35S promoter;
NPT = Neomycin phosphotransferase; Nos termi-
nator = Nopaline synthase terminator;
P19m = P19 carrying the R43W mutation. 35S
terminator = Cauliflower mosaic virus 35S
terminator.
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the setting of viable seeds. Several bioassays showed that
P19 ⁄ R43W was functionally active as a suppressor, for instance
in boosting transient expression of GFP. Transformation of
plants with constructs using the CPMV-HT system (Sainsbury
and Lomonossoff, 2008; Sainsbury et al., 2009) to simulta-
neously express GFP and P19 ⁄ R43W showed a clear increase in
GFP expression compared to levels in absence of suppressor.
We conclude that expression of P19 ⁄ R43W provides an environ-
ment in N. benthamiana cells that is not harmful to the plants
and consequently provides a suitable platform, particularly in a
transgenic context, for overexpression of heterologous genes.
Results
Suppression of RNA silencing by transient expression
of P19 ⁄R43W
Even though it had been demonstrated that P19 ⁄ R43W
(Fig. 1a) sequesters virus-derived siRNAs and suppresses TBSV-
induced RNA silencing (Qiu et al., 2002; Omarov et al., 2007),
no evidence was yet available that the protein would effectively
suppress RNA silencing of heterologous genes outside the con-
text of TBSV infection. To test this, N. benthamiana plants were
infiltrated with Agrobacterium tumefaciens cultures expressing
GFP and with cultures expressing either wt-P19 or P19 ⁄ R43W
(Fig. 1b) and the levels of GFP expression were assessed (Johan-
sen and Carrington, 2001; Voinnet et al., 2003). Several T-DNA
constructs for the transient expression of P19 ⁄ R43W in different
Agrobacterium strains were tested in these experiments
(Fig. S1). The co-infiltration tests revealed some quantitative dif-
ferences in GFP expression that were dependent on the T-DNA
construct and ⁄ or bacterial strain. However, it was evident that
the expression of P19 ⁄ R43W enhanced and prolonged the
green fluorescence but to a lesser extent than wt-P19 (Fig. S1).
To investigate whether P19 ⁄ R43W would be effective in con-
junction with a high-level protein expression system, modifica-
tion of the highly efficient CPMV-HT expression system
(Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2009) was
undertaken using the vector pEAQspecialK-GFP-HT (Sainsbury
et al., 2009). This is a vector that contains the GFP expression
cassette, the P19 cassette and the kanamycin resistance gene
all on the T-DNA region of a single binary vector (Fig. 1b). It is
effective for the high-level transient expression of GFP in plants
and, as all the components are located on a single T-DNA,
could potentially also be used for stable transformation. Plasmid
pEAQspecialKm-GFP-HT was constructed by a single nucleotide
substitution on pEAQspecialK-GFP-HT, resulting in the R43W
mutation in P19 (Fig. 1b). Levels of GFP expression obtained
after agroinfiltration of N. benthamiana leaves with pEA-
QspecialKm-GFP-HT (P19 ⁄ R43W) were compared with those
obtained after infiltration with pEAQspecialK-GFP-HT (wt-P19)
and pEAQselectK-GFP-HT, which does not express any suppres-
sor of silencing (Fig. 2). In the absence of a suppressor (pEAQse-
lectK-GFP-HT), GFP expression levels of 0.1 g ⁄ kg of fresh
weight tissue (FWT) were obtained, while pEAQspecialK-GFP-HT
gave GFP levels of 1.4 g ⁄ kg of FWT, a result similar to that
reported previously (Sainsbury et al., 2009). In the case of pEA-
QspecialKm-GFP-HT, GFP levels of 0.7 g ⁄ kg of FWT were
achieved, approximately half that observed when the wt-P19
was used and about sevenfold greater than obtained in the
absence of a suppressor.
The ability of P19 ⁄R43W to enhance transient expression of a
biotechnologically important protein was explored by expressing
the heavy and light chains of the human anti-HIV antibody
2G12 (Buchacher et al., 1994) in N. benthamiana (Fig. 3).
Assembled and active molecules of 2G12 have previously been
expressed in N. benthamiana leaves to levels of 400 mg ⁄ kg of
FWT by infiltration of a pEAQ construct encoding the 2G12
heavy (H) and light (L) chains plus wt P19 (Sainsbury et al.,
2009). In this study, the two pEAQ constructs were created to
express the H and L chains of 2G12 in presence of either wt-
P19 (pEAQspecialK-HEL) or P19 ⁄ R43W (pEAQspecialKm-HEL), all
from a single T-DNA. Levels of 2G12 were estimated by SDS–
PAGE of total protein extracts under reducing and nonreducing
conditions and using known amounts of Chinese hamster ovary
(CHO)-produced 2G12 as standards (Fig. 3). In presence of
wt-P19, 2G12 expression levels approaching 400 mg ⁄ kg of
FWT were attained, while in presence of P19 ⁄ R43W, 2G12
expression levels appeared to be about half as much. This is
consistent with the results obtained with GFP expression and
reiterates the observation that P19 ⁄ R43W retains significant, if
reduced, activity to suppress gene silencing when deployed in
conjunction with the CPMV-HT expression system.
Transgenic expression of P19 ⁄R43W does not lead to
negative effects on plant growth and development
The first questions to be addressed if P19 ⁄R43W is to prove
useful in a transgenic context were whether plants transformed
solely for expression of P19 ⁄ R43W would yield detectable levels
of a functional suppressor protein and would such plants be
developmentally normal. To assess this, the transformation con-
struct pKYLX7-P19 ⁄ R43W was created (Fig. 1b). Transient
assays with two different Agrobacterium strains showed that
pKYLX7-P19 ⁄ R43W expressed readily measurable levels of
P19 ⁄ R43W protein that enhanced GFP expression though, as
expected, at somewhat reduced levels compared to wt-P19
(Fig. 4). Also, the levels obtained with this construct, designed
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Figure 2 Effect of P19 ⁄ R43W on transient GFP expression in Nicotiana
benthamiana. Transient expression of GFP was assessed by visual inspec-
tion of leaves under UV light (upper panel) or by fluorimetry (lower
panel) in the absence of any suppressor (a), presence of wt-P19 (b) and
presence of P19 ⁄ R43W (c). P19 ⁄ R43W enhances expression by about
7-fold, which is half the level achieved with wt-P19. Error bars represent
the standard deviation for the triplicate samples.
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for the creation of transgenics plants, were comparable to
those achieved with a vector normally used for transient assays
only (Fig. 4b, lane 7).
The pKYLX-P19 ⁄R43W construct was used for plant transfor-
mation, and 14 N. benthamiana T0 plants (1–15; plant number
10 was inadvertently omitted) were selected and grown to
maturity; these all flowered and set seed that was collected
from each plant. Western blot analyses on the T0 plants using a
routine (but with relatively inferior sensitivity) alkaline phospha-
tase-mediated detection showed that P19 ⁄ R43W protein was
accumulating in three individuals (43-3, 43-12 and 43-15).
However, only the SDS-recalcitrant P19-dimer (Park et al., 2004)
and not the monomer was discernable (data not shown). The
phenotype of these T0 plants accumulating detectable levels of
P19 ⁄ R43W was quite similar to those not expressing the pro-
tein, although upon very close inspection some evidence of
cup-shaped leaves and mild swelling or blistering was visible
(Fig. 5a). The T0 plants developed normally, flowered and set
seed that was collected and germinated on MS agar plates in
presence of kanamycin to select for transgenic T1 individuals
followed by Western blot screening on progeny plants from
each original transgenic T0 line. Progeny from 43-3, 43-12 (but
not 43-14 or -15) tested positive for P19 expression and, in
addition, 43-2, -5, -6, -8, -11, -13 now yielded P19 ⁄R43W pro-
tein monomers and ⁄or dimers (Fig. 5b). It is important to note
in the context of these positive immune-detection results for
the T1 plants that the germination rate of each batch of T0-
produced seed was approximately 95% illustrating that the
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Figure 3 Comparison of 2G12 expression in the presence of wt-P19 or P19 ⁄ R43W. Total protein extracts of infiltrated leaves were subjected to SDS–
PAGE under nonreducing (left-hand panel) or reducing conditions (right-hand panel) and the gel stained with InstantBlue Coomassie stain. Lane M:
protein markers; Lane 1: Negative control (Empty pEAQ-HT vector); Lane 2: pEAQspecialK-HEL (containing 2G12 H chain, L chain and wt-P19 in pEAQ-
HT; Lane 3: pEAQspecialKm-HEL (containing 2G12 H chain, L chain and P19 ⁄ R43W in pEAQ-HT); Lane 4: 1 lg CHO-expressed 2G12; Lane 5: 2 lg
CHO-2G12. 2G12 expression levels can be estimated from the gel to be 400 mg ⁄ kg of FWT in presence of wt-P19 and 200 mg ⁄ kg of FWT in pres-
ence of P19 ⁄ R43W.
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Figure 4 Transient suppression of GFP silencing by P19 ⁄ R43W expressed from a plant transformation construct. (a) Fluorescence on Nicotiana benth-
amiana leaves co-infiltrated with pGFP, a GFP-expressing construct (GFP) (Voinnet et al., 1998; Qiu et al., 2002) and either pKYLX7-P19 or pKYLX7-
P19 ⁄ R43W. All constructs were transformed into Agrobacterium strain C58 for this transient assay. (b) Western blot detection of TBSV P19 monomers
(1x) and dimers (2x) in total protein extracts from 7 dpi Agrobacterium-infiltrated N. benthamiana leaves. Lane 1: pKYLX7-P19 ⁄ R43W isolate 1 in C58;
Lane 2: pKYLX7-P19 ⁄ R43W isolate 2 in C58; Lane 3: pKYLX7-P19 ⁄ R43W isolate 1 in EHA; Lane 4: pKYLX7-P19 ⁄ R43W isolate 2 in EHA; Lane 5: Mock
(infiltration buffer only); Lane 6: pKYLX7-wt-P19 in C58; Lane 7: pCass4N-wt-P19 in C58. (c) Codetection of GFP and P19 protein in co-infiltrated
leaves at 7 dpi. Lane 1: pKYLX7-wt-P19; Lane 2: pKYLX7-P19 ⁄ R43W; Lane 3: GFP only; Lane 4: Mock; the two panels are from the same blot with
irrelevant lanes removed.
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readily detectable levels of P19 ⁄ R43W had no negative effect
on seed fertility, germination and growth.
Collectively, these tests provided evidence that P19 ⁄ R43W
can accumulate at detectable levels in transgenic N. benthami-
ana with minimal effects on plant morphology, flowering and
setting of fertile seed.
Functionality of transgenically expressed P19 ⁄R43W
Several approaches were used to address whether the transgen-
ically expressed P19 ⁄R43W (Line 3 and Line 12) was functional.
Briefly, the experiments showed that the transgenically
expressed P19 ⁄ R43W often complemented p19-defective TBSV
constructs (Fig. S2), but for reasons not yet understood, this
was not always evident. Most importantly, for this study that
focuses on determining the effect of P19 ⁄ R43W on expression
of heterologous foreign genes, we showed that agroinfiltration
of the transgenic plants with pGFP (Fig. 1b) yielded higher levels
of GFP when compared to that in nontransgenic plants (Fig. 6).
In fact, the effect mimicked that observed upon co-infiltration
of pGFP with a wild-type P19-expressing construct in nontrans-
genic plants (Fig. 6).
In summary, the P19 ⁄ R43W-transgenic plants were shown to
(i) express the suppressor protein at detectable levels, (ii) suffer
no harmful developmental effects and (iii) express a P19 ⁄ R43W
protein that is functional for the suppression of transiently- or
virus-induced gene silencing. These observations provided confi-
dence and impetus for pursuing the biotechnologically attractive
prospect of cotransgenic expression of P19 ⁄ R43W with target
foreign genes, as described in sections below.
P19 ⁄R43W-mediated enhancement of a co-expressed
heterologous transgene
To examine whether P19 ⁄ R43W can be used to enhance
expression of a heterologous transgene, the pEAQspecialKm-
GFP-HT (P19 ⁄ R43W), pEAQspecialK-GFP-HT (wt-P19) and pEAQ-
selectK-GFP-HT (no suppressor) (Fig. 1b) were used to stably
transform N. benthamiana using the leaf disc method of Horsch
and Klee (Horsch and Klee, 1986). While a number of primary
transformants (T0) could be isolated when pEAQspecialKm-
GFP-HT or pEAQselectK-GFP-HT was used for transformation,
no plants could be regenerated when pEAQspecialK-GFP-HT,
expressing wt-P19, was used, a result consistent with previously
reported toxigenic properties of wt-P19 (Scholthof, 2006). One
line for each of the plants transformed with pEAQspecialKm-
GFP-HT (Line 5, expressing P19 ⁄ R43W) or pEAQselectK-GFP-HT
(Line 3, no suppressor) was selected for more detailed analysis.
The T0 plants representing Line 3 and Line 5 grew normally and
fluoresced under UV light, showing successful stable integration
of the GFP gene. The T0 plants were self-fertilized, and a T1
population of over 50 plants from each line was produced by
germinating the resultant seeds. The T1 plants of both Lines 3
and 5 showed no developmental defects and grew and flow-
ered normally. Initial characterization of GFP expression was
performed by visually scoring each T1 plant for green fluores-
cence under UV light followed by verification with a quantita-
tive GFP assay (data not shown). The progeny from both Lines
3 and 5 appeared to give three distinct levels of GFP fluores-
cence, with the ratio of plants with high, medium and no GFP
1 2 3 4 5 6 7 8 WT 9 11 12 13 14 15 N WT
P19 monomer
P19 dimer
43-3
43-3
43-12
43-12
*
(a)
(b)
Figure 5 P19 ⁄ R43W-transgenic plants. (a) Representative P19 ⁄ R43W transgenic lines 43-3 (Left) and 43-12 (Right) displaying mild morphological fea-
tures such as leaf cupping, wrinkling or blistering. (b) Detection of P19 ⁄ R43W in total protein extracts from putative transgenic Nicotiana benthamiana
T1 lines using Western blotting with alkaline phosphatase-mediated detection. Lanes denote lines with the same number, and those in grey show accu-
mulation of monomers and dimers, or only dimers that appear as a fuzzy band above the sharper band representing a protein that for unknown rea-
sons cross-reacts with the P19 antiserum (*); those in black colour failed to give a positive signal for P19 ⁄ R43W. The WT sample is from
nontransformed wt-TBSV infected N. benthamiana plants, and N denotes non-P19 ⁄ R43W-transgenic N. benthamiana obtained after transformation.
The origin of the nonspecific band in these plants is not known, nor why it is absent in WT nontransformed plants.
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fluorescence being approximately 1 : 2 : 1 for both Lines 3 and
5. Even though we cannot assume a strict correlation between
zygosity and level of expression, this potentially fits with a single
integration event occurring in both cases, with the ratio
1 : 2 : 1 corresponding to homozygotes:heterozygotes:null se-
gregants.
From the T1 population, leaf tissue was harvested from the
15 highest expressing plants of each Line (3 and 5) and fluores-
cence was again measured by spectrofluorometry. Although
there was considerable variation in the levels of GFP expression
in the different T1 plants from the same line, overall, T1 plants
from Line 5 (containing P19 ⁄ R43W present as transgene) had
higher GFP expression levels in comparison with those from Line
3 (not expressing any suppressor of silencing) (Fig. 7), indicating
that transgenically expressed P19 ⁄ R43W enhances expression of
a heterologous transgene. Upon comparing the average yield of
homozygous plants of both lines, the presence of P19 ⁄ R43W
appears to enhance the expression approximately 1.7-fold in a
statistically significant manner (Fig. 7).
Plants homozygous for co-expression of GFP and
P19 ⁄R43W are phenotypically normal
If transformation with P19 ⁄ R43W is to be a practical method of
enhancing transgene expression, it will be essential that plants
homozygous for the mutant suppressor are phenotypically nor-
mal and fertile. To identify homozygotes among the T1
progeny, high-expressing individuals of Lines 3 and 5 were self-
fertilized and the seeds from 10 of these plants were germi-
nated on kanamycin-containing plates. T1 plants numbered
3.26, 5.5, 5.10 and 5.12 were identified as homozygotes
because 100% of their progeny was resistant to kanamycin and
expressed GFP (Fig. S3). Because kanamycin resistance is con-
ferred by the nptII gene present in the integrated T-DNA region
and the entire T2 generation of these plants was resistant, we
conclude that the T1 plants listed earlier are homozygous for
the T-DNA region, including the genes encoding GFP and
P19 ⁄ R43W (Fig. 1b). Homozygous individuals of Line 3 (express-
ing only GFP) and Line 5 (expressing GFP and P19 ⁄ R43W) exhi-
bit a phenotype that is indistinguishable from that of
nontransformed plants (Fig. 8).
Discussion
Transient and transgenic expression of P19 ⁄R43W
In previous studies, we demonstrated that the TBSV P19 mutant
P19 ⁄ R43W (Fig. 1a) was a suppressor of VIGS, that it seques-
tered siRNAs and that its symptom induction was substantially
attenuated compared to wt-P19 (Chu et al., 2000; Qiu et al.,
2002; Omarov et al., 2006). Therefore, the initial objective was
to examine the capacity of P19 ⁄ R43W to suppress RNA silenc-
ing of heterologous genes and to compare this with the perfor-
mance of wt-P19 tested under the same conditions using
transient agroinfiltration experiments. These results provided
evidence that P19 ⁄ R43W was an effective suppressor of GFP
silencing albeit with a capacity that was somewhat reduced
(estimated 50%–70%) compared to wt-P19 (Figs S1 and 4).
We also observed differential effects regarding the efficiency of
suppression by wt-P19 or P19 ⁄ R43W depending on the Agro-
bacterium strain (Fig. S1), in agreement with strain variations
observed by others (Wroblewski et al., 2005). The ability of
P19 ⁄ R43W to act as a transient suppressor was maintained
when it was used in conjunction with the CPMV-HT expression
system. Collectively, the transient expression-based results
showed that P19 ⁄ R43W is an effective suppressor of RNA
silencing that can be used to significantly boost the transient
expression of foreign proteins in plants.
Previous reports have shown that transgenic expression of
wt-P19 in Arabidopsis thaliana, N. tabacum and N. benthami-
ana often failed to yield detectable levels of P19, although the
Non-transgenic N. benthamiana
GFP GFP + P19
P19/R43W-3 transgenic N. benthamiana
GFP
Figure 6 Suppression activity of transgenically
expressed P19 ⁄ R43W in Nicotiana benthamiana.
Images are of abaxial sides of leaves photo-
graphed with same exposure times under ultravi-
olet light four days post-infiltration with
Agrobacterium cultures. The top panels show
transient GFP expression in nontransgenic
N. benthamiana upon (co-)infiltration with con-
structs expressing either GFP only (left) pGFP or
GFP plus wild-type P19 (right) using pGFP and
pKYLX-P19 (Figs 1b and S1). The panel on the
bottom shows a leaf of the P19 ⁄ R43W trans-
genic Line 3 infiltrated with a construct express-
ing only GFP. The differences in the digital
images accurately reflect what was observed
upon visual examination of the leaves in three
biological repeats.
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plants exhibited deforming phenotypes (Silhavy et al., 2002;
Papp et al., 2003; Dunoyer et al., 2004; Scholthof, 2006;
Alvarez et al., 2008; Siddiqui et al., 2008). These effects include
variegated leaves, aberrant flower phenotype on A. thaliana,
curled leaves on N. benthamiana and compromised fertility in
those plants and in tomato. In comparison, transgenic N. benth-
amiana lines constitutively expressing P19 ⁄ R43W had minor
phenotypic differences with some oval, mildly puckered and
blistered leaves (Fig. 5), which were not observed in nontrans-
genic plants. Several observations supported a conclusion that
P19 ⁄ R43W expressed in these normally developing transgenic
N. benthamiana was functionally active; most relevant for this
study was that the transient expression of an agroinfiltrated
GFP construct was enhanced in the transgenic plants compared
to that in nontransgenic plants (Fig. 6).
Transgenic co-expression of P19 ⁄R43W and GFP
Because transgenic expression of P19 ⁄ R43W yielded fertile
plants that accumulated measurable amounts of the function-
ally active suppressor, we explored an additional highly attrac-
tive possibility of co-expressing the suppressor with a target
foreign gene in plants. The utility of P19 ⁄ R43W for biotechno-
logical uses was demonstrated by showing that P19 ⁄ R43W
retained its ability to enhance gene expression when used as a
component of the pEAQ expression system. Transgenic
N. benthamiana lines were obtained that showed elevated
levels of GFP expression (Fig. 7). Even though the suppressor
activity of P19 ⁄ R43W is weaker than that of wt-P19, these
results confirmed the distinct advantage of the mutant that it is
tolerated within stably transformed plants, even in the homozy-
gous state (Figs 8 and S3). This could not be achieved using
constructs expressing wt-P19.
Plants transgenic for P19 ⁄R43W produced higher levels of
GFP than were found in the absence of the suppressor, and the
lack of detrimental phenotypic effects allowed the identification
of lines of plants homozygous for both transgenes. The ability
to produce homozygous plants is a prerequisite for the creation
of true-breeding transgenic lines, and thus this study paves the
way for development of lines of transgenic plants expressing
high levels of heterologous proteins. The enhancement of the
GFP expression level over that seen in the absence of a suppres-
sor (an average of 1.7-fold) was relatively modest. However,
because the emphasis was on providing a proof-of-concept, no
attempt has yet been made to optimize the level of P19 ⁄ R43W
expression in the transgenic lines. Furthermore, despite the
absence of developmentally disturbing effects, it is possible that
a substantial portion of the P19 ⁄ R43W protein pool is seques-
tering siRNAs or miRNAs unrelated to GFP-mRNA, and therefore
the effectively available levels of P19 ⁄ R43W left over to sup-
press GFP silencing might be lower than originally expected.
The expression associated with the CPM-HT system was previ-
ously in itself already shown to be superior to other systems
(Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2009), and
this study shows that P19 ⁄ R43W enhances this utility even
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Figure 7 GFP expression levels in 15 highest
expressing plants of Line 3 and Line 5 as
assessed by fluorimetry of extracts. Overall, GFP
expression was higher in Line 5, because of the
suppression of silencing by P19 ⁄ R43W. Homo-
zygotes have been marked with an asterisk (*).
The p-value in a one-sided t-test for Line 3 and
Line 5 is 0.007832 at 95% confidence level.
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further. A particular advantage of the pEAQ vector system that
we have used for the co-expression of GFP and P19 ⁄ R43W is
that the same construct can be used for both transient and sta-
ble transgenic expression. Thus, it is possible to rapidly screen a
number of candidate proteins and optimize their expression
using the transient approach prior to undertaking the more time-
consuming process of plant transformation and regeneration.
Conclusion
While TBSV P19 has already enjoyed considerable success in
enhancing gene expression in transient assays, it has not been
deployed in stably transgenic plants because of its deleterious
effects on development. Our study on the nontoxic but sup-
pression-active P19 mutant (P19 ⁄ R43W) is the first to report the
accumulation of readily detectable levels of constitutively
expressed P19-protein in transgenic plants without severe mor-
phological effects, allowing the transgenic plants to flower nor-
mally and set fertile seed. In turn, this permitted the generation
of lines of developmentally normal, fertile transgenic N. benth-
amiana plants which co-expressed P19 ⁄ R43W and GFP from
the same T-DNA using the CPMV-HT high level expression sys-
tem. This P19 ⁄ R43W-based technology, especially in combina-
tion with the versatile CPMV-HT system, may find application in
a variety of biotechnologically attractive plant species. The appli-
cation of P19 ⁄ R43W might reach even further because it is
known that P19 functions as a suppressor in a variety of
organisms because of its ability to bind siRNAs in a sequence-
independent manner.
Experimental procedures
Constructs- and DpnI- mediated site-directed
mutagenesis PCR
Plasmids for transient expression that expressed TBSV P19 were
pCB301-p19 (provided by S. Kamoun, Norwich research park,
Norwich, UK), pJL-p19 (provided by J. Lindbo, Ohio State Univ.,
Wooster, USA) and pCass4N-P19 (provided by S. Gowda and
Bill Dawson, Univ. Florida, Lake Alfred, USA). The QuickChange
kit (Stratagene, La Jolla, CA, USA) was used for site-directed
mutagenesis, and standard molecular biology protocols were
followed for the isolation and manipulation of plasmid DNA
(Sambrook et al., 1989). The construct pCass4N-P19 ⁄ R43W
was generated by site-directed mutagenesis PCR (P19 ⁄ R43W-F
primer- 5¢-actgagtggTggctacataacgatgagacgaattcgaat-3¢; P19 ⁄
R43W-R primer- 5¢-tatgtagccAccactcagtccaactcggactttcgtcag-3¢).
For construction of pKYLX7-R43W, plasmid pKYLX7-p22
(expressing both P22 and P19) (provided by J. Schoelz, Univer-
sity of Missouri, Colombia, USA) was first mutated to inactivate
the start codon of P22 (pKYLX-p22 stop-F primer- 5¢-ctc-
gagaGggatactgaatacgaa-3¢; pKYLX-p22 stop-R primer- 5¢-ttcgt-
attcagtatccCtctcgag-3¢) to solely express P19 and subsequently
was verified by Western blot analysis. pKYLX7-R43W was
obtained using the mutagenesis protocol and primer described
for pCass4N-P19 ⁄ R43W above. All mutations were verified by
sequencing.
Creation of pEAQ constructs
pEAQspecialK-GFP-HT was made by sub-cloning the P19 cas-
sette into the AsiSI ⁄MluI site of pEAQselectK-GFP-HT (Sainsbury
et al., 2009). Site-directed mutagenesis of P19 in pGEM-T EASY
(Promega, Madison, WI) was performed using QuickChange
method (Stratagene) to create the R43W mutation with the fol-
lowing primers: pGEM-P19-R43W-F, 5¢- CGAGTTGGACTGAG
TGGTGGCTACATAACGATGAG -3¢; pGEM-P19-R43W-R 5¢- CT
CATCGTTATGTAGCCACCACTCAGTCCAACTCG -3¢. The expres-
sion cassette containing the mutant P19 gene was sub-cloned into
the AsiSI ⁄MluI site of pEAQselectK-GFP-HT to make pEA-
QspecialKm-GFP-HT.
To create pEAQ constructs that express the IgG 2G12 in
presence of wt-P19 or P19 ⁄ R43W, pEAQspecialK-HEL and
pEAQspecialKm-HEL were constructed as follows: the expres-
sion cassettes containing the endoplasmic reticulum-retained
heavy chain (HE) and light chain (L) genes of 2G12 were
amplified from pEAQex-2G12HEL (Sainsbury et al., 2009).
Using designed primers, PacI sites were introduced on both
ends of the HE gene cassette and AscI sites were introduced
on both ends of the L gene cassette. The GFP cassettes
from pEAQspecialK-GFP-HT and pEAQspecialKm-GFP-HT was
removed by PacI ⁄AscI digestion and replaced with a multiple
cloning site (Sainsbury et al., 2009). The HE and L cassettes
were cloned into the PacI and AscI sites of pEAQspecialK
and pEAQspecialKm to create pEAQspecialK-HEL and pEA-
QspecialKm-HEL, respectively.
Agroinfiltration of N. benthamiana
Binary vectors were transformed into A. tumefaciens strains
LBA4404, C58 or EHA101 by electroporation (GIBCO-BRL Cell-
Porator system). Media for overnight induction contained
200 lM MES, pH 5.85 [monohydrate 2-(N-morpholino) ethane-
sulfonic acid] and 19.5 lM acetosyringone. The agrobacterium
infiltration buffer included 10 mM MES (pH 5.85), 10 mM MgCl2
and 2.25 mM acetosyringone. Agrobacterium suspensions were
infiltrated into expanded leaves at the abaxial surface of
approximately 4-week-old N. benthamiana plants using a simple
syringe. The use of the 35S:GFP T-DNA construct in Agrobacte-
rium C58C1 was described previously (Voinnet et al., 1998; Qiu
et al., 2002).
Figure 8 Phenotype of P19 ⁄ R43W-expressing plants. Individuals of
Lines 3 and 5 were brought to flower to illustrate their normal develop-
ment independent of the presence of P19 ⁄ R43W. Under UV light, GFP
fluorescence is evident and even though this is not a quantitative assay,
the enhanced fluorescence is notable for Line 5. Furthermore, based on
weekly inspections with UV illumination, GFP is expressed throughout
the lifetime of the plants and there is a visible difference in expression
level with P19 ⁄ R43W in plants up to 8 weeks old. After this, the differ-
ence becomes less distinct. In all cases, maximum fluorescence is
observed in the youngest leaves, as is apparent in the figure.
Plant Biotechnology Journal ª 2010 Society for Experimental Biology, Association of Applied Biologists and Blackwell Publishing Ltd, Plant Biotechnology Journal, 9, 703–712
No claim to original US government works
Pooja Saxena et al.710
Inoculation and analysis of plant tissues
Tomato bushy stunt virus virions purified from infected
N. benthamiana plants infected with in vitro–generated tran-
scripts of full-length TBSV cDNAs expressing wt-P19 and defec-
tive P19 (DP19) were used for inoculation. Plants were
inoculated with virus plus 1% Celite, 50 mM KH2PO4 (pH 7.0),
following standard procedures (Scholthof et al., 1993). Tran-
scripts from TBSV-GFP and the mutant derivative were prepared
as described previously (Qiu and Scholthof, 2007).
Transgenic plants
Plasmid pKYLX7-P19 ⁄ R43W was sequenced to confirm its iden-
tity and sent to the Ralph M. Parsons Foundation Plant Transfor-
mation Facility, U. C. Davis, for transformation of
N. benthamiana using routine transformation and selection pro-
tocols (David M. Tricoli, personal communication), similar to
those used for the transformation and regeneration of plants
expressing another virus (symptom causing) protein (Goldberg
et al., 1991). Fourteen lines were regenerated by this facility,
which were labelled as 072106-001 to 072106-009, 072106-
011 to 072106-015 (072106-010 was missing). For our pur-
poses, these lines were later abbreviated as 43-1, etc. Healthy
nontransgenic N. benthamiana plants regenerated at same facil-
ity from the same callus were used as negative controls. These
P19 ⁄ R43W transgenic N. benthamiana plants were grown in
the laboratory on light shelves at ambient temperature (approxi-
mately 25–28 C) with a 14-h photoperiod. Seeds from parental
transgenic plants were harvested separately from each plant.
The F1 seed was germinated in MS (Murashige and Skoog)
medium (Life Technologies, Rockville, MD, USA) with 30 lg ⁄ml
kanamycin. For genome integration of the T-DNA region of
pEAQ vectors, N. benthamiana leaf discs were transformed with
A. tumefaciens with strain LBA4404 cultures harbouring the
desired pEAQ construct using the ‘leaf disc method’ (Horsch
and Klee, 1986).
Protein extractions and detection
Upon co-infiltration or when analysing P19 ⁄ R43W transgenic
lines, leaves were extracted with Tris-EDTA (TE) buffer, and pro-
tein samples were separated by standard SDS–PAGE in 15%
polyacrylamide gels and transferred to nitrocellulose membranes
(Osmonics, Westborough, MA, USA). The membranes were
stained with Ponceau S (Sigma, St. Louis, MO, USA) to verify
the efficiency of protein transfer. The P19 antiserum was
applied at the dilution of 1 : 5000. Alkaline phosphatase–conju-
gated goat anti-mouse or rabbit antiserum (Sigma) was used as
the secondary antibody and applied at a dilution of 1 : 1000.
The immune complexes were visualized by hydrolysis of the
substrate tetrazolium-5-bromo-4-chloro-3-indolyl phosphate
(BCIP) in the presence of nitro-blue tetrazolium chloride. In
some experiments, horseradish peroxidase-conjugated to goat
anti-mouse antiserum (Bio-Rad, Hercules, CA, USA) was used as
the secondary antibody at the dilution of 1 : 5000, and the
immune complexes were visualized by using the enhanced
chemiluminescence detection kit (Pierce, Rockford, IL, USA).
Mouse monoclonal IgG2a GFP antibody [GFP (B-2): sc-9996;
Santa Cruz Biotechnology, CA, USA] was used to quantify GFP
expression.
In case of plant material used in combination with the pEAQ
system, GFP was extracted from infiltrated leaf tissue by
homogenizing 60 mg of leaf tissue in 240 ll of extraction buf-
fer [50 mM Tris–HCl pH 7.25, 150 mM NaCl, 2 mM ethylenedi-
aminetetraacetic acid (EDTA), 0.1% (v ⁄ v) Triton X-100]. To
extract 2G12, 60 mg of infiltrated leaf tissue was homogenized
in 240 ll of phosphate-buffered saline (PBS) with 5 mM EDTA,
3 mM b-mercaptoethanol and 0.05% (v ⁄ v) Triton X-100. Lysates
were clarified by centrifugation, and protein concentrations
determined by the Bradford assay. A 1 : 100 dilution of the
GFP-containing extract was used for the GFP fluorescence assay.
Approximately 12.5 lg of the 2G12-containing protein extract
was separated by Tris-Glycine SDS–PAGE using 12% NuPAGE
gels (Invitrogen, Paisley, UK) under reducing and nonreducing
conditions and stained with InstantBlue Coomassie stain (Expe-
deon, Cambridge, UK).
GFP imaging and fluorescence assay
Green fluorescent protein (GFP) signals on the inoculated
N. benthamiana leaves were monitored with a 100 W handheld
long-wave ultraviolet (UV) lamp (Black Ray model B100AP; UV
products, Upland, CA, USA). An Olympus DP70 camera was
used for the image acquisition of DIC and wide field fluorescent
images.
GFP fluorescence measurements were made using a slightly
modified version of a previously described protocol (Richards
et al., 2003). Soluble protein extracts were diluted in 0.1 M
Na2CO3 and loaded in triplicate onto a fluorescently neutral
black 96-well plate. Recombinant GFP from Clontech, which is
the same variant of GFP as the one used in this study, was used
to generate standard curves in a control plant extract at the
same dilution as the test samples. Excitation (395 nm) and
emission (509 nm) maxima were matched to Clontech’s GFP
and read using a SPECTRAmax spectrofluorometer (Molecular
Devices; http://www.moleculardevices.com). Measurements
were carried out in triplicate on the pooled samples of 6 inde-
pendently infiltrated leaves to account for experimental varia-
tion and averaged to give a final value for each sample.
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Introduction
Viruses and virus-like particles (VLPs) are attracting much atten-
tion in the field of biomedicine as they have a number of poten-
tial applications. These include the display of antigens to create 
novel vaccines, their use as imaging agents and their potential 
as drug delivery vehicles. Systems based on bacteriophage, yeast 
Ty particles and animal viruses have been investigated for one or 
more of these applications. Cowpea mosaic virus (CPMV) was 
the first plant virus to be developed as a system for the display of 
foreign peptides1-3 and the particles have been used extensively 
for chemical modification.4 CPMV is a bipartite RNA virus, 
whose particles of approximately 28 nm diameter consist of 60 
copies each of a Large (L) and a Small (S) coat protein arranged 
with icosahedral symmetry (Fig. 1). The L protein contains two 
β-barrel domains (marked the B and C domains in Fig. 1B) while 
the S protein consists of a single β-barrel (marked A domain in 
Fig. 1B). Both coat proteins are produced by proteolytic cleav-
age of a precursor (VP60) by the virus-encoded 24K protein-
ase.5,6 The virus coat proteins encapsidate a single copy of either 
RNA-1 (6 kb) or RNA-2 (3.5 kb) and both RNAs are required 
for infection. Infectious clones of both RNA molecules have 
been available for over 20 years and the most efficient method 
of initiating an infection is by the “agro-infiltration” of cloned 
viral DNAs.7 This approach makes use of the ability of the soil-
living bacterium, Agrobacterium tumefaciens, to efficiently deliver 
part of its DNA (the T-DNA) to the nucleus of plant cells where 
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Particles of cowpea mosaic virus (CPMV) have enjoyed 
considerable success as a means of presenting peptides for 
vaccine purposes. However, the existing technology has 
limitations in regard to the size and nature of the peptides 
which can be presented and has problems regarding bio-
containment. Recent developments suggest ways by which 
these problems can be overcome, increasing the range of 
potential applications of CPMV-based particle technology.
Recent advances of cowpea mosaic virus-based 
particle technology
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it is integrated into the plant’s genomic DNA. This allows the 
transferred DNA to be transcribed by the plant cell as if were 
part of the normal complement of plant genes. To make use of 
this ability of A. tumefaciens to transfer DNA, full-length dou-
ble-stranded DNA copies of the CPMV RNAs were positioned 
between a plant-specific promoter (the cauliflower mosaic virus 
35S promoter) and a transcription terminator and the cassettes 
were introduced into the T-DNA region of an A. tumefaciens plas-
mid. Infection is initiated by simply infiltrating bacterial suspen-
sions into leaf tissue, where the liquid displaces the air in the 
intercellular spaces. After T-DNA transfer and transcription, the 
transcribed RNA is able to initiate a virus infection. In fact, the 
transfer and transcription of inserted genes is so efficient using 
this technique, that constructs which can no longer replicate can 
also be expressed to high level. All the research described in this 
paper utilizes this approach.
CPMV particles are attractive candidates for both genetic and 
chemical modification for a number of reasons: they can be puri-
fied in large quantities from infected tissue, they are very robust, 
surviving at 60°C for at least one hour, across the range of pH 
4–9, and in some organic solvent-water mixtures. Furthermore, 
the three-dimensional (3D) structure of the particles is known 
to atomic resolution8 and they can be readily purified by a sim-
ple procedure involving precipitation with polyethylene glycol 
(PEG) and differential centrifugation—a process that can be car-
ried out within a single day. The availability of infectious cDNA 
clones of both RNAs has enabled precise genetic changes to be 
introduced into the capsid proteins. Knowledge of the detailed 
3D structure of the virus particles has also enabled a rational 
choice to be made regarding potential sites for the insertion of 
heterologous peptides into the viral coat proteins such that they 
would be surface-exposed and would not adversely affect particle 
assembly.9,10 A number of sites were identified as suitable for the 
insertion of foreign peptides. In most cases, the foreign peptide 
has been inserted into the most exposed loop of the virus sur-
face, the βB-βC loop of the S protein (indicated by the arrow 
Fig. 1A and B). However, other sites, such as the βE-αB loop of 
the L protein and the βC’-βC” loop of the S protein, have also 
been used successfully.11-14 Generally, provided the inserted pep-
tide was less than 40 amino acids and had a pI below 9.0,14 the 
yields of modified particles were similar to those obtained with 
wild-type CPMV (up to 1 mg of particles per gram of infected 
leaf tissue). In each case, the chimaeric virus particles present 60 
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manifested themselves in terms of reduced infectivity on plants, 
reduced or no yield on purification and loss of all or part of the 
inserted sequence on virus passage. One problem concerns the 
size of the insert which is tolerated; generally the maximum size 
of insert that can be stably incorporated is approximately 30 
amino acids. Once this size is exceeded, deletions readily occur 
within the insert and it is difficult, if not impossible to isolate 
particles expressing the full-sized epitope.14 The reason for this 
instability has not been investigated in detail but is unlikely to be 
directly due to the increase in size of RNA-2 affecting its replica-
tion since constructs containing heterologous sequences up to 1 
kb have been shown to be relatively stable.24 It is more likely that 
the expression of large peptides on the surface of particles inter-
feres either with the ability of the particles to assemble or with 
their ability to interact productively with the plasmodesmata to 
allow virus spread. Thus any deletions which alleviate these prob-
lems are likely to be selected and come to dominate an infection.
The size of a peptide is not the only factor limiting the abil-
ity to propagate CPMV chimaeras. One of the first chimaeras to 
be created presented a 19 amino acid epitope consisting of resi-
dues 141–159 from VP1 of FMDV serotype O1 inserted into the 
βB-βC loop of the CPMV S protein to give chimaera FMDV-V.2 
However, this chimaera was unable to produce a systemic infec-
tion, was difficult to passage and purification of the virus from the 
infected leaves yielded little or no viral particles. Further inves-
tigation showed that the particles with the FMDV-V sequence 
remained in the pellet formed from the initial low speed spin of 
the purification protocol.2 It was subsequently noticed that many 
of the chimaeras which proved problematic contained inserts 
copies of the inserted peptide on the virus surface. Work on the 
production of chimaeras for vaccine purposes culminated in the 
demonstration of protective immunity in target animals,15,16 the 
dissection of a major antigenic site of HIV17,18 and the ability to 
correlate the structure that a peptide adopts with its immunologi-
cal properties.12,19 For further information on the immunological 
properties of CPMV chimaeras, see references 20–24.
Despite the considerable success in the development of 
CPMV-based chimaeras, it is noticeable that none have been 
developed for commercial use. There are probably two main rea-
sons for this: the limitations on the range of peptides that can 
be stably expressed14 and the fact that preparations of chimaeras 
isolated from infected plants contain the viral RNAs and hence 
are infectious. The first issue limits the application of the CPMV 
technology and it is significant that chimaeras containing anti-
genic sequences from a number of important pathogens, such 
as foot-and-mouth disease virus (FMDV), proved impossible to 
propagate or purify.2,14 The second causes problems with bio-
containment and causes regulatory issues. This article describes 
recent advances in CPMV-based particle technology based on 
research carried at the John Innes Centre, Norwich, UK which 
have shown how these problems can be relieved.
Systems Based on Infectious Virus Particles
Propagating recalcitrant chimaeras. Though CPMV parti-
cles have been used to present a wide variety of peptides, there 
have been several instances where the propagation and purifica-
tion of specific chimaeras has proved problematic. These have 
Figure 1. Cowpea mosaic virus (CPMV) as a peptide-presentation system. The βB-βC loop of the small (S) coat protein (indicated by the arrows in 
A and B) is the most commonly used site for the insertion of foreign peptides. (A) Genome organization of CPMV RNAs. (B) Ribbon diagram of the 
icosahedral asymmetric unit, consisting of the two domains of the large (L) coat protein (light grey) and the S coat protein (dark grey). (C) Space-#lling 
drawing of the CPMV capsid displaying an epitope from HRV-14 inserted into the βB-βC loop of the S protein. ProC, proteinase cofactor; VPg, genome-
linked protein; Pro, 24K proteinase; 48/58K, movement protein; L, large coat protein; S, small coat protein. (C) was kindly provided by Dr. T. Lin and Prof. 
J.E. Johnson, The Scripps Research Institute, La Jolla, CA. Modi#ed from reference 24.
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to a wild type infection and gave a very low virus yield (in the 
order of 0.1 μg/g of primary leaf tissue). However, after four pas-
sages the yield of virus had increased to ~0.2 mg/g of primary 
leaf tissue and the virus was able to move systemically. Sequence 
analysis of the RNA isolated from purified virus particles indi-
cated that no reversions or mutations had taken place following 
serial virus passaging. The functionality of the inserted FMDV-
specific sequence was confirmed by showing that they were able 
to bind to anti-FMDV specific antibodies and the integrin, αvβ6 
(Montague N, Burman A, Clark S, Lomonossoff GP and Jackson 
T, unpublished). These results indicate that the charge neutrali-
sation strategy had been successful in the case of FMDV-V.
For the inserts with higher pIs, the strategy of adding acidic 
residues to the ends of the inserted sequence proved less success-
ful. In the case of FMDV-B DE-DD (with two acidic residues at 
both ends of the insert) and FMDV-B EDED (with four acidic 
residues at the C-terminus), only mild symptoms were observed 
on serial virus passaging and a systemic infection rarely devel-
oped; attempts to purify virus particles gave only very low yields. 
In the case of BPV-L1 DEDE-DDE (with a total of seven acidic 
residues positioned either side of the insert), attempts at virus 
passaging failed to produce any visible infection and no virus-
specific RNA could be detected by RT-PCR. Thus it appears that 
BPV-L1 is truly non-infectious even after the charge of the insert 
has been neutralized.
Adjustment of the pI by addition of charged residues at the 
end of an inserted peptide, as well as only being partially success-
ful, has additional disadvantages. The incorporation of acidic 
residues could cause problems with the structure that the insert 
adopts, and hence affect its immunological properties. It also 
inevitably increases the size of the insert, which could adversely 
affect virus yield. An alternative approach is to compensate for 
high positive charge within an epitope by the addition of acidic 
residues into an adjacent loop on the virus surface. This should 
help the foreign inserted peptide to produce as natural a confor-
mation as possible and obviate the need to increase the length 
of the peptide within a given loop. To this end, acidic residues 
have been expressed on the adjacent βC’-βC’’ loop, a surface 
exposed loop near to the βB-βC loop on CPMV, which has 
previously been successfully used to express foreign sequences.12 
with a high pI.14 Multiple virus passage with such chimaeras in 
some cases eventually led to the production of particles which 
could be purified in reasonable amounts. However, these invari-
ably contained mutations which reduced the pI of the insert.14 
This suggested that it may be possible to propagate recalcitrant 
chimaeras by deliberately incorporating acidic amino acids to 
reduce the overall pI of the particles.
To examine whether adjustment of the pI of an insert by the 
incorporation of flanking acidic residues could render problem-
atic CPMV chimaeras more amenable to effective virus passage 
and particle purification, three chimaeras which had previously 
proved difficult or impossible to propagate were modified. These 
were FMDV-V (insert pI 11.47) which was discussed above, a 
chimaera (FMDV-B) expressing a tandem repeat sequence from 
VP1 of FMDV25 which has an even higher pI (12.10) and a 
chimaera (BPV-L1) expressing an epitope from the L1 protein 
of Bovine papilloma virus (BPV) with an extremely high pI of 
12.57.14 These were chosen as the size of the insert should not 
be a factor in their propagation. Though FMDV-V had previ-
ously been shown to give a phenotype of reduced severity on 
cowpea plants (see above), the other two, FMDV-B and BPV-
L1, appeared to be completely non-infectious.14 The pI of these 
inserts was adjusted to be close to 7 by addition of an appropriate 
number of acidic residues (D or E) at either or both sides of the 
insert. Details of the constructs are given in Table 1. In each case, 
the construct was introduced into cowpea plants by agro-infiltra-
tion in the presence of RNA-1 and compared to the performance 
of the original, non-pI-adjusted construct introduced in the same 
way. In all cases, no symptoms were observed on the infiltrated 
primary leaves. This is usual when constructs are introduced by 
agro-infiltration, as the leaf is flooded with inoculum so no spe-
cific infection foci are produced. To determine if infection was 
occurring, sap from the infiltrated leaves was serially passaged to 
healthy cowpea plants.
In the case of FMDV-V, no infection could be passaged to fur-
ther plants, consistent with previous observations.2,14 For FMDV-
V-DD (with two aspartic acid residues at the C-terminus of the 
FMDV-specific insert) and FMDV-V D-D (with one aspartic 
acid at either end of the insert), the first two passages (P1 and P2) 
resulted in symptoms that appeared more slowly when compared 
Table 1. Properties of CPMV chimaeras with pI-adjusted inserts in the βB-βC loop of the S protein
Name of Chimaera Sequence of inserta Size of insert
pI of 
insert
Symptoms
Virus yield
Inocc upperc
CPMV FMDV-V VPN LRG DLQ VLA QKV ART L 19 11.47 None none N/A
CPMV FMDV-V D-D DVP NLR GDL QVL AQK VAR TLD 21 6.50 WT MSSb Reduced
CPMV FMDV-V-DD VPN LRG DLQ VLA QKV ART LDD 21 6.50 WT MSSb Reduced
CPMV FMDV B RYS RNA VPNV RYS RNA VPN V 20 12.10 None none N/A
CPMV FMDV B EDED EDE DRY SRN AVP NVR YSR NAV PNV 24 6.93 Mildb MSSb Very low
CPMV FMDV B ED-ED EDR YSR NAV PNV RYS RNA VPN VED 24 6.93 Mildb MSSb Very low
CPMV BPV TRN SSK PAK RKK IKA 15 12.57 None none N/A
CPMV BPV DEDE-DDE DED ETR NSS KPA KRK KIK ADD E 22 7.06 None none N/A
aIntroduced acidic residues (D or E) are shown in bold typeface. bDelayed appearance of symptoms compared to wild-type CPMV. cSymptoms on 
inoculated and upper leaves after serial passaging: WT, wild-type symptoms; MSS, mild systemic symptoms.
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In an alternative approach, 456 nucleotides encoding the cen-
tral region of the 48K movement protein (Fig. 1) were deleted 
from an infectious clone of RNA-2. Deletions within this region 
of the genome still permit RNA-2 to be replicated by RNA-1 
and particles to be formed within infected cells but prevent virus 
movement to neighboring cells.27 Such spread is not required to 
obtain adequate quantities of virus particles when agro-infiltra-
tion is used to initiate an infection as the process is so efficient, 
with more than 90% of cells in an infiltrated region of a leaf 
being infected. However, the purified particles are unable to 
cause anything other than a symptomless subliminal infection 
when mechanically inoculated on to plants. Thus this approach 
provides a high degree of bio-containment. Insertion of heterolo-
gous sequences into the deleted RNA-2 construct is facilitated by 
the positioning of a pair of unique restriction enzyme sites down-
stream of the region encoding the S protein and it is now possible 
to rapidly produce a wide range of mimics to order. Encapsidated 
mimics produced in this way are currently marketed by the 
Veterinary Laboratories Agency (UK).
Production of CPMV Virus-Like Particles  
without the Need for Virus Infection
All the studies described above have been conducted using par-
ticles, either wild-type or genetically modified, produced by the 
infection of plants. Approximately 90% of the particles produced 
in this way contain either RNA-1 or RNA-2 and the prepara-
tions retain their ability to infect plants, if only subliminally. In 
addition, while CPMV RNAs have not been shown to be able to 
replicate in mammalian cells, uptake of particles does occur both 
in vitro and in vivo,4 raising biosafety concerns. The presence of 
RNA within CPMV particles has also prevented them being used 
to encapsidate other, foreign material, limiting their potential use 
as nanoscale vessels.
Initial attempts to address these issues involved inactivation or 
elimination of the viral RNAs within CPMV preparations either 
by irradiation with ultraviolet (UV) light16,28 or chemically.29,30 
However, these post-production processes have to be carefully 
monitored as they risk altering the structural properties of the par-
ticles and require that the original virus retains its ability to infect 
and spread in plants. Furthermore, UV irradiation, though elimi-
nating infectivity, does not remove the RNA from the particles.
Recent developments in plant-based expressed technologies24 
have provided an alternative route for producing RNA-free part-
cles of CPMV. In particular, it has been observed that co-expres-
sion in plants of separate Agrobacterium plasmids containing the 
sequences of the precursor to the L and S coat proteins (VP60) 
and the viral proteinase (24K) (Fig. 2A), introduced by the 
agroinfiltration technique, resulted in the production of empty 
(RNA-free) CPMV capsids (eVLPs).6 Particles produced in this 
way are devoid of RNA yet stable and amenable to modification. 
Thus many future studies involving the modification of the outer 
surface may well be conducted using particles produced in this 
manner rather than by infection.
Increasing the efficiency of eVLP production. The produc-
tion of eVLPs requires the co-expression of VP60 and 24K in 
Either two, five or seven acidic residues were inserted into the 
βC’-βC’’ loop to give a broad range of compensatory charges so 
that epitopes with a range of high pIs could be simultaneously 
expressed on the CPMV surface using the βB-βC loop. Initially, 
the viability of chimaeras with just the acidic residues within 
the βC’-βC’’ was determined. Only those chimaeras with two 
and five, but not seven, acidic residue inserts in the βC’-βC’’ 
loop were viable (Table 2). The apparent non-infectivity of the 
chimaera with seven acidic acid amino acids was ascribed to the 
excessive negative charge introduced into S protein when no 
compensating high pI insert was present in the βB-βC loop. The 
simultaneous expression of the FMDV-B epitope in the βB-βC 
loop and either two or seven acidic residues in the βC’-βC’’ gave 
rise to a detectable infection and it proved possible to purify 
virus particles, albeit at reduced yield compared with wild-type 
CPMV. This represents the first time it has proved possible to 
purify a chimaera expressing the FMDV-B sequence and con-
firmed that the infectivity of chimaera with seven acidic amino 
acids could be restored by the simultaneous presence of a high pI 
insert. However, none of the BPV-L1 chimaeras with the acidic 
residues in the βC’-βC’’ loop proved viable. Nonetheless, as a 
result of these studies, a new series of CPMV-based vectors is 
now available with two, five and seven acidic residues in the 
βC’-βC’’ loop and these can be used to display epitopes with a 
range of high pIs.
Bio-contained encapsidated mimics. As a result of stud-
ies aimed at developing CPMV as a vector for the expression of 
polypeptides in plant cells,24 it was demonstrated that RNA-2 
molecules harboring additional lengths of heterologous sequence 
can be efficiently packaged in virions. Such encapsidated RNA 
is highly resistant to degradation. These observations have been 
exploited to design modified versions of RNA-2 harboring patho-
gen-specific sequences that can act as positive controls (encapsid-
ated mimics) in highly sensitive real-time PCR-based diagnostic 
reactions.26 However, one problem with the technology is that it 
involves the use of infectious virus particles with concomitant 
problems of bio-containment. These can be reduced by isolating 
only those particles which contain RNA-2 which is not infec-
tious in the absence of RNA-1.26 However, this approach, which 
involves multiple rounds of density gradient centrifugation, is 
time consuming and often only partially successful.
Table 2. Effect of presence of acidic residues in βC’-βC” loop of the S 
protein on yield of virus particles with high pI inserts in βB-βC loop
Name of 
 chimaera
βB-βC charge 
at pH 7a
βC’-βC’’ charge 
at pH 7b Yield
BPV-L1C’C’’+2 +7 -2 No yield
BPV-L1C’C’’+5 +7 -5 No yield
FMDV-B-C’C’’+2 +4 -2 Reducedc
FMDV-B-C’C’’+7 +4 -7 Reduced
C’C’’+2 / -2 Reduced
C’C’’+5 / -5 Very low
C’C’’+7 / -7 No yield
aCalculated on number of basic residues within insert. bCalculated on 
number of acidic residues within insert. cCompared with wild-type virus.
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green or red rather than yellow (Fig. 3B). On serial two-fold 
dilution, this situation became more noticeable, eventually lead-
ing to cells expressing only one or the other protein (data not 
shown). In contrast, tissue infiltrated with pEAQexpress-ECFP-
EYFP showed efficient co-expression of both proteins in every 
cell which had received the construct, as witnessed by their yel-
low fluorescence, though the total number of fluorescent cells 
decreased with increasing inoculum dilution (data not shown). 
These results confirm the benefit of expressing two proteins from 
the same T-DNA.
To exploit the above findings for eVLP production, sequences 
encoding VP60 and 24K were cloned into the T-DNA region 
of pEAQexpress to generate pEAQexpress-VP60-24K (Fig. 2B). 
Infiltration of pEAQexpress-VP60-24K into N. benthamiana and 
purification of particles using a protocol adapted from that used 
for the purification of wild-type CPMV particles32 resulted in 
yields of eVLPs up to 0.5 mg/g leaf tissue which is considerably 
in excess of those achieved when VP60 and 24K were expressed 
from separate plasmids (Fig. 4). The use of pEAQexpress-VP60-
24K, in conjunction with vacuum- rather than syringe-infil-
tration, has enabled the production of significant quantities of 
eVLPs for further studies.
Genetic modification of eVLPs. To investigate the potential 
ability of eVLPs to tolerate radical modifications, the carboxyl 
terminus of VP60 was modified by replacing the terminal 24 
amino acids of the S protein with 6 histidine residues in the vec-
tor pEAQ-HT-VP60 (Fig. 2A). Previous attempts to introduce 
modifications at this position using the infection route resulted in 
the recovery of only very low levels of particles.33 Plants were co-
infiltrated with the modified VP60 construct, pEAQ-HT-VP60-
His and pEAQ-HT-24K and a leaf extract subsequently applied 
to a nickel-affinity chromatography column. Proteins possessing 
a histidine sequence were eluted from the column with imidazole 
and analyzed by polyacrylamide gel electrophoresis and sucrose 
gradient centrifugation. Protein products corresponding to both 
CPMV capsid proteins, L and S, were present in the affinity-puri-
fied extracts indicating that the viral proteinase was able to cleave 
the modified VP60. Furthermore, sedimentation of the extract in 
same plant cell. Originally,6 this was achieved by co-infiltration 
of leaves with a mixture of two Agrobacterium strains, each har-
boring a plasmid, pEAQ-HT-VP60 or pEAQ-HT-24K encoding 
one of the two genes (Fig. 2A). To ensure efficient co-expression, 
each strain had to be present at a high concentration, making the 
inoculum dense and difficult to infiltrate. Even then, it could not 
be guaranteed that every cell would receive both genes, and con-
sequently the yields of eVLPs were considerably lower than those 
found for RNA-containing particles produced as a result of the 
natural infection process.
A potential solution to the inefficient delivery of separate 
T-DNA constructs is to co-deliver the two genes of interest from 
the same T-DNA. Cloning two genes into the same T-DNA 
has been made possible by the development of the pEAQ vec-
tor series, a versatile and user-friendly CPMV-based expression 
vector system.31 The vector pEAQexpress contains a suppressor 
of gene silencing (P19) cassette and cloning sites for two further 
expression cassettes within the same T-DNA region. To dem-
onstrate the benefits of co-expression of two proteins from one 
T-DNA on pEAQexpress as compared to expression from two 
separate T-DNAs, expression cassettes for two reporter genes, 
eyfp and ecfp, were cloned either into two separate pEAQ vec-
tors, to give pEAQ-HT-EYFP and pEAQ-HT-ECFP or into a 
single pEAQexpress vector, to give pEAQexpress-ECFP-EYFP 
(Fig. 3A). These three constructs were agro-infiltrated separately 
at an optical density (OD600) of 0.2, and a mixture of constructs 
pEAQ-HT-EYFP and pEAQ-HT-ECFP was co-infiltrated at an 
overall OD600 of 0.4. Confocal microscopy was used to detect 
expression of both fluorescent proteins in the infiltrated leaf tis-
sue with EYFP appearing green and ECFP appearing red, while 
co-expression results in a yellow color (Fig. 3B).
When infiltrated individually, pEAQ-HT-EYFP and pEAQ-
HT-ECFP constructs express only EYFP or ECFP, respectively 
and an OD600 of 0.2 was sufficient to achieve expression in every 
cell. Co-infiltration of these two constructs resulted in fluorescent 
protein expression in all cells, as expected, but the co-expression 
was not uniform, with most cells showing more accumulation 
of one protein in relation to the other, thus appearing either 
Figure 2. Production of CPMV empty virus-like particles (eVLPs). (A) Schematic representation of the two constructs, pEAQ-HT-VP60 and pEAQ-HT-
24K, originally used to create empty virus-like particles (eVLPs). (B) Structure of the T-DNA region of pEAQexpress-VP60-24K which contains the coding 
regions of both VP60 and the 24K proteinase.
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sucrose gradients indicated that the coat proteins co-sedimented 
at a position characteristic of eVLPs. Transmission electron 
microscopy confirmed the presence of eVLPs in the preparation 
(Fig. 5A), indicating that capsid assembly was not affected by 
the replacement of the naturally occurring C-terminal 24 amino 
acids of the S protein with the six histidine residues. These results 
demonstrate that it is possible to replace the C-terminal region of 
the S protein with a heterologous sequence when eVLP technol-
ogy is used. Furthermore, the incorporation of a His-tag opens 
further possibilities for particle purification.
To determine whether it is possible to present a whole pro-
tein on the surface of eVLPs, green fluorescent protein (GFP) 
was fused to the C-terminus of the wild type S coat protein of 
the VP60 precursor in the vector pEAQ-HT-VP60 (Fig. 2A), 
resulting in the production of pEAQ-HT-VP60-GFP. Plants co-
infiltrated with this vector and pEAQ-HT-24K, exhibited GFP 
fluorescence three days post infiltration, suggesting correct fold-
ing of the GFP expressed from the construct. To check whether 
the GFP remained attached to the S protein after the processing 
of VP60, virus particles were purified from the infiltrated tis-
sue and subjected to western blot analysis using an anti-GFP 
Figure 3. Co-expression of EYFP and ECFP in N. benthamiana cells. (A) Schematic representation of the T-DNA regions of pEAQ-HT-ECFP, pEAQ-HT-
EYFP and pEAQexpress-ECFP-EYFP. (B) Leaf tissue was agro-in#ltrated with inocula of above constructs at OD600 = 0.2 (* for co-in#ltration an overall 
OD600 of 0.4 was used). Six days post in#ltration, leaf tissue was imaged for EYFP (green) and ECFP (red) and channels digitally merged, showing co-
localization in yellow.
antibody. This detected bands the size of free GFP, GFP attached 
to the S protein and GFP attached to uncleaved VP60 (Fig. 5B). 
These results show that while a portion of GFP is still attached 
to virus particles, some is cleaved off during purification, 
probably as a result of cleavage which occurs at the last 24 
amino acids of the S protein.8 The presence of VP60-GFP 
also suggests that the presence of GFP may interfere with the 
correct processing of VP60. Nonetheless, these studies suggest 
that the display of whole proteins on the surface of eVLPs should 
be possible.
Conclusions
One of the initial attractions of using plant virus particles for bio-
medical purposes was the fact that the infection process is highly 
productive, potentially enabling gram quantities of wild-type or 
modified particles to be produced with ease. In terms of epit-
ope presentation, this opened up the prospect of producing novel 
vaccines at low cost. However, although some CPMV chimaeras 
have been shown to be capable of acting as experimental vac-
cines, the limitations on the size and sequence of the epitopes that 
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are tolerated on particles produced from infected plants severely 
curtailed the development of this technology. The presence of 
infectious RNA within the particles also raised major regulatory 
issues, though, as described above, the encapsidated RNA can be 
used to develop real-time PCR-based diagnostic reagents.
The recent developments reported in this article, using both 
infection-based and eVLP technologies have given a new impetus 
to the development of CPMV particles for a number of poten-
tial applications including their use as novel vaccines and drug 
delivery vehicles. The development of an efficient method for the 
production of particles devoid of RNA, as well as increasing the 
range of modifications that can be introduced, also enables the 
particle to be loaded with a range of foreign materials.34 Though 
there is still clearly quite a way to go before their full potential 
is realized, the authors are confident that CPMV-based particle 
technologies have a bright future in several fields, including the 
production of new vaccines for use in humans.
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ABSTRACT: The development of multifunctional nano-
particles for medical applications is of growing technological
interest. A single formulation containing imaging and/or drug
moieties that is also capable of preferential uptake in speciﬁc
cells would greatly enhance diagnostics and treatments. There
is growing interest in plant-derived viral nanoparticles (VNPs)
and establishing new platform technologies based on these
nanoparticles inspired by nature. Cowpea mosaic virus (CPMV)
serves as the standard model for VNPs. Although exterior
surface modiﬁcation is well-known and has been comprehensively studied, little is known of interior modiﬁcation. Additional
functionality conferred by the capability for interior engineering would be of great beneﬁt toward the ultimate goal of targeted
drug delivery. Here, we examined the capacity of empty CPMV (eCPMV) particles devoid of RNA to encapsulate a wide variety
of molecules. We systematically investigated the conjugation of ﬂuorophores, biotin aﬃnity tags, large molecular weight polymers
such as poly(ethylene glycol) (PEG), and various peptides through targeting reactive cysteines displayed selectively on the
interior surface. Several methods are described that mutually conﬁrm speciﬁc functionalization of the interior. Finally, CPMV and
eCPMV were labeled with near-infrared ﬂuorophores and studied side-by-side in vitro and in vivo. Passive tumor targeting via the
enhanced permeability and retention eﬀect and optical imaging were conﬁrmed using a preclinical mouse model of colon cancer.
The results of our studies lay the foundation for the development of the eCPMV platform in a range of biomedical applications.
■ INTRODUCTION
Nanomaterials are currently under investigation for platform
development for applications in nanomedicine. They have
favorable properties for the detection, imaging, and treatment
of diseases such as cancer and cardiovascular disease as they can
carry large payloads of imaging reagents and/or drugs and can
be engineered to direct the payload speciﬁcally to target cells.
The fact that multifunctional units can be designed and
developed makes nanoparticles attractive candidates for the
development of novel therapeutics and diagnostics.
Many diﬀerent platforms have been developed, including
synthetic man-made nanomaterials and naturally occurring
bionanomaterials, such as protein cages and viral nanoparticles
(VNPs).1 Although viral nanotechnology is considered a novel
and emerging ﬁeld, recombinant virus-based materials have
been used as vaccines and gene delivery vectors since the 1970s.
Several recombinant virus-like particle-based vaccines are now
used in the clinic, e.g., the Human papillomavirus (HPV)
vaccine Gardasil (Merck & Co Inc.). Several gene therapies
based on Adenovirus, Adeno-associated virus, and Lentivirus are
undergoing clinical trials.2−4 For the past 20 years chemists,
materials scientists, and engineers have developed a range of
methodologies that can be applied to ﬁne-tune and engineer
VNPs for desired applications. VNPs are genetically encoded
biomaterials and can therefore be genetically modiﬁed. In
addition, chemical engineering procedures including chemical
bioconjugation, mineralization, infusion, and encapsulation
techniques have been widely developed and applied.5,6 VNPs
oﬀer several sites for modiﬁcation: the exterior surface, the
interior surface, the coat protein interface, and the interior
cavity, all of which have been utilized for modiﬁcation. The
application of a combination of techniques facilitates the
development of highly sophisticated multifunctional nano-
probes.7
In this work we turned toward the development of the plant
virus Cowpea mosaic virus (CPMV). CPMV is a 30 nm-sized
icosahedron; it has been used as a model system for various
applications ranging from electronic materials8−10 and
sensors11,12 to imaging probes.13,14 CPMV has been studied
extensively because of its biocompatibility, high stress tolerance,
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low toxicity, and diverse possibilities for surface modiﬁcation by
conjugation and genetic engineering. CPMV nanoparticles
consist of 60 copies each of a large (L) and small (S) coat
protein. Wild-type CPMV can be produced with ease and in
high yields in black-eyed pea plants. Recently a RNA-free
version of the capsid, referred to as empty CPMV (eCPMV),
has been developed. These are produced by agroinﬁltrating
Nicotiana benthamiana leaves with a construct expressing the
precursor of the L and S coat proteins (VP60) and the virus-
derived proteinase (24K) required for its processing.15 The
particles produced in this way are completely devoid of RNA of
either viral or host origin although structurally identical to wild-
type particles in terms of their proteins.
Several bioconjugation chemistries have been successfully
applied to modify the exterior surface of CPMV. These include
exterior lysine modiﬁcation using N-hydroxysuccinimide
(NHS) esters,16,17 carbodiimide-mediated amine coupling to
solvent-exposed carboxylates,18 and maleimide coupling to
genetically or chemically introduced thiols.19,20 Further,
advanced bio-orthogonal reactions such as Cu(I)-catalyzed
azide−alkyne cycloaddition21 and hydrazone ligation proce-
dures22 have been applied with great success. Exterior surface
modiﬁcation of CPMV has been extensively studied and is well
understood. In stark contrast, only few studies have been
reported that address the chemical engineering of the interior
CPMV surface.23,24
With growing interest to develop CPMV-based nanomateri-
als for applications in materials and medicine, the generation of
multifunctional materials is a requirement and thus interior
engineering in addition to exterior labeling is becoming more
and more important. For example, CPMV nanoparticles have a
natural aﬃnity to cancer cells such as HeLa (cervical cancer),
HT-29 (colon cancer), and PC-3 (prostate cancer); surface
domains of CPMV speciﬁcally interact with cell surface-
expressed vimentin and promote cell internalization.25−27
This property can be utilized to image cancer neovasculature
or to target CPMV to cancer cells in vitro and in vivo.14,25,28 To
utilize CPMV probes for the study or targeting of surface
vimentin-expressing cells, it is desired to develop chemistries on
the interior particle surface, e.g., to install imaging moieties; this
will ensure conservation of the particle surface and CPMV-
vimentin interaction. CPMV can also be redirected to other
receptors, such as folic acid receptors,29 vascular endothelial
growth factor receptor-1,29 and gastrin-releasing peptide
receptors,13 by decorating the CPMV particle surface with
the appropriate targeting ligands. With the long-term
application of targeted drug delivery or optical imaging in
mind, it is of interest to establish chemistries that allow interior
cargo loading in addition to exterior surface modiﬁcations.
The recent development of the eCPMV formulation now
opens a new avenue to further advance the CPMV platform
technology. In this study, we systematically investigated the
interior labeling capacity of RNA-free eCPMV and RNA-
containing wild-type CPMV nanoparticles using negatively and
positively charged ﬂuorophores, small molecule biotin tags,
large polymers such as poly(ethylene glycol) (PEG), and
negatively and positively charged peptide sequences: penta-
(arginine), hexa(histidine), and FLAG tag peptide. The in vitro
and in vivo properties of ﬂuorescently labeled CPMV and
eCPMV were investigated in tissue culture and a preclinical
mouse model of colon cancer.
■ MATERIALS AND METHODS
Materials. Oregon Green 488 (OG488) maleimide, OG488
succinimidyl ester, and Rhodamine Red C2 (RR) maleimide were
purchased from Invitrogen. DyLight 488 (DL488) maleimide, sulfo-
NHS-LC-biotin, and maleimide-PEG2-biotin were purchased from
Pierce. Poly(ethylene glycol) maleimide (MW 2000 Da) and
poly(ethylene glycol) succinimidyl ester (MW 2000 and 5000 Da)
were purchased from Nanocs. Maleimido trioxa-6-formyl benzamide
(MTFB), succinimidyl-4-formyl benzoate (S-4FB), His6 Tag-HyNic,
and FLAG Tag-HyNic were purchased from Solulink. A biotinylated
6-hydrazinopyridyl-polyarginine peptide (bio-R5-HyNic) was synthe-
sized as described elsewhere.30 Aniline and dimethyl sulfoxide
(DMSO) were purchased from Fisher.
Propagation and Isolation of Wild-Type and eCPMV
Particles. CPMV Production. Black-eyed peas (Vigna unguiculata)
were inoculated with 100 ng/μL CPMV in 0.1 M potassium phosphate
buﬀer (pH 7.0) and propagated for 18−20 days using established
procedures.31 Virus concentration in plant extracts was determined by
UV/vis spectroscopy (ε260 nm = 8.1 mg
−1 mL cm−1), and virus integrity
was determined by size exclusion chromatography (SEC; see below).
eCPMV Production. Agrobacterium LBA4404 cultures harboring
the binary plasmid pEAQexpress-VP60-24K, which encodes the coat
protein precursor VP60 and viral proteinase 24K,32 were introduced
into N. benthamiana leaves using syringe-inﬁltration. Inﬁltrated tissue
was harvested 6 days post inﬁltration and homogenized in 0.1 M
sodium phosphate buﬀer (pH 7.0). eCPMV was puriﬁed further using
a protocol adapted from established procedures for wild-type CPMV31
and the particle concentration was determined by UV/vis spectros-
copy (ε280 nm = 1.28 mg
−1 mL cm−1). eCPMV integrity was examined
using transmission electron microscopy (TEM) on an FEI Technai20.
Bioconjugation Using CPMV and eCPMV. For all reactions
using maleimide and NHS chemistries, CPMV and eCPMV particles
were used at a ﬁnal concentration of 2 mg/mL in 0.1 M potassium
phosphate buﬀer (pH 7.0) and incubated with the chemical label (e.g.,
dye, biotin) at room temperature overnight, with agitation. For all
hydrazone ligation reactions, CPMV and eCPMV particles modiﬁed
with MTFB (ﬁnal concentration 0.5 mg/mL) were incubated with the
peptide (e.g., FLAG-HyNic) in 0.1 M potassium phosphate buﬀer (pH
7.0) containing 10 mM aniline catalyst overnight at room temperature,
with agitation. The ﬁnal DMSO concentration was adjusted to 10% of
the reaction volume. Particles were puriﬁed with 10 kDa molecular
weight cutoﬀ centrifugal ﬁlter units (Millipore) and analyzed with UV/
vis spectroscopy, native and denaturing gel electrophoresis, and SEC.
For initial studies, labeling with dyes, S4FB, and MTFB was performed
using 6000 molar excess of the chemical per particle, with biotin and
PEG using 2000 molar excess, and with peptides using 360 molar
excess. For comparisons between externally and internally dye-labeled
CPMV and eCPMV, the molar excess was adjusted to match the
number of dyes, as conﬁrmed by UV/vis spectroscopy. For in vivo
studies, 4500 molar excess of mPEG5000-NHS was used. Western
blotting was performed for biotinylated particles. The 4FB labeling
eﬃciency of CPMV-S4FBE and CPMV-MTFBI was determined using
the Solulink 4FB molar substitution ratio protocol (MSR), in which 10
μg of 4FB-modiﬁed CPMV particles were mixed with a 0.5 mM
solution of 2-hydrazinopyridine-2-HCl (2-HP) prepared in 0.1 M 2-
(N-morpholino)ethanesulfonic acid (MES) buﬀer (pH 5.5). The
reaction was incubated at 37 °C for 30 min and analyzed by UV/vis
spectroscopy. The number of 4FB labels per particle was calculated
using the bond-speciﬁc extinction coeﬃcient at 350 nm (ε = 18,000
M−1 cm−1). Similarly, peptide attachment was quantiﬁed using the
bond-speciﬁc extinction coeﬃcient at 354 nm (ε = 29,000 M−1 cm−1)
for the hydrazone bond.
Size Exclusion Chromatography. All labeled particles were
analyzed by SEC using a Superose6 column on the ÄKTA Explorer
chromatography system (GE Healthcare). Samples (100 μg/100 μL)
were analyzed at a ﬂow rate of 0.4 mL/min using 0.1 M potassium
phosphate buﬀer (pH 7.0).
Transmission Electron Microscopy. Drops of labeled particles
were placed on carbon-coated copper TEM grids (5 μL, 0.1 mg/mL),
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allowed to adsorb for 5 min, washed with deionized (DI) water, then
negatively stained with 2% (w/v) uranyl acetate for 1 min. Samples
were examined using a Zeiss Libra 200FE transmission electron
microscope operated at 200 kV.
Gel Electrophoresis. Native gel electrophoresis was performed
using 1.2% agarose gels in 1x Tris/Borate/EDTA (TBE) buﬀer (45
mM Tris, 45 mM boric acid, 1.25 mM EDTA in Milli-Q water) with
1x TBE running buﬀer and 10 μg of sample. Protein subunits were
analyzed on denaturing 4−12% NuPAGE gels (Invitrogen) using 1x 3-
(N-morpholino)propanesulfonic acid (MOPS) running buﬀer (In-
vitrogen) and 10 μg of sample. After separation, the gel was
photographed using an AlphaImager (Biosciences) imaging system
before and after staining with Coomassie Blue, or further processed for
Western blotting.
Western Blotting. To detect biotinylated particles, CPMV,
CPMV-bioE, eCPMV-bioI, and eCPMV-R5-bioI were analyzed by
Western blotting. One microgram samples were separated on a 4−12%
NuPAGE Bis-Tris gel using MOPS buﬀer (see above). After
separation, the proteins were transferred onto a nitrocellulose
membrane (Thermo Scientiﬁc) using NuPAGE Transfer Buﬀer
(Invitrogen). The membrane was blocked at room temperature for
1 h using 0.1 M TBS (pH 7.6) containing 5% w/v skimmed milk
powder and 0.05% w/v Tween 20. Detection was carried out using
alkaline phosphatase-conjugated streptavidin (Sigma Aldrich)
(1:1000) in blocking buﬀer solution. Alkaline phosphatase activity
was detected using the BCIP/NBT liquid substrate system (Sigma
Aldrich).
Avidin Agarose Aﬃnity Binding Assay. CPMV, CPMV-bioE,
and eCPMV-bioI were tested for binding to avidin agarose resin
(Pierce) to conﬁrm interior eCPMV modiﬁcation with biotin
maleimide. The batch method provided by the supplier was used,
with some modiﬁcations: 50 μg of the samples in 50 μL of 0.1 M
potassium phosphate buﬀer (pH 7.0) were added to 50 μL of the resin
(100 μL of slurry) and mixed for 1 h at room temperature, with
agitation. The supernatant was then recovered, and the resin was
washed twice using 50 μL of 0.1 M potassium phosphate buﬀer (pH
7.0). Any bound sample was eluted with 50 μL of 0.5 M glycine-HCl
buﬀer (pH 2.8), and the pH was immediately adjusted with 5 μL of 1
M Tris buﬀer (pH 7.5). The samples were analyzed by running 30 μL
of the ﬁrst recovered and eluted fractions on a denaturing gel.
Ni-NTA Aﬃnity Binding Assay. CPMV, eCPMV, CPMV-His6E,
and eCPMV-His6I were tested for binding to HisPur Ni-NTA resin
(Pierce) to conﬁrm interior eCPMV modiﬁcation with His6. The
batch method provided by the supplier was used, with some
modiﬁcations: 50 μg of the samples in 100 μL of equilibration buﬀer
(20 mM sodium phosphate, 300 mM sodium chloride, 10 mM
imidazole, pH 7.4) were added to 50 μL of the resin (150 μL of slurry)
and mixed for 30 min at room temperature, with agitation. The
supernatant was then recovered, and the resin was washed twice using
100 μL of wash buﬀer (20 mM sodium phosphate, 300 mM sodium
chloride, 25 mM imidazole, pH 7.4). Any bound sample was eluted
with 50 μL of elution buﬀer (20 mM sodium phosphate, 300 mM
sodium chloride, 250 mM imidazole, pH 7.4). The samples were
analyzed by running 30 μL of the ﬁrst recovered and eluted fractions
on a denaturing gel.
Cell Cultures. HeLa cells (ATCC) were grown and maintained in
minimal essential medium (MEM), while HT-29 cells (ATCC) were
cultured in RPMI medium at 37 °C in a 5% CO2 humidiﬁed
atmosphere. The media were supplemented with 10% (v/v) heat
inactivated fetal bovine serum (FBS), 1% (v/v) L-glutamine, and 1%
(v/v) penicillin−streptomycin. All reagents were obtained from Gibco.
Confocal Microscopy Imaging. HeLa cells (20 000 cells/750 μL
MEM/well) were grown for 24 h on glass coverslips placed in an
untreated 24-well plate. The media was then replaced with 250 μL of
fresh MEM containing 10 μg of CPMV-OG488E or eCPMV-OG488I
(∼5 × 107 VNPs/cell) and incubated at 37 °C, 5% CO2 for 2 h. Post
incubation, cells were washed thoroughly with sterile saline and
incubated for a further 24 h in fresh medium. The cells were then ﬁxed
using 4% v/v paraformaldehyde and 0.3% v/v glutaraldehyde in
Dulbecco's phosphate-buﬀered saline (DPBS) (pH 7.2) for 5 min. Cell
membranes were stained using wheat germ agglutinin (WGA)
conjugated with Alexa Fluor 555 (WGA-A555) (Invitrogen) at 1
μg/mL in 5% goat serum (GS) (Invitrogen) for 45 min. Cell nuclei
were stained using 4′,6-diamidino-2-phenylindole (DAPI) (MP
Biomedicals) at 0.13 μg/mL in DPBS for 5 min. All steps were
carried out in the dark at room temperature; in between each step the
coverslips were washed 3x with DPBS. The coverslips were then
mounted using Permount (Fisher) on glass slides and sealed using nail
polish. Confocal images were obtained using Olympus FluoView
FV1000 LSCM and data processed using Image J 1.44o (http://
imagej.nih.gov/ij).
Fluorescence Measurements. Fifty microliters of dye-labeled
CPMV and eCPMV were added to a black 384-well plate at a
concentration of 50 μM. Potassium phosphate buﬀer (0.1 M) was used
for pH 7.0 measurements, and 0.1 M MES buﬀer was used for pH 5.0
measurements. Particles were incubated in their respective buﬀers for 3
h. Fluorescence intensity was measured using a Tecan Inﬁnite 200
plate reader (Ex/Em wavelengths 600/665 for A647 and 435/495 for
OG488).
Flow Cytometry. HeLa cells (750 000 cells/200 μL MEM/well)
were added to an untreated 96-well v-bottom plate. CPMV, CPMV-
A647E, eCPMV, and eCPMV-A647I particles were added at a
concentration of 100 000 particles/cell in triplicates and incubated
for 3 h at 37 °C and 5% CO2. Following incubation, cells were spun
down at 500g for 4 min. The supernatant was removed, and the cells
were resuspended in FACS buﬀer (0.1 mL 0.5 M EDTA, 0.5 mL FBS,
and 1.25 mL 1 M HEPES, pH 7.0 in 50 mL Ca2+ and Mg2+ free PBS).
This washing step was repeated twice. The cells were then ﬁxed in 2%
(v/v) paraformaldehyde in FACS buﬀer for 10 min at room
temperature and washed another three times. Analysis was carried
out using the BD LSR II ﬂow cytometer, and a total of 10 000 events
per sample were collected.
Tumor Homing with HT-29 Xenografts. All animal procedures
were performed in accordance with approved protocols from the
Institutional Animal Care and Use Committee at Case Western
Reserve University. Tumor xenografts were established by injecting 5
× 106 HT-29 cells/100 μL of a 1:1 preparation of RPMI medium and
Matrigel (Fisher) subcutaneously in the ﬂanks of six week old NCr-
nu/nu mice. The mice were maintained on an alfalfa free diet (Teklad)
to reduce tissue autoﬂuorescence. Animals were observed closely, and
tumor size was measured using calipers. After the tumors reached an
average volume of 20 mm3 (10−12 days), the mice were randomly
divided into three groups: PBS, CPMV, and eCPMV (n = 5).
PEG5000E-eCPMV-A647I was administered intravenously at a dose of
200 μg/100 μL sterile PBS and PEG5000E-CPMV-A647E at a dose of
284.3 μg/100 μL sterile PBS to match the number of particles. Both
formulations had 50 dyes/particle. Animals were sacriﬁced 24 h post
administration, and the tumors on the ﬂanks were excised and imaged
using a Maestro ﬂuorescence imaging instrument (yellow excitation
and emission ﬁlters with an exposure time of 800 ms). After
background subtraction in Maestro, the average ﬂuorescence intensity
over the tumor area was analyzed using ImageJ.
■ RESULTS AND DISCUSSION
Production of CPMV and eCPMV. CPMV particles were
puriﬁed from infected black-eyed pea plants yielding 0.5−1 mg
of CPMV per 1 g of infected leaves. The purity of the virus was
conﬁrmed based on the A260:A280 ratio (a ratio of 1.7−1.8
indicates pure and intact particles) and SEC. eCPMV particles
were produced by coexpression of the precursor to the L and S
coat proteins (VP60) and the viral proteinase (24K) in N.
benthamiana leaves, and the particles were puriﬁed using a
modiﬁed CPMV extraction procedure. Yields of up to 0.5 mg/g
leaf tissue were achieved, somewhat lower than the yields
achieved for wild-type CPMV via infection.
Structural Properties of (e)CPMV. One of the advantages
of working with bionanoparticles such as VNPs is that their
structures are known to atomic resolution. The structure of
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CPMV has been solved to 2.8 Å resolution, and its coordinates
are available at the Virus Particle Explorer database (http://
viperdb.scripps.edu). The 30 nm-sized CPMV capsids have
icosahedral symmetry and are formed by 60 copies of two
diﬀerent types of coat proteins, the S and L subunits. The S
subunit (213 amino acids) folds into one jelly roll β-sandwich,
the A domain, and the L subunit (374 amino acids) folds into
two jelly roll β-sandwich domains: the B domain that covers the
carboxy-terminus and the C domain that covers the amino-
terminus. The three domains form the asymmetric unit and are
arranged in a similar surface lattice to T = 3 viruses, except they
have diﬀerent polypeptide sequences; therefore the particle
structure is described as pseudo T = 3, or P = 3, symmetry.
While the B and C domains are clustered around the
icosahedral 3-fold axis and form hexamers, the A domain is
clustered around the 5-fold axis, forming pentamers33 (Figure
1A,B). The interior surface is accessible through 12 pores at the
5-fold axis; at its narrowest point, the opening of the pore is
0.75 nm (as measured using PyMol 1.4.1 software) (Figure
1C).
The chemical addressability of the exterior surface has been
extensively studied, and it is known that CPMV displays up to
300 reactive solvent-exposed surface lysine side chains (Figure
1D), all of which can be chemically labeled.16,17 CPMV
particles do not display any reactive cysteine side chains on
their exterior particle surface. However, reactive cysteine
residues are located on the solvent-exposed interior particle
surface (Figure 1E,F). In earlier studies, Wang et al. showed
that small chemical modiﬁers such as ethylmercury phosphate
(EMP), 5-maleimidoﬂuorescein,23 and thiol-selective stilbene
derivatives24 could be introduced to CPMV and covalently
attached to interior cysteine residues.
Studying the structure of CPMV using PyMol software, we
located eight cysteines per asymmetric unit on the solvent-
exposed interior surface (Figure 1E,F): Cys 4 on the S protein,
and Cys 108, 119, 132, 177, 187, 295, and 355 on the L protein.
Thiols from two cysteine side chains, Cys 295 on L and Cys 4
on S, were found to be solvent-exposed (the thiol of Cys 4
appears to be exposed in a small pocket, which can be seen
when looking at the asymmetric unit; see inset in Figure 1F).
The thiols of Cys 187 and Cys 355 appear to be engaged in a
disulﬁde bond (Figure 1E,F). Previous data from Wang et al.
indicated that EMP reacted with Cys 295 on L but also
indicated that 5-maleimidoﬂuorescein attached to cysteines on
both the S and L subunit; the exact positions could not be
identiﬁed.23 On the basis of the structural data, we propose that
CPMV nanoparticles display at least 120 reactive cysteine
residues, one each on L (Cys 295) and S (Cys 4) subunits. It is
important to note that VNPs, although often depicted as rigid
closed shells, are highly dynamic structures that can undergo
various reversible structural transitions. The structural data
generated from crystallography is just a snapshot.
Interior Labeling with Fluorophores. We studied the
chemical reactivity of both eCPMV and CPMV toward several
ﬂuorophores. Prior to chemical labeling, eCPMV and CPMV
were treated with 10 mM tris(2-carboxyethyl)phosphine
(TCEP) in 0.1 M phosphate buﬀer pH 7.0. TCEP is a
reducing reagent; treatment was performed to ensure that thiols
were reduced and reactive toward maleimide-containing
compounds. The reducing agent was removed using centrifugal
spin ﬁlters with a cutoﬀ of 10K prior to introduction of
maleimide-containing ﬂuorophores: Oregon Green 488
(OG488), DyLight 488 (DL488), Rhodamine Red (RR), and
Alexa Fluor 647 (A647) (Figure 2A). Diﬀerent conditions were
tested, i.e., varying incubation times and excess of reagent used
(see Materials and Methods), and we found that the reaction
eﬃciency reached a plateau using a 2000-fold excess of
reagents. To ensure maximum labeling, the reactions were
carried out under forcing conditions using a molar excess of
Figure 1. The structure of CPMV. CPMV consists of 60 copies of a
small subunit (S, blue) and a large two-domain subunit (L, green and
red). (A) Exterior view and (B) interior view. (C) Pore structure at the
5-fold axis; the pore diameter was measured to be 0.75 nm. (D)
CPMV displays 300 reactive lysines on the surface, ﬁve per asymmetric
unit. (E) CPMV also displays cysteines selectively on the interior
surface, 8 per asymmetric unit (Cys 4 − yellow, 108 − forest green,
119 − cyan, 132 − purple, 177 − orange, 187 − green, 295 − blue,
and 355 − red). Inset shows 90 degree rotation, revealing hidden
reactive thiol of Cys 4. (F) View of interior with surface-exposed thiols
highlighted (Cys 4 − brown, 187 − pale green, 295 − sky blue, and
355 − light orange).
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6000 ﬂuorophores per eCPMV and CPMV particle; the protein
concentration was kept at 2 mg/mL (350 nM for CPMV, 500
nM for eCPMV). The reaction was allowed to proceed
overnight, eCPMV-dye and CPMV-dye conjugates were
puriﬁed using centrifugal ﬁlters with a size cutoﬀ of 10K, and
samples were resuspended in buﬀer and analyzed by UV/vis
spectroscopy, SEC, TEM, and native and denaturing gel
electrophoresis (Figures 2, S1, and S2).
In all cases, SEC and TEM conﬁrmed that the particles
remained structurally sound (Figures S1 and S2). The degree of
conjugation was quantiﬁed, with the number of dye moieties
per particle calculated based on the UV/vis spectrum using the
concentration ratio of dye to eCPMV or CPMV. The
concentrations were calculated using the Beer−Lambert law
and the respective extinction coeﬃcients: OG488 ε491 nm = 81
000 M−1 cm−1, DL488 ε493 nm = 70 000 M
−1 cm−1, RR ε573 nm =
119 000 M−1 cm−1, A647 ε651 nm = 265 000 M
−1 cm−1, CPMV
ε260 nm = 8.1 mg
−1 mL cm−1, MW of CPMV = 5.6 × 106 g
mol−1, eCPMV ε280 nm = 1.28 mg
−1 mL cm−1, and MW of
eCPMV = 3.94 × 106 g mol−1. The data are summarized in
Figure 2B. Overall, the labeling eﬃciency was signiﬁcantly
higher for each dye tested using eCPMV compared to CPMV.
For eCPMV, it was found that approximately 110 OG488, 140
DL488, 60 RR, and 50 A647 were attached, while for CPMV,
there were only 30 OG488, 30 DL488, less than 10 RR, and 10
A647 attached. The reproducibility and error lies within 10
dyes per particle. CPMV and eCPMV are structurally identical,
but CPMV contains nucleic acids and eCPMV is nucleic acid-
free. Labeling studies thus indicate that the presence of nucleic
acids reduces labeling eﬃciency. It is possible the nucleic acids
block the pores and thus reduce diﬀusion of the dyes into the
capsid cavity. Electrostatic repulsion may also play a role. It is
interesting to note that labeling with the negatively charged
OG488 dye was most eﬀective for eCPMV (see Figure 2A).
The negative dye mimics the charge of the natural nucleic acid
cargo; diﬀusion into the interior cavity and conjugation might
thus be favored.
eCPMV- and CPMV-dye conjugates were analyzed by native
and denaturing gel electrophoresis, and the gels were visualized
under UV light before and white light after Coomassie staining
(Figure 2C-E). In native gels, intact VNPs are analyzed. The
appearance of ﬂuorescent bands under UV light conﬁrms that
the labels were indeed covalently attached to the particles, with
brighter bands corresponding with more dyes attached. We had
previously shown that exterior dye conjugation alters the
mobility of CPMV in native agarose gels.13 The conjugation of
chemical modiﬁers neutralizes the positive charge from the
exterior lysine side chains, leading to increased mobility toward
the anode. CPMV and eCPMV particles labeled with negatively
or positively charged dyes on interior cysteines do not show an
altered mobility in the gel, indicating that the labels are indeed
attached to the interior.
Denaturing gels were analyzed to determine whether the
dyes were attached to the S or L protein. A greater shift was
observed in RR labeling of the L protein compared to OG488
labeling, most likely due to the almost 50% greater molar mass
of RR (Figure 2D,E). It was found that in any case, dyes were
attached to both the S and L proteins. Selective attachment to S
or L was not observed for any formulation tested, indicating
that a reactive cysteine is present on both subunits. This was
found to be true even for the CPMV-RR formulation in which
we quantiﬁed less than 10 dyes per CPMV. The fact that the
dye distribution follows a random pattern might indicate that
Figure 2. Characterization of CPMV-dye conjugates. (A) Schematic of
internal functionalization of eCPMV and CPMV with OG488 and RR
(DL488 and A647 structures are proprietary). (B) Representative data
of the labeling eﬃciency of the various dyes for eCPMV vs CPMV.
eCPMV data are shown as solid bars on the left, while CPMV data are
shown as striped bars on the right. Asterisks denote statistical
signiﬁcance between eCPMV and CPMV formulations (** p < 0.01).
(C) eCPMV− and CPMV−OG488 conjugates on a 1.2% agarose gel.
The gel was visualized under UV light (left) and after Coomassie
staining (right). 1 = CPMV; 2 = eCPMV; 3 = CPMV-OG488; 4 =
eCPMV-OG488. (D) Same particles on a denaturing 4−12% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel
visualized under UV light (left) and after Coomassie staining (right).
M = SeeBlue Plus2 molecular weight marker. (E) eCPMV-RR and
CPMV-RR conjugates on a SDS-PAGE gel visualized under UV light
(left) and after Coomassie staining (right). 1 = CPMV; 5 = CPMV-
RR; 6 = eCPMV-RR.
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the thiols on S and L are both highly reactive. This is consistent
with previous data from Wang et al. that indicated 5-
maleimidoﬂuorescein was attached to cysteines on both the S
and L subunits of CPMV at higher dye-to-subunit ratios.23
CPMV− and eCPMV−Biotin Conjugates: Labeling
(e)CPMV Inside and Out. Next, we sought to determine
whether labels were indeed attached to the interior surface. The
employed maleimide chemistry is selective toward thiols;
however, cross-reactivity with lysines has been reported.34
Since CPMV and eCPMV display 300 reactive lysine side
chains on the exterior, we sought to rule out that nonspeciﬁc
conjugation to exterior lysines instead of interior cysteine
conjugation occurred. To do this, we chose biotin as a label.
Biotin is a small molecule, a vitamin that speciﬁcally binds with
high aﬃnity to streptavidin and avidin. It is a popular label
employed in biochemistry. Two particle conjugates were made:
(1) CPMV was labeled at exterior lysines using 2000 molar
excess of an NHS reactive biotin probe (referred to as CPMV-
bioE) and (2) eCPMV was labeled at interior cysteines using
2000 molar excess of a maleimide-activated biotin derivative
(referred to as eCPMV-bioI) (Figure 3A).
Puriﬁed CPMV-bioE and eCPMV-bioI conjugates were
analyzed on native and denaturing gels and by Western
blotting (Figure 3B−D). Native gel electrophoresis gave a ﬁrst
indication that biotin labels were indeed attached to interior
cysteine side chains. Altered mobility is observed comparing
CPMV and eCPMV. The absence of negatively charged RNA
in eCPMV results in a retardation of movement through the gel
toward the anode (Figure 3B), as previously described.19
Exterior labeling of CPMV with biotin results in an increased
mobility of CPMV-bioE versus CPMV toward the anode. The
increased mobility can be explained by altered exterior surface
modiﬁcation. Biotin is a noncharged chemical modiﬁer;
conjugation to the exterior lysines of CPMV results in
neutralization of the positive charged derived from lysine side
chains, resulting in an overall more negatively charged particle.
Labeling the interior of eCPMV does not aﬀect the size or
charge of the particle. Despite having a degree of biotin labeling
similar to that of CPMV-bioE (Figure 3D), eCPMV-bioI
appears to have comparable electrophoretic mobility to
eCPMV, thus indicating that labels were indeed attached to
the interior cysteines (as opposed to nonspeciﬁc external lysine
conjugation) (Figure 3B).
To analyze the S and L proteins and to determine whether
labels introduced were selective to just one or both coat
proteins, denaturing gel electrophoresis and Western blotting
were conducted. Membranes were probed with an alkaline
phosphatase-labeled streptavidin. Data conﬁrm successful
biotinylation. Further, data indicate that biotin was attached
to both the S and L proteins for both formulations, CPMV-bioE
and eCPMV-bioI. This is in agreement with ﬂuorescent dye
attachment and indicates that reactive thiols are present on
each coat protein unit (Figure 3D).
We developed an assay using avidin agarose beads to
determine whether labels were indeed attached on the interior
capsid surface using eCPMV (Figure 3E). CPMV, CPMV-bioE,
and eCPMV-bioI particles were mixed with avidin agarose
beads. CPMV and eCPMV-bioI were not expected to bind to
the beads, as neither of these formulations display surface-
exposed biotin groups. By contrast, CPMV-bioE displaying
multiple biotin labels on its exterior surface was expected to
strongly bind to the beads via the biotin−avidin interaction.
Each formulation was incubated with the beads, beads were
washed, and the ﬂow through was collected. Then, the beads
were treated with 0.5 M glycine-HCl buﬀer, pH 2.8, to disrupt
the biotin−avidin interaction and elute any bound particles
from the beads. Both the ﬂow through from the washing steps
and the eluent after treatment were collected and analyzed on a
denaturing gel (Figure 3F). As expected, CPMV and eCPMV-
bioI were detected in the washing steps, indicating these
formulations did not interact with the avidin agarose beads.
CPMV-bioE was not detected in the ﬂow through but was
detected in the ﬁnal eluent, as these particles did bind to the
beads (Figure 3F). These observations support that maleimide
chemistry is indeed selective and that biotin labels in eCPMV-
bioI were attached to the interior cysteine residues.
Labeling the eCPMV and CPMV Interior with High
Molecular Weight Polymers. Next, we sought to test
whether labeling with high molecular weight polymers could
also be achieved. Polymers present an important building block
in medical research; they can be used for covalent or
noncovalent drug loading and controlled drug release. For
example, the chemotherapeutic doxorubicin was loaded onto
the polymer polystyrene sulfonic acid and subsequently
Figure 3. (A) Schematic of biotin functionalization of eCPMV-bioI
and CPMV-bioE, respectively. (B) Biotinylated particles on a 1.2%
agarose gel visualized after Coomassie staining. 1 = CPMV; 2 =
eCPMV; 3 = CPMV-biotin; 4 = eCPMV-biotin. (C) Same particles on
a 4−12% denaturing SDS-PAGE gel stained with Coomassie. M =
SeeBlue Plus2 molecular weight marker. (D) Western blot probed
with streptavidin-alkaline phosphatase conﬁrms biotinylation. (E)
Schematic of the avidin bead binding assay. (F) Flow through and
eluted particles from binding assay on a SDS-PAGE gel after staining
with Coomassie. 5 = CPMV ﬂow through; 6 = CPMV-bioE ﬂow
through; 7 = eCPMV-bioI ﬂow through; 8 = bound CPMV; 9 = bound
CPMV-bioE; 10 = bound eCPMV-bioI.
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encapsulated into VNPs from Hibiscus chlorotic ringspot virus
(HCRSV).35 In a diﬀerent study, PEG-based polymers were
grown on the surface of the phage Qβ; the chemotherapeutic
doxorubicin was then covalently introduced into multivalent
binding pockets provided by the polymers.36
Our goal was to test whether high molecular weight polymers
could diﬀuse inside the interior cavity and covalently attach to
the interior cysteine side chains; we chose PEG-maleimide with
a MW of 2000 Da as a test molecule. We compared the labeling
eﬃciency of eCPMV with CPMV when treated with
mPEG2000-maleimide. To rule out cross-reactivity and conﬁrm
functionalization of the interior, we carried out the same
reactions using eCPMV and CPMV particles with surface
lysines labeled with succinimidyl-4-formyl benzoate (S-4FB).
Reaction of S-4FB-covered eCPMV and CPMV with an NHS
ester-activated PEG with a MW of 2000 Da (mPEG2000-NHS)
was used as a control to verify that the lysines are unavailable
for modiﬁcation with PEG (Figure 4A).
An electrophoretic mobility shift assay using denaturing gel
electrophoresis was carried out to ascertain covalent attachment
of PEG. Successful PEG conjugation was veriﬁed by the
appearance of a laddering eﬀect on the gel (Figure 4B). The
additional, lower mobility bands correspond to coat proteins
that have been labeled with PEG. With the surface lysines free,
PEG labeling was achieved using both maleimide (lanes 1A and
2A) and NHS (lanes 1B and 2B) chemistries. However, while
PEG could be attached to eCPMV and CPMV covered with S-
4FB using mPEG2000-maleimide (lanes 3A and 4A), as
expected, no PEG conjugation was observed with
mPEG2000-NHS (lanes 3B and 4B). In addition, densitometry
analysis of the S protein bands was performed to determine an
estimate of the degree of labeling. The L protein bands were
not used because they were less distinct, but the degree of
covalent modiﬁcation appears to be comparable if not greater
than the S protein. The density ratio of labeled to unlabeled S
coat proteins indicate approximately 80% PEG labeling for
eCPMV and 75% for CPMV, regardless of S-4FB coverage.
These ﬁndings indicate that mPEG2000-maleimide is indeed
attached to the interior cysteine residues. This is further
supported by SEC data, where CPMV particles labeled at the
exterior surface with mPEG2000-NHS elute earlier from the
column, consistent with an increase in size. By contrast, the
elution proﬁle of eCPMV particles labeled with mPEG2000-
maleimide at the interior surface resembles that of unlabeled
particles, suggesting that PEG chains are presented on the
interior surface (Figure S2).
It is interesting that the high molecular weight polymer PEG
was able to diﬀuse into the eCPMV and CPMV formulations
and react with interior cysteines. The pore at the 5-fold axis
(Figure 1C) was measured to be 0.75 nm at its narrowest point.
Consistent with these structural measurements, previous
experiments showed that rigid gold nanoparticles with a
diameter of 1.4 nm could not diﬀuse inside CPMV particles.23
Now, the size of PEG in solution can be calculated based on the
Flory dimension with RF = aN
3/5, where a is the persistence
length of the PEG monomer (a = 0.35 nm)37 and N is the
number of PEG monomers (N = 45 for PEG2000).38 This
gives a Flory dimension for PEG with a MW of 2000 Da of
RF PEG2000 = 3.45 nm. On the basis of the Flory dimension, it
would appear that their size would prevent the polymers from
being able to diﬀuse inside the cavity and react with interior
cysteines. However, the Flory radius is only an estimate of the
size when PEG is in a mushroom conformation. PEG is a highly
ﬂexible polymer, and its conformation in solution is dynamic.
The steric hindrance from the small pore size would promote
the brush conformation. When the PEG is stretched out in this
conformation, it is small enough to diﬀuse through the pores.
In addition, the pore size of CPMV was determined by the
crystal structure and based on a snapshot. The combination of
the ﬂexible polymer and dynamic CPMV structure provides
access for large polymer systems to enter the interior of the
nanoparticles. At this point, it is unknown whether the whole
molecule is within the particle. It is possible that only the
maleimide portion of the molecule entered the cavity and
reacted with the Cys 4 residue that is in close proximity to the
pore. Nevertheless, these ﬁndings of polymer loading may open
the door for polymer-mediated drug loading studies.
Interior Peptide Loading of CPMV and eCPMV Using
Hydrazone Ligations. Recently, it has been shown that it is
possible to chemically link peptides to the outer surface of
CPMV particles in order to catalyze the deposition of speciﬁc
minerals around the particles.39 Here we have investigated
whether peptides could be introduced to the interior of
eCPMV and CPMV in order to promote speciﬁc mineralization
within particles since mineralized particles could have
applications in nanomedicine. Three candidate peptides were
chosen: the positively charged penta(arginine) and hexa-
(histidine) peptides as well as the negatively charged FLAG
tag peptide (Figure 5A). To facilitate eﬃcient loading with
charged peptides, we turned toward bio-orthogonal chemistries.
Standard coupling procedures using maleimide-activated
reagents have slow reaction kinetics, and large excesses of
reagents have to be used to facilitate eﬃcient labeling. Cu(I)-
catalyzed azide−alkyne cycloaddition and hydrazone ligation
chemistry overcome these limitations;5 these chemistries are
highly eﬃcient bioconjugation methods that require low
concentrations and excesses of the reagent or ligand of interest.
Figure 4. (A) Reactions to determine functionalizability of eCPMV
and CPMV with maleimide- and NHS-mPEG2000 when surface
lysines are either available or unavailable for modiﬁcation. (B) Results
of the reactions on a 4−12% denaturing SDS-PAGE gel stained with
Coomassie Blue. M = SeeBlue Plus2 molecular weight marker; 1 =
CPMV; 2 = eCPMV; 3 = CPMV-S4FB; 4 = eCPMV-S4FB; A =
mPEG2000-maleimide; B = mPEG2000-NHS.
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Peptide conjugation was carried out using a two-step hydrazone
ligation procedure: ﬁrst, interior cysteines on eCPMV and
CPMV were labeled with benzaldehydes using the maleimide-
reactive linker MTFB; second, peptide coupling was performed
using hydrazinopyridine-modiﬁed peptide conjugates (Figure
5A,B). MTFB was introduced using a 6000-fold excess to
ensure maximum labeling. Quantiﬁcation of MTFB modiﬁca-
tion was determined using the Solulink MSR assay and 2-
hydrazinopyridine. The resulting hydrazone bond is UV
traceable (A at 350 nm, ε = 18,000 M−1 cm−1). We found
that reaction with MTFB showed poor reproducibility; between
40 and 80 MTFB linkers were attached (Figure 5C, solid bars).
No statistically signiﬁcant diﬀerences between eCPMV and
CPMV were observed. This is consistent with observations
made using PEG2000 and may be explained by the hydrophilic
nature of the ligand; MTFB contains a PEG3 spacer (Figure
5A).
The aldehyde moiety of eCPMV-MTFBI and CPMV-MTFBI
was then coupled with the hydrazine functionality of the
penta(arginine), hexa(histidine), and FLAG tag peptides.
Hydrazone chemistry has recently been applied to the CPMV
platform and was shown to be a versatile strategy allowing the
Figure 5. Hydrazone ligation. (A) Functionalization of the exterior of CPMV with S-4FB (top) and the interior of eCPMV and CPMV with MTFB
(middle) to provide aldehyde ligation handles. Example of hydrazone ligation using 2-hydrazinopyridine to quantify the MSR (bottom). (B)
Polyarginine, hexahistidine, and FLAG peptides attached using hydrazone ligation. (C) Representative data of the labeling eﬃciency of MTFB (solid
bars) and the various peptides (striped bars) to the interior of eCPMV vs CPMV. (D) Western blot probed with streptavidin-alkaline phosphatase
conﬁrms successful incorporation of biotinylated R5 peptide into the interior of eCPMV. M = SeeBlue Plus2 molecular weight marker; 1 = eCPMV;
2 = eCPMV-bioI; 3 = eCPMV-R5I. (E) Aﬃnity of Ni-NTA to histidines was exploited for testing the binding of CPMV, CPMV-His6E, eCPMV, and
eCPMV-His6I to Ni-NTA beads using a similar test as performed for biotinylated particles. (F) Schematic of the bead binding assay (top) illustrates
the expected results. SDS-PAGE gel stained with Coomassie (bottom) conﬁrms only CPMV-His6E binds to the beads, indicating internal attachment
of His6 to eCPMV. M = SeeBlue Plus2 molecular weight marker; 4 = washed CPMV; 5 = washed CPMV-His6; 6 = washed eCPMV; 7 = washed
eCPMV-His6; 8 = eluted CPMV; 9 = eluted CPMV-His6; 10 = eluted eCPMV; 11 = eluted eCPMV-His6.
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decoration of CPMV with targeting ligands speciﬁc for vascular
endothelial growth factor receptor-1.22 We optimized the
ligation reaction further using the catalyst aniline, which
accelerates the rate of hydrazone bond formation by 2 orders
of magnitude, allowing the reaction to proceed rapidly even at
neutral and basic pH (the optimum of pH for hydrazone
chemistry is 4.5).40
eCPMV and CPMV peptide conjugates were puriﬁed from
excess reagents and characterized using SEC, UV/vis spectros-
copy, denaturing gel electrophoresis, and Western blotting. The
R5 peptide used in this study displays a biotin tag (Figure 5B),
allowing detection using enzyme-tagged streptavidin probes
and Western blotting. Western blotting was performed using
alkaline phosphatase-conjugated streptavidin. Alkaline phos-
phatase activity was detected using the BCIP/NBT liquid
substrate system. Data conﬁrmed the covalent decoration of
eCPMV and CPMV with R5 peptides. In agreement with dye-,
biotin-, and PEG-labeling, labels were found to be introduced
to both the S and L proteins (Figure 5D).
Quantiﬁcation of peptide labeling was based on the UV-
traceable hydrazone bond formed (A at 354 nm, ε = 29,000
M−1 cm−1). Overall, eCPMV appeared to show better
reactivity. From the data, it was not clear whether the charges
of the various peptides impact the success of labeling. It appears
that peptide labeling using hydrazone ligation results in high
variability. Statistical analysis showed no signiﬁcant diﬀerences
between the conjugates. The previous dye-labeling studies
indicated that negatively charged molecules may be preferred
for entrance through the pores. However, the negatively
charged FLAG tag is also larger than the positively charged
penta(arginine) and hexa(histidine) peptides, a fact that could
explain why this trend was not observed for the peptides.
Between 20 and 40 peptides could be introduced using a molar
excess of 360 peptides per CPMV/eCPMV. We attempted to
increase the labeling eﬃciency by increasing the molar excess of
peptides used or by extending the incubation time. However, in
both cases, aggregation was observed, and the recovered yield
was less than 10%, indicating that the charged peptides induce
electrostatically driven aggregation upon a threshold. We have
observed similar trends in exterior peptide conjugation
experiments using charged peptides. It has been shown that
metals ions can be diﬀused into the internal cavity and
converted to metal or metal oxide.41 On the basis of previous
observations showing that 60 genetically introduced hexa-
(histidine) peptides were suﬃcient to serve as nucleation
centers to promote external mineralization of eCPMV with
cobalt,42 we propose that chemical labeling with up to 40
peptides will achieve similar results.
To verify that peptide labels were indeed conjugated to the
interior particle surface, we adapted the agarose bead assay
aforementioned for use in determining the spatial location of
introduced biotin labels (see above). Agarose beads labeled
with nickel-nitrilotriacetic acid (Ni-NTA) were used. Hexa-
(histidine) sequences have a high aﬃnity to Ni-NTA (Figure
5E). We tested four particle formulations: eCPMV, CPMV,
eCPMV-His6I and CPMV-His6E. The latter formulation was
generated by decorating the exterior CPMV surface with
benzaldehydes using the NHS derivative S-4FB, followed by
hydrazone ligation using the HyNic-hexa(histidine) peptide.
eCPMV, CPMV, eCPMV-His6I, and CPMV-His6E were all
found in the ﬂow through. However, only CPMV-His6E
displaying exterior hexa(histidine) tags was detected in the
eluent after treatment with imidazole, a chemical known to
disrupt the Ni-NTA−hexa(histidine) interaction. Thus, out of
all the formulations, only CPMV-His6E had any aﬃnity to the
Ni-NTA beads. This is as expected and indicates that the
peptide sequences in eCPMV-His6I were indeed attached to
the interior surface; there was no indication of eCPMV-His6I
being bound to the beads. Since CPMV-His6E was also found
in the initial ﬂow through, binding to the beads was incomplete
(Figure 5F). The diﬀerence in binding between this assay and
the previous assay for biotinylated particles could be due to the
9 orders of magnitude lower aﬃnity of the interaction between
His6 and Ni-NTA (Kd = 10
−6 M)43 compared to the
interaction between biotin and avidin (Kd = 10
−15 M).44
Overall, these data support that peptide labels were selectively
attached to the interior surface. This opens a new avenue for
peptide-mediated internal mineralization of CPMV.
Toward Medical Applications: Cellular Imaging and
Tumor Homing of Internally and Externally Labeled
(e)CPMV. Fluorescent dyes are widely employed in optical
imaging, and the versatility of ﬂuorescently labeled CPMV
nanoparticles has been demonstrated for several applications:
CPMV-dye conjugates have been used (i) to target and image
cancer cells in vitro and in vivo,13,25,29 (ii) for intravital vascular
imaging, including tumor neovasculature mapping,14,45 and (iii)
to study its biodistribution in vivo.46 In each case, the
ﬂuorophores were attached to the exterior CPMV surface.
The conjugation of the imaging labels to the interior surface
would oﬀer a clear advantage. For example, it would allow
modiﬁcation of exterior residues with other biomedically
relevant moieties such as targeting ligands to redirect and
target speciﬁc cells and tissues and PEG, a hydrophilic polymer
used to shield nanomaterials and increase their pharmacoki-
netics while reducing undesired side eﬀects such as
immunogenicity. Here, we evaluated the use of internally
labeled eCPMV versus externally labeled CPMV for optical
imaging applications in tissue culture and preclinical tumor
mouse models.
First, we evaluated the optical stability and molecular
quenching of dye-labeled CPMV and eCPMV (Figure 6). We
examined CPMV-OG488E particles labeled with 80 OG488 at
exterior surface lysine side chains and eCPMV-OG488I labeled
with 70 OG488 at interior cysteines for potential use in
confocal microscopy studies. In addition, we looked at non-
PEGylated and PEGylated formulations of CPMV-A647E and
eCPMV-A647I labeled with 50 dyes each for use in ﬂow
cytometry and tumor homing studies, respectively. Fluores-
cence was measured for 50 μM solutions of the particles,
Figure 6. Fluorescence intensity data of interior labeled eCPMV
compared to exterior labeled CPMV in pH 7.0 potassium phosphate
buﬀer (left) and of A647-labeled particles in pH 5.0 MES buﬀer
(right). eCPMV data are shown as solid bars on the left, while CPMV
data are shown as striped bars on the right. Asterisks denote statistical
signiﬁcance between ﬂuorescence intensities of eCPMV and CPMV
formulations (* p < 0.05, ** p < 0.01, *** p < 0.001).
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maintaining equal amounts of dyes and particles for
comparison. Measurements indicated that some quenching
occurred when labels were conjugated to the interior eCPMV
surface, and the ﬂuorescence intensity reached only about half
of the ﬂuorescence intensity measured for CPMV decorated
with dyes on its exterior surface. This phenomenon was
independent of the dye used, i.e., OG488 or A647, and was also
pH-independent, i.e., pH 7.0 versus 5.0 (Figure 6). Despite the
weakened ﬂuorescence signal of the eCPMV formulation
compared to CPMV, the ﬂuorescence is still suitable for optical
imaging applications, and the potential for additional
functionalities on the exterior of eCPMV remains promising.
As the interior labeled eCPMV particles appeared strongly
ﬂuorescent in gels even though they are less ﬂuorescent when
measured in bulk in aqueous buﬀers, environmental factors
clearly play a role in observed ﬂuorescence. A diﬀerence may
also be observed when imaging the particles within cells.
Consequently, we went on to evaluate the in vitro and in vivo
properties of eCPMV.
Cell imaging was studied using HeLa cells, a cervical cancer
cell line. HeLa cells are an ideal model for this analysis because
previous studies have shown that CPMV binds to vimentin
displayed on the surface of HeLa cells and is then taken up by
endocytosis.26 OG488- and A647-labeled constructs from the
ﬂuorescence measurements were used for confocal microscopy
imaging and ﬂow cytometry analysis, respectively. For confocal
microscopy studies, live cells were incubated with CPMV-
OG488E and eCPMV-OG488I, washed, and subsequently ﬁxed.
Cell membranes were stained with WGA, and nuclei were
stained with DAPI (Figure 7A-D). There were no apparent
diﬀerences between the CPMV-OG488E and eCPMV-OG488I
formulations, and ﬂuorescent signals were comparable. From z-
stacks analyzed using ImageJ software, CPMV and eCPMV
nanoparticles were found to be internalized. Flow cytometry
measurements were performed to gain quantitative data (Figure
7E,F). Signals obtained from eCPMV-A647I were reduced
compared to signals derived from cells that were treated with
CPMV-A647E. Nevertheless, both formulations were detectable
in HeLa cells at similar levels as reported previously.25,26
Finally, the in vivo tumor homing properties of internally
labeled eCPMV versus externally labeled CPMV were studied
using a nude mouse xenograft model of colon cancer. In a one-
pot synthesis reaction, CPMV and eCPMV were conjugated
with A647 on their exterior and interior surfaces, respectively,
together with mPEG5000-NHS on their exterior. These
reactions yielded formulations with 50 ﬂuorophores and
approximately 30% PEGylation, as indicated by UV/vis
spectroscopy, denaturing gels, and band analysis (not shown).
Integrity of the particles was veriﬁed by TEM and SEC (Figures
S1 and S2).
NCr-nu/nu mice were used and tumors were induced
through subcutaneous injection of HT-29 colon cancer cells.
The mice were kept on an alfalfa-free diet to reduce tissue
autoﬂuorescence. Equal amounts of the particles (and thus
equal amounts of dye) were injected intravenously (200 μg of
eCPMV and 284.3 μg of CPMV) and allowed to circulate for
24 h for delivery to the tumors. The animals were then
sacriﬁced, and their tissues were collected and imaged ex vivo
using a Maestro imaging system (Figure 8). No ﬂuorescence
was observed for the PBS control, while there was prominent
ﬂuorescence in the liver and some in the spleen for the eCPMV
and CPMV particles due to clearing by the reticuloendothelial
system (not shown). There was clear tumor homing via the
enhanced permeability and retention eﬀect, with ﬂuorescent
signal observed for both eCPMV and CPMV. The average
signal over the tumor area for each mouse was analyzed using
Figure 7. In vitro evaluations of CPMV-OG488E and eCPMV-OG488I. Representative confocal images depict uptake of CPMV-OG488E (A,C) and
eCPMV-OG488I (B,D) by HeLa cells. Side panels in C and D are orthogonal sections from the respective images conﬁrming internalization of
VNPs. Both CPMV and eCPMV were tagged with OG488 (green), the cell membrane was stained with WGA-Alexa Fluor 555 (red), and the
nucleus was stained with DAPI (blue). Flow cytometry was performed to measure cell uptake (E). Cells to the right of the vertical line were
considered positive for A647, and the percent of positive cells for each sample was quantiﬁed (F). Unpaired asterisks denote statistical signiﬁcance as
compared to cells only control (* p < 0.05, *** p < 0.001). Diﬀerence in ﬂuorescence intensity between eCPMV and CPMV formulations was also
statistically signiﬁcant (p < 0.05).
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ImageJ. There is some variability between the animals, but the
ﬂuorescence intensities from mice injected with the eCPMV
formulation appear to be consistently higher, with the
diﬀerence between the two formulations being statistically
signiﬁcant (p < 0.05). This is an interesting result given the
previous ﬂuorescence measurements and ﬂow cytometry
studies. Some possible explanations for this diﬀerence could
be that the display of A647 on the outside of the CPMV
somewhat hinders its delivery to the tumor or the exterior dyes
may be more easily degraded in vivo.
HT-29 tumor cells express surface vimentin, and targeting of
CPMV to these tumor cells has been previously conﬁrmed in
vitro and in vivo.25 PEG was used in our design, as this allows
shielding of the particles during circulation and increased tumor
homing. Over short time periods (a few hours), PEGylation
shields CPMV from cell interactions. However, over longer
time periods, vimentin-speciﬁc cell uptake has been observed.25
On the basis of these previous observations, we propose the
eCPMV formulation provides an advantage for in vivo tumor
homing applications. The imaging labels can be installed on the
interior surface, thus preserving cellular interactions with the
native particle surface. Furthermore, eCPMV provides the
possibility for additional modiﬁcations on the exterior for
synthesis of multifunctional nanoparticles for targeted delivery
applications.
■ CONCLUSION
In this study, we successfully established the use of
bioconjugation methods for interior cargo loading of CPMV.
We illustrated that this method can be used to encapsulate
dyes, large PEG polymers, and a variety of negatively and
positively charged peptides. From our ﬁndings, we hypothesize
that the factors that may govern the entrance of molecules
through the pore and into the cavity of eCPMV include size,
charge, and hydrophobicity. The pore size was measured to be
0.75 nm, which excludes larger molecules other than ﬂexible
polymers that can adapt their conformation such as PEG. In
terms of charge, the greatest extent of labeling was observed
using negatively charged dyes. Their diﬀusion into the cavity
may be favored because they mimic the charge of the natural
nucleic acid cargo. This trend was not observed for peptide
labeling, but the negatively charged FLAG tag also had greater
steric hindrance. Finally, hydrophilic molecules such as
PEG2000 and MTFB appear to be able to diﬀuse into the
cavity more freely than other molecules, as no diﬀerence in
labeling between eCPMV and wild-type CPMV was observed.
Our results lead the way for imaging, polymer-mediated drug
loading, and peptide-mediated mineralization applications. We
have shown that RNA-free eCPMV is necessary to achieve
signiﬁcant dye loading compared to wild-type CPMV and that
these interior dye-labeled eCPMV are suitable for ﬂuorescence
imaging in vitro and in vivo. eCPMV is able to passively
accumulate in tumors through the EPR eﬀect and has a higher
signal intensity in vivo than exterior labeled CPMV. In addition
to these individual applications, interior modiﬁcation leaves
reactive lysines on the exterior surface free for functionalization
with other moieties such as PEG for masking nonspeciﬁc
interactions and prolonging circulation time, targeting ligands
to confer tissue-speciﬁcity, and contrast agents for magnetic
resonance and PET imaging. Interior conjugation is thus the
ﬁrst step in the advancement of the eCPMV platform for
further development of multifunctional nanoparticles for in vivo
applications. The feasibility to encapsulate biomedically
relevant molecules within CPMV has great potential for future
therapeutics incorporating tissue-speciﬁc targeting, drug deliv-
ery, and/or imaging in a single formulation.
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References 201AbstractA series of vectors (the pEAQ series) based on cowpea mosaic virus has been developed
which allows the rapid transient expression of high levels of foreign protein in plants
without the need for viral replication. The plasmids are small binary vectors, which
are introduced into plant leaves by agroinfiltration. They are modular in design and
allow the insertion of multiple coding sequences on the same segment of T-DNA. These
properties make the pEAQ vectors particularly suitable for use in situations, such as
the investigation and manipulation of metabolic pathways, where the coexpression
of multiple proteins within a cell is required.185
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The past 20 years have seen the development of many RNA viruses asvectors for the transient expression of foreign peptides and polypeptides in
plants (Porta & Lomonossoff, 2002; Scholthof, Scholthof, & Jackson,
1996). The advantages of using viruses, as opposed to stable genetic transfor-
mation, for such expression include the facts that (i) viral genomes are small
and therefore easy tomanipulate, (ii) infection of plantswithmodified viruses
ismuch simpler and quicker than the regeneration of stably transformed lines,
and (iii) a sequence inserted into a virus vectorwill be highly amplified during
viral replication. Initially, plant virus-basedvectorswerebasedon replication-
competent full-size virus genomes,with the gene to be expressed being added
to the full complement of viral genes. Inevitably, there were a number of dis-
advantages to this approach: there are size constraints on the sequences
which can be inserted while retaining virus viability, the inserted sequence
is susceptible to “genetic drift” during virus replication, and there are
bio-containment concerns over the use of vectors based on fully competent
viruses as these retain their ability to spread in the environment. As a result, in
the past decade, attention has turned toward the development of plant virus-
based expression systems based on defective versions of viral RNAs, which
alleviate some or all of these disadvantages (Can˜izares, Liu, Perrin, Tsakiris,
& Lomonossoff, 2006; Gleba, Marillonnet, & Klimyuk, 2004). These
studies have resulted in the creation of systems in which the ability of the
virus to spread both within the plant and in the environment is curtailed
and has culminated in the development of a system in which the need for
replication to achieve high-level expression has been eliminated.
2. DELETED VECTORS BASED ON COWPEA
MOSAIC VIRUSAmong the plant viruses which have been developed into an expres-
sion system is cowpea mosaic virus (CPMV; Sainsbury, Can˜izares, &
Lomonossoff, 2010). This virus infects a number of legume species and
grows to particularly high titers in its natural host, cowpea (Vigna
unguiculata); it also infects the commonly used experimental host, Nicotiana
benthamiana. The genome of CPMV consists of two separately encapsidated
positive-strand RNA molecules of 5889 (RNA-1) and 3481 (RNA-2) nu-
cleotides. The RNAs each contain a single open reading frame (ORF) and
187Manipulation of Plant Biosynthetic Pathways
Author's personal copyare expressed through the synthesis and subsequent processing of precursor
polyproteins. RNA-1 encodes proteins involved in the replication of viral
RNAs and polyprotein processing while RNA-2, which is entirely depen-
dent on the proteins encoded by RNA-1 for its replication, encodes the
movement protein and the two coat proteins, large (L) and small (S) that
are essential for cell-to-cell movement and systemic spread. The develop-
ment of CPMV-based expression systems has focused entirely on modifying
the sequence of RNA-2; replication functions, when required, are provided
by coinoculating the RNA-2 constructs with RNA-1 (Fig. 9.1A).
A particular attraction of CPMV as a virus-based vector is the fact that it
is naturally bipartite. This means that two RNA molecules have to be rep-
licated within the same cell, implying that virus exclusion will not occur.
Virus exclusion is the phenomenon whereby the presence of a replicating
RNA within a cell effectively excludes the replication of a second construct
based on the same virus. Thus, systems based on monopartite, replication-
competent viruses, such as tobaccomosaic virus, are essentially limited to the
production of a single protein within a given cell unless a second, different
noncompeting virus is used for the expression of the second protein (Giritch
et al., 2006). The utility of CPMV for the coexpression of multiple proteins
was first demonstrated using full-length versions of RNA-2 harboring either
the yellow or cyan fluorescent protein (YFP or CFP) or the heavy and light
chains of an IgG. In each case, the two RNA-2-based constructs were
inoculated in conjunction with RNA-1 to provide the replication functions
(Sainsbury, Lavoie, D’Aoust, Vezina, & Lomonossoff, 2008). However,
although successful coexpression was demonstrated in the inoculated tissue,
segregation of the different RNA-2-based constructs occurred on systemic
movement, leading to cells expressing either YFP or CFP but rarely both.
Since, for practical purposes, this limits the expression of multiple genes to
the inoculated tissue, it was rationalized that there was little to be lost in
terms of levels of expression if those features necessary for the spread of
the virus were removed from RNA-2. This would have the advantage of
creating vectors which are unable to spread in the environment and are
therefore biocontained.
2.1. Replication-competent deleted vectors
An expression system based on a defective form of CPMV RNA-2
(Fig. 9.1B) was created using the observation that the sequences nec-
essary for replication of RNA-2 by the RNA-1-encoded replication com-
plex lie exclusively at the 50 and 30 ends of the RNA (Rohll, Holness,
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Figure 9.1 Development of CPMV-based expression vectors. (A) Full-length vectors
based on the entire genome of CPMV where RNA-1 provides replication functions for
RNA-2 molecules modified to contain the gene of interest (gray) following the FMDV
2A catalytic peptide. Also shown is an example of an expression pattern following infil-
tration and systemicmovement (black tissue). (B)DeletedRNA-2 vectorswhere the entire
coding sequence of RNA-2 is replaced by the gene of interest. RNA-1 provides replication
functions andP19 supplies silencingsuppressor functions in lieuof the small coatprotein.
(C)CPMV-HTvectorsbasedon themodifiedUTRsofRNA-2whereP19provides a silencing
suppressor function. (D) Schematic representation of pEAQ-HT where all elements
for CPMV-HT are present on a single T-DNA. (i) Time-course of GFP expression from
CPMV-HT, (ii) TEM image of crude extracts showing assembled HBcAg particles following
expression from CPMV-HT, (iii) purified anti-HIV antibody following expression from de-
letedRNA-2andCPMV-HT, (iv) examplehighperformance liquid chromatography (HPLC)
trace representing metabolic engineering enabled by CPMV-based vectors.
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deletedwithoutaffecting theabilityofRNA-2 tobe replicated.However,while
the essential 30-terminal sequences lie exclusively within the 30-UTR, the
essential 50 sequence extends beyond the first in-frame AUG (position 161)
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mutations introduced between the two AUG codons abolish replication, as
does elimination of the AUG at 161 (Holness, Lomonossoff, Evans, &
Maule, 1989; Rohll et al., 1993). This means that initiation of translation
of the foreign gene must be driven by the second in-frame AUG at
position 512 if the ability of the construct to be replicated by RNA-1 is
to be retained (Can˜izares et al., 2006). To create a vector in which the
heterologous coding sequence can be precisely fused to AUG 512, site-
directed mutagenesis of a full-length copy of RNA-2 in an Escherichia coli
plasmid was used to introduce a BspHI site (TCATGA) around AUG
512 and a StuI site (AGGCCT) after UAA 3299, the termination codon
for the RNA-2-encoded polyprotein; in addition, two BspHI sites from
the vector backbone were removed (Liu & Lomonossoff, 2002). The
resulting vector, termed pM81B-S2NT-1, allows the whole of the RNA-
2 ORF downstream of AUG 512 to be excised by digestion with BspHI
and StuI and replaced with any sequence with BspHI and StuI (blunt)-
compatible ends. The use of the BspHI site is important as it preserves
the AUG at 512 and this initiator is used to drive translation of the
inserted gene. To express the foreign gene in plants, the pM81B-S2NT-
1-derived plasmids are digested with AscI and PacI and the fragment
containing the foreign sequence flanked by the CaMV 35S promoter and
nos terminator, as well as the CPMV RNA-2-derived UTRs, is
transferred to similarly digested pBINPLUS and the resulting plasmids are
finally introduced by transformation into Agrobacterium tumefaciens. For
expression, A. tumefaciens suspensions harboring the desired RNA-2-based
constructs are coinfiltrated into N. benthamiana leaves with plasmids
encoding a full-length copy of RNA-1 and a suppressor of gene
silencing, usually P19 from Tomato bushy stunt virus (TBSV; Fig. 9.1B).
This approach has been used successfully to express assembled particles of
Hepatitis B core antigen (HBcAg; Mechtcheriakova, Eldarov, Beales,
Skryabin, & Lomonossoff, 2008) and to express a fully assembled,
functional IgG (Sainsbury, Sack, et al., 2010). Initially, it was believed
that replication of the deleted RNA-2 by RNA-1 was essential for high
levels of protein expression. However, the presence of a strong suppressor
of silencing, such as P19, increases the stability of mRNA to such a
degree that amplification of RNA levels by replication results in little
further increase in expression levels (Sainsbury, Sack, et al., 2010). As a
result, the deleted RNA-2-based vectors (delRNA-2 vectors) described
above, though replication competent, can be deployed for expression of
190 Frank Sainsbury et al.
Author's personal copyproteins in plants in the absence of RNA-1. Details of the construction and
method of use of these replication-competent vectors are described in detail
in Sainsbury, Liu, and Lomonossoff (2009).
The vectors described above were originally created to express proteins,
such as vaccine candidates and antibodies, which would be subsequently pu-
rified and characterized. However, Mugford et al. (2009) showed that the
vectors could also be used to express active enzymes within N. benthamiana
leaves with the aim of manipulating plant metabolism and analyzing enzyme
function rather than obtaining the protein itself. In these experiments, the
expression of a serine carboxypeptidase-like acyltransferase from oat leaves
(Sad 7, an enzyme from the avenicin biosynthetic pathway; see Chapter 6)
was shown to be able to catalyze the transfer of bothN-methyl anthraniloyl-
and benzoyl-groups to des-acyl avenacins when expressed inN. benthamiana.
These studies paved the way for the use of virus-based vectors for the
manipulation of metabolic pathways in plants. The use of replication-
competent CPMV RNA-2 based vectors for the expression of active
enzymes in plants is described in detail in Chapter 14.2.2. The CPMV-HT expression system
A major drawback with the replication-competent RNA-2 system is the
need to precisely fuse the sequence to be expressed to AUG 512. This makes
the cloning strategy a somewhat cumbersome, two-step procedure (see
Sainsbury, Liu, & Lomonossoff, 2009). Further, coinfiltration with a sepa-
rate construct containing a suppressor of silencing is necessary to obtain high
levels of expression. The observation that replication is not essential for
high-level protein expression led Sainsbury and Lomonossoff (2008) to ex-
amine whether it is possible to simplify the structure of the expression plas-
mids, particularly around the 50-UTR, to facilitate the insertion of foreign
sequences. These studies showed that elimination of both AUG 161 and an
upstream out-of-frame AUG at position 115, though abolishing replication,
actually substantially increased expression levels of a variety of proteins. This
effect was caused by the modified 50-UTR rendering the mRNAs “hyper-
translatable” and expression systems using them have been termed CPMV-
HT. The levels of foreign protein produced using the HT leaders far
exceeded those achieved from replicating full-length or delRNA-2 vectors
in transient expression studies. Achieving high-level expression without
replication has a number of substantial advantages: the problems associated
with genetic drift and virus exclusion are eliminated and there is no obvious
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Thus, CPMV-HT is ideally suited to the simultaneous expression of multi-
ple proteins within the same cell. A number of pharmaceutically relevant
proteins have been expressed to high level using the CPMV-HT system
(Fig. 9.1C and D). They include approximately 1 g/kg of agroinfiltrated tis-
sue of assembled HBcAg particles (Sainsbury & Lomonossoff, 2008), and up
to 0.4 g/kg of the human antihuman immunodeficiency virus IgG, 2G12
(Sainsbury, Sack, et al., 2010). However, in its initial form the CPMV-
HT expression system still required a two-step cloning procedure and coi-
nfiltration with a suppressor of silencing (Fig. 9.1C).2.3. The pEAQ series of vectors
To refine the CPMV-HT expression system, its various components (the
CPMV-HT expression cassette and the P19 sequence) were placed on
the T-DNA region of a binary vector for Agrobacterium-mediated delivery
to plant cells (Fig. 9.1D). This was achieved by constructing a new series of
binary vectors, the pEAQ series (Table 9.1; Fig. 9.2A). These vectors are less
than half the size of the original pBINPLUS plasmid while retaining all the
essential components for efficient transient expression and stable transforma-
tion (Sainsbury, Thuenemann, & Lomonossoff, 2009). In addition to a va-
riety of T-DNA configurations, each pEAQ vector contains a polylinker of
unique restriction sites that, while designed for use with the modular cloning
of the CPMV-HT cassette as discussed below, may also be used to insert any
expression cassette or sequence (Fig. 9.2A). The removal of reading frame
dependence, essential for replication but evidently adversely affecting
translation, permits the use of a one-step cloning procedure either through
the use of a multiple cloning site for restriction enzyme-based cloning or
via the GATEWAYÒ system of recombination-based cloning. Further
expanding their usefulness, these expression vectors also contain the ap-
propriate sequences for N- or C-terminal His-tagging of proteins of inter-
est, allowing for straightforward purification from plant tissue (Tables 9.2
and 9.3). The use of such pEAQ-based CPMV-HT vectors has so far
enabled high-level expression and purification via a His-tag of a number of
heterologous proteins, including human gastric lipase (Vardakou, Sainsbury,
Rigby, Mulholland, & Lomonossoff, 2012) and a rice chitinase (Miyamoto
et al., 2012).
Though expression of a single protein during transient expression is use-
ful in several cases, there are many instances where coexpression of more
Table 9.1 The pEAQ vector series
Plasmid name
GenBank
accession Features
pEAQ-HT GQ497234 Designed for easy and quick cloning of a gene of
interest into the CPMV-HT system.
Its T-DNA comprises:
• the CPMV-HT expression cassette with a
polylinker (Table 9.2) to insert the gene of
interest;
• the suppressor of gene silencing P19;
• neomycin phosphotransferase II (nptII) to
confer resistance to kanamycin.
pEAQexpress GQ497230 Designed for cloning multiple CPMV-HT
expression cassettes in the same vector for
transient expression only. Its T-DNA comprises:
• a multiple cloning site for insertion of multi-
ple expression cassettes digested using en-
zymes PacI and AscI;
• the suppressor of gene silencing P19.
pEAQselectK GQ497231 Designed for expression from a CPMV-HT
expression cassette in the absence of a suppressor
of silencing. Its T-DNA comprises:
• a multiple cloning site for insertion of the ex-
pression cassettes;
• neomycin phosphotransferase II (nptII) to
confer resistance to kanamycin.
pEAQspecialK GQ497232 Designed for expression from a CPMV-HT
expression cassette in the presence of a suppressor
of silencing. Its T-DNA comprises:
• a multiple cloning site for insertion of the ex-
pression cassette;
• the suppressor of gene silencing P19;
• neomycin phosphotransferase II (nptII) to
confer resistance to kanamycin.
pEAQspecialKm GQ497233 Best suited for stable expression of proteins in
whole plants. Its T-DNA comprises:
• a multiple cloning site for insertion of the ex-
pression cassette;
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Table 9.1 The pEAQ vector series—cont'd
Plasmid name
GenBank
accession Features
• the modified suppressor of gene silencing
P19/R43W (Saxena et al., 2011);
• neomycin phosphotransferase II (nptII) to
confer resistance to kanamycin.
pEAQ-HT-
DEST1
GQ497235 Designed for easy and quick cloning using the
gatewayÒ system to express wild-type protein in
plants. Its T-DNA comprises:
• the CPMV-HT expression cassette with attR
sites to introduce the gene of interest from the
entry clone via recombination;
• the suppressor of gene silencing P19;
• neomycin phosphotransferase II (nptII) that
confers resistance to kanamycin.
pEAQ-HT-
DEST2
GQ497236 Designed for easy and quick cloning using the
gatewayÒ system to express N-terminally His-
tagged protein in plants. Its T-DNA comprises:
• the CPMV-HT expression cassette with attR
sites to introduce the gene of interest from the
entry clone via recombination;
• the suppressor of gene silencing P19;
• neomycin phosphotransferase II (nptII) that
confers resistance to kanamycin.
pEAQ-HT-
DEST3
GQ497237 Designed for easy and quick cloning using the
gatewayÒ system to express C-terminally His-
tagged protein in plants. Its T-DNA comprises:
• the CPMV-HT expression cassette with attR
sites to introduce the gene of interest from the
entry clone via recombination;
• the suppressor of gene silencing P19;
• Neomycin phosphotransferase II (nptII) that
confers resistance to kanamycin.
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Author's personal copythan one protein is required. The simplest way of achieving this is to
coinfiltrate Agrobacterium suspensions each containing a plasmid designed
to express a single protein. Although this is a highly flexible approach, to
ensure efficient coexpression of constructs within the same cell, each
AgeI/NruI - 6xHis - XmaI/SmaI - 6xHis - XhoI/StuI
PacI-AseI-StuI-XhoI-SbfI-MfeI-BstZ17I-AvrII-BspEI-AgeI-SnaBI-SmaI-XmaI-AscI-AsiSI-MluI-FseI
pEAQ Multiple cloning site:
pEAQ-HT polylinker:
PacI AscI
pM81-FSC2
viral UTRs
pEAQ-HT polylinkerCaMV promoter
nos terminator
PacI PacI
pM81-FSC3
AscI AscI
pM81-FSC4
PacI SbfI
pM81-FSC5
SbfI AscI
pM81-FSC6
B
A
OriV
TrfA
NPTIII
ColE1
RB
LB
pEAQ
5203 bp
pM81B-S2NT-1
BspHI
512
PacI AscIStuI
MP L S
NPTII
NPTII
NPTII
P19
P19
P19
P19 NPTII
pEAQ-HT
pEAQ-HT-DEST1
pEAQexpress
pEAQselectK
pEAQspecialK
GW
DEST2
DEST3
Figure 9.2 Schematic representation of the pEAQ vector system. The series of vectors
enables direct cloning into expression vectors of the assembly of multiple expression
cassettes via a modular series of cloning vectors. (A) Representation of theminimal plas-
mid backbone of the pEAQ series and various configurations of the T-DNA designed for
different applications. GW, GATEWAY. (B) Representation of the modular series of clon-
ing vectors each containing the pEAQ-HT polylinker and designed for CPMV-HT cassette
insertion into the pEAQ multiple cloning site.
Table 9.2 Restriction enzyme pairs to use for restriction enzyme-based cloning into
pEAQ-HT depending on whether or not a His-tag is required
For expression of wild-type protein NruI or AgeI
at the 50 end
XhoI or StuI at the 30 end
For expression of protein with a
His-tag at the N-terminus
XmaI or SmaI
at the 50 end
XhoI or StuI at the 30 end
For expression of protein with a
His-tag at the C-terminus
NruI or AgeI
at the 50 end
XmaI or SmaI at the 30 end
Each position contains the option of using a restriction enzyme that leaves an overhang or a blunt end.
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Table 9.3 Appropriate pEAQ-HT-DEST vector to use depending onwhether or not a His-
tag is required
For expression of wild-type protein Do the LR reaction of your entry clone with
pEAQ-HT-DEST1
For expression of protein with a
His-tag at the N-terminus
Do the LR reaction of your entry clone with
pEAQ-HT-DEST2
For expression of protein with a
His-tag at the C-terminus
Do the LR reaction of your entry clone with
pEAQ-HT-DEST3
195Manipulation of Plant Biosynthetic Pathways
Author's personal copybacterial suspension has to be present at a high concentration, making the in-
oculumdense and difficult to infiltrate. Even then, it cannot be guaranteed that
every cell will receive all the infiltrated constructs (Montague et al., 2011). This
problem can be addressed by expressing multiple CPMV-HT expression
cassettes from the sameT-DNA,which is facilitated by the fact that an essential
part of the design of the pEAQ vector series is its modular nature (Fig. 9.2).
The CPMV-HT cassette, consisting of the gene of interest flanked by the
35S promoter and themodifiedRNA-2 50-UTRonone side and the 30-UTR
and nos terminator on the other, is also present on a series of cloning vectors
based on pM81B-S2NT-1, named pM81-FSC2 through to pM81-FSC6
(Fig. 9.2B). Each cassette contains the same polylinker found in pEAQ-HT
(Table 9.2; Fig. 9.2B) replacing the entire coding region of RNA-2 and en-
abling N- or C-terminal His-tagging of proteins to be expressed. They are
flanked by restriction sites that allow for the insertion of multiple cassettes into
the pEAQ polylinker (Fig. 9.2). For example, up to five cassettes may be
inserted sequentially into the basic transient expression vector, pEAQexpress.
Alternatively, two CPMV-HT cassettes can be simultaneously inserted
through multipart ligations into PacI/AscI-digested pEAQ vectors. This ap-
proach has been used to assemble an antibody-expression construct in
pEAQspecialK using pM81-FSC3 and pM81-FSC4 containing the heavy and
light chain of an IgG molecule, respectively (Frank Sainsbury, Pooja Saxena &
George Lomonossoff, unpublished data).
The benefit of expressing genes from the same T-DNA rather than
coinfiltrating separate constructs has been illustrated for the production of
assembled antibodies, where coexpression of the heavy and light chains in
the same cell is required (Sainsbury, Thuenemann, & Lomonossoff, 2009)
and for the production of empty (RNA-free) particles of CPMV, which
requires the coexpression of the coat protein precursor and the enzyme
necessary for its processing (Montague et al., 2011).
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tions where the simultaneous expression of multiple proteins within the
same cell is required. Thus, the pEAQ series of vectors have proved
extremely useful not only in situations where large amounts of a protein
are required (e.g., Matic´, Rinaldi, Masenga, & Noris, 2012; Saunders,
Sainsbury, & Lomonossoff, 2009; Vardakou et al., 2012) but also in
situations where manipulation of metabolism, through the coexpression
of several enzymes, is required. This has been illustrated in experiments
in which an oxidosqualene cyclase and a CYP450 from oat were
expressed in N. benthamiana leaves, either separately or in combination.
Expression of the oxidosqualene cyclase alone resulted in the
N. benthamiana leaves producing b-amyrin (Fig. 9.3), a metabolite not
normally produced by this species. Infiltration with a pEAQexpress-based
construct containing the sequence of both the oxidosqualene cyclase and
the CYP450 resulted in reduction of the signal for b-amyrin and the
appearance of a new peak representing a novel compound, the structure
of which is currently being examined. Thus, the pEAQ vectors can be
used to express metabolic enzymes with the aim of understanding their
function, the analysis of intermediates produced by their action or,
ultimately, to produce novel compounds in plants.
3. EXPRESSION OF ENZYMES IN PLANTS USING
pEAQ VECTORSThis section constitutes a practical guide for using the pEAQ vector
series to express foreign proteins, including active enzymes in plants.
3.1. Materials
3.1.1 Media, buffers, and solutions
• Luria-Bertani (LB) medium: 10 g/L bacto-tryptone, 10/L NaCl, and
5 g/L yeast extract, pH 7.0.
• LB agar: as LB with 10 g/L agar added.
• SOC: 20 g/L bacto-tryptone, 5 g/L yeast extract, 0.58 g/L NaCl,
0.19 g/L KCl, 2.03 g/L MgCl2, 2.46 g/L magnesium sulfate 7-hydrate,
3.6 g glucose.
• MMA: 10 mM MES (2-[N-morpholino]ethanesulfonic acid; Sigma-
Aldrich), pH 5.6, 10 mM MgCl2, 100 mM acetosyringone (Sigma-
Aldrich).
• 1 TBE: 10.8 g/L Tris–HCl, 5.5 g/L boric acid, 2 mM EDTA.
P19
P19CYP450
P19OSC
P19CYP450OSC
pEAQexpress
pEAQ-OSC
pEAQ-CYP450
pEAQ-OSC-CYP450
β-Amyrin
β-Amyrin
Figure 9.3 Use of CPMV-HT-based vectors for metabolic engineering. N. benthamiana
leaves were infiltrated with either: the empty vector pEAQexpress, which contains just
the P19 silencing suppressor expression cassette, Fig. 9.2; pEAQ-OSC, which contains
the sequence of an oat oxidosqualene cyclase (OSC) in a CPMV-HT cassette; pEAQ-
CYP450, which contains a cytochrome P450 (CYP450) in a CPMV-HT cassette;
pEAQ-OSC-CYP450, which contains the sequences of both OSC and CYP450 on
the same T-DNA. The position of b-amyrin is indicated in the HPLC traces on
the right. The arrowhead indicates the presence of a novel compound resulting
from the expression of both OSC and CYP450 from a single construct.
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• One ShotÒ TOP10 chemically competent E. coli (Invitrogen) is used for
propagation of recombinant plasmids.
• One ShotÒ ccdB survival 2T1R chemically competent E. coli
(Invitrogen) is used for propagation of pEAQ-DEST plasmids before
recombination with entry clones.
• A. tumefaciens strain LBA4404 (Hoekema, Hirsch, Hooykaas, &
Schilperoort, 1983) is used for plant transformations.
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N. benthamiana plants are grown in glasshouses maintained at 25 ºC with
supplemental lighting to provide 16 h of daylight throughout the year.
Plants are watered daily.
3.2. Creating expression plasmids
3.2.1 Choice of expression vector
Using the features described in Table 9.1, choose the most appropriate
pEAQ vector for the expression of your gene of interest.
3.2.2 Restriction enzyme-based cloning
1. Generate the insert with appropriate restrictions sites at both ends using
PCR.
2. Digest both the insert and plasmid pEAQ-HT with appropriate restric-
tion enzymes (Table 9.2) by mixing components including the appropri-
ate buffer according to the enzymemanufacturer’s recommendation. For
expression using pEAQ vectors other than pEAQ-HT, the insert should
first be cloned in the polylinker of pEAQ-HT or one of the FSC cloning
vectors (Fig. 9.2B). Then, the entire expression cassette can moved to
other pEAQ vectors using the appropriate restriction enzymes.
3. Dephosphorylate linearized vector with alkaline phosphatase following
the manufacturer’s instructions. This should be done after heat inactiva-
tion of the restriction enzymes.
4. Resolve digests on a 1% agarose gel and purify the vector and inserts
using QIAQuick gel extraction kit.
5. Combine the vector and insert (in molar ratio 1:3) in ligase buffer
with T4 DNA ligase and incubate according to manufacturer’s
recommendations.
6. Transform competent E. coli and plate onto LB agar plates with kanamy-
cin (50 mg/mL) selection.
7. Colonies may be screened by PCR or restriction analysis. Positive clones
are grown overnight and plasmids are extracted for sequencing (to con-
firm insertion) and Agrobacterium transformation.
3.2.3 Cloning by GATEWAY recombination
1. Generate the insert with bacteriophage lambda attachment B (attB) sites
at both ends using PCR.
2. UsingBPclonaseII, transfer thePCRfragment toaGATEWAYdonorvec-
tor via directional recombination. The resultant plasmid is the entry clone.
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the appropriate pEAQ-HT-DEST vector (see Table 9.3).
4. Transform competent E. coli and plate onto LB agar plates with kanamy-
cin (50 mg/mL) selection.
5. Colonies may be screened by PCR or restriction analysis. Positive clones
are grown overnight, and plasmids are extracted for sequencing (to con-
firm insertion) and Agrobacterium transformation.
3.2.4 Transformation of Agrobacterium
Once the expression construct is generated, it is introduced into
A. tumefaciens strain LBA4404 or AGL1 using electroporation. After electro-
poration at 2.5 kV, cells are recovered at 28 C for 1 h and plated on LB agar
containing rifampicin 50 mg/mL (for LBA4404) and kanamycin 50 mg/mL
(for carried plasmid). Transformed colonies are visible on plates in 2–3 days.
3.3. Agroinfiltration of N. benthamiana
3.3.1 Preparation of Agrobacterium suspensions
1. Prepare 10–100 mL LB with appropriate antibiotics for the
Agrobacterium strain (rifampicin 50 mg/mL for LBA4404) and carried
plasmid (kanamycin 50 mg/mL for pEAQ vectors). The volume of the
culture depends on the scale of your experiment. Generally, a 10-mL
culture is enough to infiltrate 4–5 leaves (ca. 5 g fresh-weight tissue).
2. Inoculate the liquid culture by picking a single colony from a plate. Grow
the culture at 28 C in a shaking incubator until the optical density (OD)
at 600 nm is 2. Typically, inoculate the culture in the afternoon and
grow overnight.
3. Spin cells at 4000 g for 10 min at room temperature to pellet them and
discard the supernatant.
4. Resuspend cells gently in the required volume of MMA to make a so-
lution of final OD600¼0.4. For coexpression of two constructs, prepare
solutions of individual OD600¼0.8 which when mixed 1:1 will result in
a final OD600¼0.4 for each construct.
5. Leave the solutions at room temperature for 0.5–3 h.
3.3.2 Infiltration of leaves with Agrobacterium suspensions
There are two different methods for introducing Agrobacterium suspensions
into leaves. The method of choice largely depends on the scale of the
experiment.
• Syringe-infiltration (small-scale expression; 1–10 plants)
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pipette tip. Aspirate infiltration solution into a sterile 1-mL plastic syringe
(take care to avoid bubbles) and, place the syringe over the leaf wound while
keeping a finger behind the leaf for support. Gently press the solution into
the intercellular space. For best results, 3–4-week-old N. benthamiana plants
are used and the youngest fully expanded leaves are chosen for infiltration.
• Vacuum-infiltration (large-scale expression; 10–100 plants)
Cover the base of a 3–4-week-old plant such that the soil is retained in the pot
during the infiltration procedure. Invert the plant into a beaker containing the
Agrobacterium suspension and place the beaker in the center of the vacuum
desiccator unit. Ensure that all the leaves are submerged in theAgrobacterium
suspension.Close and seal thedesiccator and applyvacuumfor60 s at negative
pressure of 25 in.Hg (170 mbar). Release the vacuum gently and return the
infiltrated plant to the growth room.More than one plant can be infiltrated at
the same time depending on the size of the desiccator unit.3.4. Monitoring expression levels in N. benthamiana leaves
The precise method for monitoring expression will depend on the nature of
the experiment. Harvesting ofN. benthamiana leaves is typically done at 3–10
days postinfiltration (dpi). Tissue can be processed fresh or snap-frozen and
stored at 80 C. A time-course should be done to assess optimum expres-
sion as expression levels might vary depending on the nature of your protein.
In the case of green fluorescent protein (GFP), expression is visible in vivo
under UV illumination. Therefore, it is sensible to include inoculation with
a GFP-expressing construct (such as pEAQ-HT-GFP) as a control in each
experiment. Using the HT system, expression of GFP in N. benthamiana
becomes visible after 2 days, reaches its peak at 5 dpi, and remains at this level
until day 7, after which the leaves start showing necrotic symptoms.
4. CONCLUSIONS AND PERSPECTIVES
The use of the pEAQ vector series to manipulate plant natural productbiosynthetic pathways is currently in its infancy. However, the data obtained
to date suggest that this approach is likely to be widely applicable. The ease of
use of the vectors, coupled with the speed of expression, means that many
possible combinations of enzymes can be rapidly screened. The modular
nature of the vectors means that a mix-and-match approach, in which enzymes
from different origins are combined, is feasible, raising the possibility of the
synthesis of new-to-nature compounds.
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the pEAQ series has also been adapted for stable genetic transformation.
Although the vectors can be used directly to produce transgenic cell cultures
(Sun et al., 2011), expression of the wild-type P19 suppressor of silencing is
highly detrimental to the regeneration of fertile plants. This can be overcome
by deploying versions of the pEAQ series harboring a mutant version of P19
with reduced suppression activity (Saxena et al., 2011). Using this approach,
it is possible to produce homozygous plants expressing high levels of the pro-
tein(s) of interest. Thus, transient expression can initially be used to rapidly
investigate and/or manipulate a biosynthetic pathway followed by stable
transformation to produce lines of plants with the appropriate characteristics.ACKNOWLEDGMENTS
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